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Abstract 
Performance during prolonged exercise capacity diminishes with increasing 
temperatures. The onset of fatigue under these conditions is not adequately explained 
by peripheral mechanisms. Recently, drugs which inhibit the reuptake of dopamine and 
noradrenaline in the brain have been found to improve exercise performance in warm 
conditions. The aim of this thesis was to further explore and characterise the role of 
these neurotransmitters during prolonged exercise in warm conditions by manipulating 
their reuptake or synthesis.  
The first series of experiments were designed to further investigate the effects of 
bupropion, a dopamine and noradrenaline reuptake inhibitor, which has been found to 
improve performance in warm conditions. To explore gender differences in response to 
acute bupropion administration, the effects of bupropion on prolonged exercise 
performance in warm conditions in women was investigated in Chapter 3. The results of 
this study suggest that during the follicular phase of the menstrual cycle, acute 
administration of bupropion improves exercise performance. To determine whether 
there are any dose-dependent effects of bupropion, the experiment in Chapter 4 was 
designed to test three different doses of bupropion. Exercise performance was only 
improved for the maximal dose, suggesting a threshold for the performance effects of 
bupropion. 
Catecholamine precursors do not appear to improve exercise performance as 
consistently as reuptake inhibitors. In agreement with previous studies, the dopamine 
precursor L-DOPA did not affect exercise performance in warm conditions in Chapter 5. 
In Chapter 6 the effect of the atypical antidepressant nutritional supplement S-
adenosylmethionine was investigated for its role in the synthesis of dopamine and 
noradrenaline. S-adenosylmethionine appeared to negatively influence cognitive 
function, increased skin temperature and circulating prolactin concentrations, but no 
effects on exercise performance were observed.  
Keywords: central nervous system, heat strain, central fatigue, dopamine, 
noradrenaline, serotonin.  
iv 
 
Acknowledgements 
I am privileged to be a part of a wonderful family whose love and support has given me 
the strength to do something I never dreamt possible. Without the guidance and 
encouragement of my father, I would never have thought I was capable of completing a 
PhD. He will always be a source of inspiration to me in all aspects of Life.  
 
My deepest gratitude goes to Dr. Phil Watson, who has supported me throughout my 
time at Loughborough University with seemingly inexhaustible patience. His guidance 
and friendship have been invaluable and have made working together a pleasure from 
the very first day. 
 
I would like to thank Professor Ron Maughan for providing me with this opportunity. 
Working with him has been a privilege and profound learning experience. I am grateful 
to Professor Mike Gleeson, who has been extremely helpful with my written work, which 
has benefited dramatically from his insight. My thanks also go to Professor Romain 
Meeusen, Dr. Bart Roelands, Dr. Bas de Geus, Dr. Kevin ‘Pea’ de Pauw and all the 
other kind and helpful members of the research group at Vrije Universiteit in Brussels. 
Their friendship and help made my stay in Brussels an unforgettable experience.  
 
Thanks to all the staff and students in the School of Sport, Exercise and Health 
Sciences. Whether suffering my company in the office or in the labs, everyone has been 
very helpful and friendly. Special thanks to those who endured the studies in this thesis 
as volunteers.  
 
Finally, I would like to thank Professors George Havenith and Zig St. Clair Gibson for 
agreeing to examine this thesis and for their patience in receiving it. 
v 
 
Publications and Presentations 
The findings of the studies reported in this thesis have been published and presented as 
follows: 
Publications: 
Chapter 4:  
Roelands B, Watson P, Cordery P, Decoster S, Debaste E, Maughan R & Meeusen R 
(2012). A dopamine/noradrenaline reuptake inhibitor improves performance in the heat, 
but only at the maximum therapeutic dose. Scandinavian Journal Of Medicine & 
Science In Sports 22, e93–8. 
 
Presentations:  
Chapter 3:  
Presented at the Physiological Society conference July 2012 in Edinburgh, Scotland in 
poster format  
Chapter 6:  
Presented at the International Sport and Exercise Nutrition conference December 2012 
in Newcastle, England as an oral presentation 
 
 
 
 
 
 
vi 
 
Table of Contents 
Chapter 1: General Introduction .................................................................................. 1 
1.1 Central Versus Peripheral Fatigue ......................................................................... 2 
1.2 Prolonged Exercise in Warm Conditions ................................................................ 3 
1.3 The Serotonin Hypothesis of Fatigue ..................................................................... 7 
1.4 Synthesis and Metabolism of Catecholamines ..................................................... 11 
1.5 Dopamine Receptors, Adrenoceptors and Signalling ........................................... 13 
1.6 Receptor Subtype and Distribution....................................................................... 14 
1.7 Tonic and Phasic Signalling ................................................................................. 20 
1.8 Central Catecholamine Precursors and Prolonged Exercise ............................... 22 
1.9 Catecholamine Reuptake Inhibitors and Prolonged Exercise .............................. 28 
1.10 Measuring Central Catecholaminergic Activity via Pituitary Hormones .............. 32 
1.11 Central Stress Signalling During Prolonged Exercise ........................................ 33 
1.12 Summary and Aims ............................................................................................ 40 
 
Chapter 2: General Methods ...................................................................................... 42 
2.1 Ethical Approval ................................................................................................... 43 
2.2 Participants .......................................................................................................... 43 
2.3 Experimental Design and Standardisation of Experimental Conditions ................ 45 
2.4 Measurement of Peak Oxygen Uptake ................................................................ 43 
2.5 Exercise Trials ..................................................................................................... 46 
2.6 Blood Collection, Handling and Analysis .............................................................. 48 
2.7 Statistical Analysis ............................................................................................... 49 
2.8 Coefficients of Variation of Methods ..................................................................... 50 
 
vii 
 
Chapter 3: The Role of Central Catecholamines in the Performance in Women 
during Prolonged Exercise in Warm Conditions ...................................................... 51 
3.1 Abstract ................................................................................................................ 52 
3.2 Introduction .......................................................................................................... 53 
3.3 Methods ............................................................................................................... 55 
3.4 Results ................................................................................................................. 59 
3.5 Discussion ............................................................................................................ 67 
 
Chapter 4: A Dopamine/Noradrenaline Reuptake Inhibitor Improves Performance 
in the Heat, But Only at the Maximum Therapeutic Dose ........................................ 72 
4.1 Abstract ................................................................................................................ 73 
4.2 Introduction .......................................................................................................... 74 
4.3 Methods ............................................................................................................... 76 
4.4 Results ................................................................................................................. 79 
4.5 Discussion ............................................................................................................ 85 
 
Chapter 5: The Effect of a Catecholamine Precursor on Performance during 
Prolonged Exercise in Warm Conditions .................................................................. 89 
5.1 Abstract ................................................................................................................ 90 
5.2 Introduction .......................................................................................................... 91 
5.3 Methods ............................................................................................................... 95 
5.4 Results ................................................................................................................. 93 
5.5 Discussion .......................................................................................................... 104 
 
viii 
 
Chapter 6: The Effect of One Week of Oral S-adenosylmethionine 
Supplementation on Cycling Performance and Thermoregulation in Warm 
Conditions ................................................................................................................. 107 
6.1 Abstract .............................................................................................................. 108 
6.2 Introduction ........................................................................................................ 109 
6.3 Methods ............................................................................................................. 111 
6.4 Results ............................................................................................................... 114 
6.5 Discussion .......................................................................................................... 122 
 
Chapter 7: General Discussion ................................................................................ 126 
7.1 Background ........................................................................................................ 127 
7.2 Effects of Central Dopamine/Noradrenaline Reuptake Inhibitors on Prolonged 
Exercise Performance in Warm Conditions ................................................................. 127 
7.3 Effects of a Catecholamine Precursor on Prolonged Exercise Performance in 
Warm Conditions ..................................................................................................... 132 
7.4 Effects of S-adenosylmethionine on Prolonged Exercise Performance in Warm 
Conditions ................................................................................................................... 134 
7.5 Conclusions and Future Research ..................................................................... 136 
 
References ................................................................................................................. 139 
Appendix .................................................................................................................... 170 
 
 
 
 
ix 
 
List of Tables 
Table 1.1 Dopamine Receptor and Transporter Expression in 6 Areas of the Human 
Brain .............................................................................................................................. 14 
Table 1.2 Noradrenanaline Receptor and Transporter Expression in 7 Areas of the Rat 
Brain .............................................................................................................................. 16 
Table 2.1 Coefficients of Variation of Methods .............................................................. 50 
Table 3.1 Serum Hormone Concentrations ................................................................... 65 
Table 3.2 Haematocrit, Haemoglobin and Glucose ....................................................... 66 
Table 3.3 Percentage Changes in Blood, Cell and Plasma Volume .............................. 66 
Table 4.1 Haematocrit, Haemoglobin and Glucose ....................................................... 84 
Table 4.2 Percentage Changes in Blood, Cell and Plasma Volume .............................. 85 
Table 5.1 Number of Finger Taps for Dominant and Non-Dominant Hands ................ 101 
Table 5.2 Haematocrit, Haemoglobin and Glucose ..................................................... 102 
Table 5.3 Percentage Changes in Blood, Cell and Plasma Volume ............................ 103 
Table 6.1 Haematocrit, Haemoglobin and Glucose ..................................................... 119 
Table 6.2 Percentage Changes in Blood, Cell and Plasma Volume ............................ 119 
 
 
List of Figures 
Figure 1.1 Synthesis of Dopamine and Noradrenaline .................................................. 12 
Figure 1.2 Neuroanatomical Map of Dopaminergic and Noradrenergic Projections ...... 15 
Figure 1.3 Simplified Overview of G-protein Receptor Signalling .................................. 17 
Figure 1.4 Schematic of an Action Potential .................................................................. 18 
Figure 1.5 Simplified Depiction of Different Dopaminergic Signalling within a Circuit ... 19 
Figure 1.6 Train of Action Potentials in Tonic and Phasic Firing ................................... 20 
x 
 
Figure 1.7 Relationship of Tonic and Phasic Firing in the Nucleus Accumbens ............ 21 
Figure 1.8 Simplified Metabolic Map of the Various Roles of S-adenosylmethionine .... 25 
Figure 1.9 Neuroanatomical Map of Corticotropin-Releasing Factor Projections .......... 35 
Figure 3.1 Schematic of Lab Visit Scheduling with Respect to Menstrual Cycle ........... 56 
Figure 3.2 Schematic of Experimental Protocol ............................................................ 59 
Figure 3.3 Exercise Performance by Trial (A) and Individual (B) ................................... 60 
Figure 3.4 Individual Percentage Change in Performance ............................................ 61 
Figure 3.5 Core (A) and Weighted Mean Skin Temperature (B) ................................... 62 
Figure 3.6 Heart Rate .................................................................................................... 63 
Figure 3.7 RPE During Experimental Trials ................................................................... 63 
Figure 3.8 Thermal Sensation During Experimental Trials ............................................ 64 
Figure 3.9 Sweat Losses ............................................................................................... 67 
Figure 4.1 Schematic of Experimental Protocol ............................................................ 79 
Figure 4.2 Group Time Trial Performance ..................................................................... 80 
Figure 4.3 Individual Time Trial Performance ................................................................ 80 
Figure 4.4 Core (A) and Weighted Mean Skin Temperature (B) ................................... 81 
Figure 4.5 Heart Rate .................................................................................................... 82 
Figure 4.6 RPE (A) and Thermal Sensation (B) ............................................................ 83 
Figure 4.7 Circulating ACTH (A), Cortisol (B) and Prolactin (C) Concentrations ........... 84 
Figure 4.8 Sweat Losses ............................................................................................... 85 
Figure 5.1 Schematic of Experimental Trials ................................................................. 95 
Figure 5.2 Exercise Performance by Trial (A) and Individual (B) ................................... 96 
Figure 5.3 Individual Percentage Change in Performance ............................................ 97 
Figure 5.4 Core (A) and Weighted Mean Skin Temperature (B) ................................... 98 
Figure 5.5 Heart Rate .................................................................................................... 99 
xi 
 
Figure 5.6 RPE .............................................................................................................. 99 
Figure 5.7 Thermal Sensation ..................................................................................... 100 
Figure 5.8 Serum Prolactin Concentrations ................................................................. 100 
Figure 5.9 Serum Cortisol Concentrations .................................................................. 101 
Figure 5.10 Sweat Losses ........................................................................................... 103 
Figure 6.1 Schematic of Experimental Trials ............................................................... 113 
Figure 6.2 Exercise Performance by Trial ................................................................... 114 
Figure 6.3 Individual Changes in Time to Exhaustion ................................................. 114 
Figure 6.4 Core (A) and Weighted Mean Skin Temperature (B) ................................. 115 
Figure 6.5 Heart Rate .................................................................................................. 116 
Figure 6.6 RPE ............................................................................................................ 116 
Figure 6.7 Thermal Sensation ..................................................................................... 117 
Figure 6.8 Area Under the Curve for Serum Cortisol Concentrations.......................... 117 
Figure 6.9 Area Under the Curve for Serum Prolactin Concentrations ........................ 118 
Figure 6.10 Rate of Sweat Loss .................................................................................. 120 
Figure 6.11 Rapid Visual Information Processing Proportion Correct ......................... 121 
Figure 6.12 Stroop Reaction Times ............................................................................. 122 
Figure 7.1 Drug Targets and Potential Effects on Stress Signalling ............................ 130 
 
 
 
 
 
 
xii 
 
List of Abbreviations 
Abbreviations are defined in the text in the first instance. 
AAAD Aromatic L-amino acid decarboxylase 
ACC Anterior cingulate cortex 
ACTH Adrenocorticotropic hormone 
ADHD Attention deficit hyperactivity disorder 
AMPT Alpha-methyl-para-tyrosine 
ANOVA Analysis of Variance 
AUC Area under the curve 
BCAA Branched-chain amino acid 
cAMP Cyclic adenosine monophosphate 
CCT Cytidine 5’-triphosphate: phosphocholine cytidyltransferase 
Cmax Maximum plasma concentration 
CNS Central nervous system 
CO2 Carbon dioxide 
COMT Catechol-O-methyltransferase 
CRF Corticotropin-releasing factor 
CV Coefficient of variation 
DAT Dopamine transporter 
EEG Electroencephalogram 
ELISA Enzyme-linked immunosorbent assay 
ERN Error-related negativity 
FSH Follicle stimulating hormone 
GH Growth hormone 
Hb Haemoglobin 
Hct Haematocrit 
HPA Hypothalamic-pituitary adrenal axis  
HPLC High performance liquid chromatography 
K2EDTA Potassium ethylenediaminetetraacetic acid 
L-DOPA L-3,4-dihydroxyphenylalanine 
xiii 
 
LH Luteinising hormone 
LNAA Large neutral amino acid 
MAO Monoamine oxidase 
MRI Magnetic resonance imaging 
MTHF Methyltetrahydrofolate 
NAc Nucleus accumbens 
NAT  Noradrenaline transporter 
NTS Nucleus tractus solitarius 
O2 Oxygen 
PET Positron emission tomography 
PFC Prefrontal cortex 
PVN Paraventricular nucleus of the hypothalamus 
RPE Rating of perceived exertion 
RVIP Rapid visual information processing 
SAM S-adenosylmethionine 
SD Standard deviation 
STPD Standard temperature and pressure for dry gas 
Tcore Core temperature 
TH Tyrosine hydroxylase 
TIDA Tuberoinfundibular dopamine  
TMS Transcranial magnetic stimulation 
TPH Tryptophan hydroxylase 
Tskin Weighted mean skin temperature 
TT Time trial 
VO2max Maximum oxygen uptake 
VO2peak Peak oxygen uptake 
VTA Ventral tegmental area 
W Watt 
Wmax Maximum workload 
Wout Workload of final stage 
1 
 
 
 
 
Chapter 1 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 - Central Versus Peripheral Fatigue 
Fatigue during exercise has been defined as “the inability to maintain the required or 
expected power output that leads to a loss of performance in a given task” (Edwards, 
1981) and “any exercise-induced reduction in the ability to exert muscle force or 
power, regardless of whether or not the task can be sustained” (Bigland-Ritchie & 
Woods, 1984). In this sense, performance and fatigue are intrinsically related. 
Arguments for the aetiology of fatigue during exercise have been largely divided into 
two camps: peripheral and central fatigue. The dichotomy of peripheral and central 
fatigue during exercise was considered as early as 1891 by Augustus Waller, who 
suggested that the central component may act as a protective mechanism over 
peripheral fatigue. Peripheral fatigue is predominantly characterised by changes in 
muscle contractility as a result of changes to the contractile properties in the muscle 
itself. For example, this can be a caused by changes in substrate availability, 
accumulation of metabolites or changes in muscle temperature. Central fatigue 
refers to mechanisms within the brain which control muscle contractility via 
descending corticospinal motor pathways. Alessandro Mosso (1903) later concluded 
that “there exists only one kind of fatigue, namely, nervous fatigue; this is the 
preponderating phenomenon, and muscular fatigue is also at bottom an exhaustion 
of the nervous system” (p.243), while Francis Bainbridge elaborated by suggesting 
that muscular fatigue was superadded to nervous fatigue (1919). However, following 
the famous work of Archibald Hill (Hill & Lupton, 1923), a greater emphasis was 
subsequently placed on peripheral mechanisms. Research in this area developed 
significantly with the advent of analytical techniques such as the muscle biopsy 
during the 1960s. Bergström and co-workers (1967), demonstrated the importance of 
muscle glycogen stores for performance during prolonged exercise, further 
emphasising the importance of muscle metabolism in fatigue. However, in the early 
1980s, the central component of fatigue was re-established with the application of 
twitch interpolation (Grimby et al., 1981; Belanger & McComas, 1981) and 
transcranial magnetic stimulation (TMS)(Barker et al., 1985). Experiment using these 
techniques revealed that a difference of force produced in maximal voluntary 
contractions compared to the force elicited by a superimposed contraction gradually 
increased with fatigue. This suggested that a central component was limiting the 
voluntary contractions. In addition to contributing to peripheral fatigue, the 
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mechanisms for fatigue within the muscle are detected by afferent sensory neurons, 
which sense a broad range of factors including pH, temperature and accumulation of 
metabolites. These sensory neurons provide feedback to the CNS, which can 
modulate motor neurons and inhibitory interneurons, suggesting peripheral and 
central mechanisms interact to affect performance (Gandevia, 2001). The primary 
mechanisms in the onset of fatigue depend on the type of exercise and the 
environment in which it is being performed. Complex movements such as running or 
cycling are more difficult to analyse, particularly using imaging techniques or TMS, 
because of the constant movement and ergometers required. Recently, the first 
study using TMS during prolonged cycling found that cortical excitability does not 
increase, in contrast to isolated single-muscle exercise. The authors suggest that the 
greater number of challenges to homeostasis during prolonged cycling may 
contribute to intracortical inhibitory mechanisms (Sidhu et al., 2012). Similarly, there 
is evidence that prolonged exercise is modulated by a teleoanticipatory system, 
which influences pacing relative to feedback (St Clair Gibson et al., 2004, 2006; 
Noakes et al., 2005). Nonetheless, the degree to which central and peripheral 
mechanisms determine fatigue in prolonged exercise is still hotly debated 
(Shephard, 2009; Noakes, 2011a, 2011b). However, in warm conditions, this central 
component appears to be even especially pronounced (Nybo & Nielsen, 2001a; 
Nybo, 2008), as discussed below.  
 
1.2 - Prolonged Exercise in Warm Conditions 
Endurance exercise capacity is reduced in warm conditions. This effect has been 
demonstrated to be dependent on the rate of heat-gain, which becomes impaired as 
ambient temperature increases (Galloway & Maughan, 1997). The combination of 
basal metabolic rate, external work, environmental factors and the body’s ability to 
dissipate heat contribute to this process. The 5 main routes through which heat is 
lost from the body are conduction, convection, radiation, evaporation and respiration. 
As the skin to ambient temperature gradient narrows, sweating becomes the only 
effective mechanism for heat loss. Maximal heat loss via sweating occurs when 
sweat evaporates from the skin. Large amounts of energy are required to drive the 
phase change from liquid water to vapour. As a result, the transition of sweat into 
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water vapour removes considerable thermal energy from the surface of the skin. For 
the same reason, sweat that drips off the body or is wiped away is considerably less 
effective for heat loss (Havenith, 2005). Consequently, prolonged exercise 
performance in warm conditions is further impaired by increasing humidity (Maughan 
et al., 2012). This is due to increased water vapour saturation of the air which 
increases the competition between evaporation of water molecules from the skin and 
condensation of water molecules from the air onto the skin. However, because air 
can contain larger concentrations of moisture with increased temperature, the same 
percentage relative humidity of air at higher temperatures will contain a greater 
concentration of moisture.  
 
These significant challenges to thermoregulation and fluid balance are considered to 
be the primary causes of fatigue during prolonged exercise in warm conditions 
(Hargreaves, 2008; Nybo, 2008; Maughan, 2010). During exercise in warm 
conditions the narrow core-to-skin temperature gradient results in an increased 
demand of blood flow to the skin to facilitate heat loss. The water and electrolytes 
which form the majority of sweat are mobilised from intracellular fluid compartments 
to maintain blood volume (Nose et al., 1988). As exercise continues there is a 
progressive reduction in blood volume, due to the loss of fluid as sweat, resulting in a 
fall in cardiac output and a compromised muscle and skin oxygen and nutrient 
supply via blood flow (Gonzalez-Alonso et al., 2007). Reduced blood flow also 
diminishes the capacity for convective heat loss from muscle and body core to the 
surrounding environment (Crandall & González-Alonso, 2010). Muscle 
glycogenolysis (Febbraio et al., 1996) and glucose oxidation appear to increase with 
ambient temperature, but fatigue during prolonged sub-maximal exercise in warm 
conditions occurs long before muscle glycogen depletion (Parkin et al., 1999; 
Febbraio, 2000). A critical core temperature (~39.5°C) was proposed as the 
determining mechanism for fatigue (Nielsen et al., 1993). Similarly, initial core 
temperature and rate of increase of core temperature appear to be determining 
factors for the onset of fatigue and volitional exhaustion during prolonged exercise 
(González-Alonso et al., 1999). Core temperature was also demonstrated to 
correlate more strongly to the reduction force of maximal voluntary contraction than 
muscle temperature (Thomas et al., 2006). Skin temperature has recently been 
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shown to be a determining factor as changes in cutaneous blood flow contribute to 
cardiovascular strain by requiring a higher cardiac output to circulate blood through 
the skin (Cheuvront et al., 2010). This drive to dissipate heat through the skin, paired 
with fluid loss, has been considered to be more important to the onset of fatigue than 
an elevated core temperature alone (Sawka et al., 2012). This results in increased 
relative exercise intensity at a given workload as VO2max decreases and 
cardiovascular strain increases.  
 
Hyperthermia has been found to impair maximal muscle activation, alter brain activity 
and increase perceived exertion (Nybo & Nielsen, 2001b). This is accompanied by 
reduced middle cerebral artery blood velocity (Nybo & Nielsen, 2001c), though this 
was later demonstrated not to be the cause of the changes in brain activity or fatigue 
(Rasmussen et al., 2004). These physiological responses have been implicated in 
the fatigue process during exercise in the heat via mechanisms residing within the 
CNS (Nybo, 2008). There is some evidence that central fatigue may be due to 
dysfunction in metabolic and structural function, which could ultimately lead to 
catastrophic failure. A general decrease of glucose and oxygen along with increased 
heat storage in the brain may result in general disruption of normative function (Nybo 
& Secher, 2004). Nybo and co-workers (2005) also found an increased uptake and 
retention of ammonia in the brain during prolonged exercise. Ammonia is neurotoxic, 
and can only be detoxified by conversion to glutamine (Albrecht & Norenberg, 2006). 
Nybo and co-workers (2005) suggest that this process may affect glutamate 
metabolism and subsequently both glutamatergic and GABAergic 
neurotransmission. In addition, temperature determines both the integrity and fluidity 
of cell membranes in general (Blicher et al., 2009). This is particularly significant to 
brain cells, which are especially sensitive to changes in these membrane qualities. 
Depending on the degree of integrity lost detriment to signal transduction, impulse 
conduction, metabolism and homeostasis in general would occur, which could 
ultimately lead to significant cell damage, apoptosis and eventually oedema (Kiyatkin 
& Sharma, 2009). 
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Prolonged exercise in the heat has been found to increase serum S-100β 
concentrations (Watson, Shirreffs, & Maughan, 2005), a small calcium binding 
neurotrophic protein of 27 kiloDaltons  primarily expressed by astroglial and 
Schwann cells in the CNS. The significance of this is not certain, other than it 
suggests an increase in blood-brain barrier permeability (Kapural et al., 2002). This 
could result in serious metabolic disruptions of CNS homeostasis. If a 27 kiloDaltons 
protein can escape, then a number of ions and molecules of similar or smaller size 
may escape and/or enter the CNS and affect neurotransmission. In addition to 
neuroactive substances, other proteins of similar or smaller size, such as calcium 
binding parvalbumin (12 kiloDaltons), for example, may escape the CNS and have 
deleterious effects; calcium homeostasis is essential for almost all cell function 
(Clapham, 2007), but especially so for the CNS (Heizmann, 1993; Clapham, 2007). 
Interestingly, exercise has been found to increase expression of parvalbumin in the 
hippocampus in developing male Wistar rats (da Silva et al., 2010). Despite the 
apparent changes in blood-brain barrier permeability, using magnetic resonance 
imaging (MRI), Watson and co-workers (Watson et al., 2010) found that although 
exercised-induced hyperthermia and dehydration resulted in shrinking of cerebral 
ventricles and cerebrospinal fluid  volume, but no significant changes in brain volume 
was apparent.  
 
An argument against the catastrophic models of fatigue are that even in conditions 
most conducive to catastrophic failure it is rarely observed, suggesting a protective 
mechanism terminates exercise before this can happen (Noakes et al., 2005). There 
is evidence to suggest a teleoanticipatory algorithm within the brain predicts 
expected outcome of performance relative to sensory and emotional feedback and 
adjusts power output and pacing with respect to this feedback (St Clair Gibson et al., 
2006). It is worth considering that pacing is, in part, determined by expectation based 
on previous experience. This suggests that the teleoanticipatory pacing mechanism 
and the changes to performance incurred by this mechanism might reflect a learned 
limit of expectation for performance rather than an unconscious instinct or survival 
reflex. However, as expectation and subjective experience are inherently dependent 
on learned experience, this must be viewed as another facet to central fatigue. 
Furthermore, except for in the rare cases of catastrophic failure or sudden 
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unconsciousness, the decision to stop exercising is a conscious one (Kayser, 2003). 
Nonetheless, subconscious and unconscious processes will contribute to this 
decision and appear to directly modulate performance as well. For example, the rate 
of heat storage has been found to modulate the power output in relation to a fixed 
rating of perceived exertion (RPE)(Tucker et al., 2006) further demonstrating the role 
of centrally mediated mechanisms of fatigue during prolonged exercise in warm 
conditions. Changes to the central neurotransmission which underpin the 
teleoanticipatory system would also alter its function. Though the cerebral 
mechanisms for the onset of fatigue are not fully understood, there have been many 
studies attempting to manipulate fatigue by altering CNS function. While those 
attempting to alter fatigue via manipulation of serotonin have yielded conflicting 
results (Meeusen et al., 2006b), pharmacological manipulation of central 
catecholamines has produced more consistent changes in the onset of fatigue and 
exercise performance in warm conditions (Roelands & Meeusen, 2010).  
 
1.3 - The Serotonin Hypothesis of Fatigue 
One of the first neurobiological theories for this increased sense of fatigue during 
exercise was proposed to be related to changes in brain 5-hydroxytryptophan 
(serotonin). The concept of serotonin-mediated fatigue was founded on the 
association of 5HT to feelings of drowsiness and in decreasing arousal in the sleep-
wake cycle. The basis for serotonin-mediated fatigue during prolonged exercise was 
largely due to the work of Chaouloff and co-workers which reported increased 
serotonin levels in rats during prolonged exercise (Chaouloff et al., 1985, 1986b, 
1987). They also demonstrated that provision of free tryptophan, the amino acid 
precursor for serotonin synthesis, increased this response (Chaouloff et al., 1986a). 
Soon after, Newsholme and co-workers (1987) proposed a widely cited theory linking 
changes in peripheral substrate availability and mobilisation of free-fatty acids to 
changes in neurochemistry. This hypothesis suggested that prolonged exercise 
increases plasma fatty acid concentrations, which liberate tryptophan from albumin, 
resulting in an increased uptake of tryptophan by the large neutral amino acid 
(LNAA) transporter across the blood-brain barrier. As tryptophan hydroxylase is not 
saturated under normal physiological conditions, increased delivery of tryptophan 
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would result in an elevation in brain serotonin synthesis and release (Ruddick et al., 
2006). However, the ratio of free tryptophan to albumin bound tryptophan may be of 
little importance (Pardridge, 1983), because the exchangeable tryptophan in humans 
may approximate total plasma tryptophan. Pardridge (1983) explains that this is, in 
part, due to the fact that the tryptophan-albumin complex dissociates and re-
associates many times during transit through brain capillary. As the branched-chain 
amino acids (BCAAs) compete for binding of the LNAA transporter, Blomstrand and 
co-workers (1991) suggested that supplementation with BCAA may limit the delivery 
of tryptophan to the CNS and attenuate serotonin production during exercise. They 
conducted a study in which BCAAs were administered before two long distance 
races, reporting an improvement in exercise performance in a group of slower 
runners.  
 
To substantiate the serotonin hypothesis several strategies have been employed. In 
rats, administration of serotonin precursors resulted in an enhanced increase of 
serotonin in response to prolonged exercise (Meeusen et al., 1996).Gomez-Merino 
and co-workers administered valine in rats and found that it reduced the exercise-
induced increase in serotonin levels in the hippocampus by reducing uptake of 
tryptophan (Gomez-Merino et al., 2001).Yamamoto & Newsholme (2000a) used a 
LNAA transporter blocker to prevent tryptophan uptake and subsequent serotonin 
synthesis, which prolonged exercise in rats. Subsequent human studies, however, 
have failed to support an effect of BCAA administration on central fatigue (Meeusen 
et al., 2006a). Mittleman and co-workers (1998) administered BCAAs during low-
intensity cycling in a warm environment and found a significant increase in time to 
exhaustion. However, subsequent studies have been unable to produce similar 
results (Cheuvront et al., 2004; Watson et al., 2004). It is worth noting that the 
protocol employed by Mittleman and co-workers (1998) did not induce a state of 
hyperthermia (core temperatures at fatigue of 37.3-37.7°C), due to the very low 
exercise intensity (40% VO2max). To this day only two studies have reported an 
ergogenic effect of BCAAs on prolonged exercise performance (Blomstrand et al., 
1991; Mittleman et al., 1998).  
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In addition to the serotonin hypothesis, Bailey and co-workers observed that 
dopamine  tissue content decreased at fatigue, while serotonin remained high 
(Bailey et al., 1993) leading to the theory that the ratio of serotonin to dopamine was 
the determining factor in fatigue (Davis & Bailey, 1997). A recent exercise study in 
warm conditions by Hobson and co-workers (2012) administered a tryptophan-free 
amino acid mixture, in order to reduce circulating tryptophan, and consequently 
serotonin synthesis. Despite a marked decrease in circulating serotonin, no changes 
in performance were observed. Tyrosine is an amino acid precursor to dopamine 
and noradrenaline synthesis and is also blocked by BCAA for uptake at the LNAA 
transporter. Because tryptophan depletion bypasses the problem of concomitantly 
reduced tyrosine uptake by the LNAA transporter this study provides further 
evidence that neither circulating tryptophan nor the ratio of serotonin/dopamine are 
particularly important in the genesis of central fatigue. A similar lack of convincing 
evidence has been found using pharmacological manipulation of serotonin in human 
studies. Wilson and Maughan (1992) tested the serotonin hypothesis in humans 
using the serotonin reuptake inhibitor paroxetine and found that it significantly 
decreased cycling time to exhaustion. This led to several follow-up studies with 
serotonin reuptake inhibitors, serotonin agonists and antagonists which failed to 
support those initial findings (see Meeusen et al., 2006b for review). Eventually, 
Newsholme and Blomstrand (2006) conceded that central fatigue is likely more 
complex than the serotonin hypothesis.  
 
To account for this variability in results, there are many factors to consider. Firstly, 
rat exercise studies should be regarded with caution as footshock, a consequence of 
the electric shock grids used at the rear of the treadmill in many of these studies to 
encourage the rat to perform for as long as possible, will confound the significance of 
the changes in monoamine levels throughout the brain (Dishman et al., 1997). 
Similarly, inescapable/uncontrollable stress activates the brain and alters 
monoamine levels differently than controllable stress (Weiss et al., 1981).  The 
increased level of serotonin in certain parts in the brain could be affected by several 
things, including acute stress, which increases circulating glucocorticoids, increases 
tryptophan hydroxylase (TPH) activity in a dose related manner (Clark & Russo, 
1997). Furthermore, the raphe nuclei, the source of most serotonergic projections in 
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the brain, are located in the brainstem. These neurons have been implicated with 
regulation of thermogenesis (Cao & Morrison, 2005) and stress induced cutaneous 
vasomotor tone (Blessing, 2005). serotonergic activity in the anterior 
hypothalamus/preoptic area has been implicated with stress responses including 
tachycardia and increased blood pressure (Szabó, Butz, & Alper, 1998). The 
increase of serotonin found at fatigue in the rat studies (Chaouloff et al., 1986b; 
Blomstrand et al., 1989; Bailey et al., 1993) could therefore be a result of fatiguing 
processes, rather than being the cause of fatigue. Furthermore, serotonin is 
considered to play an important role in stimulating locomotion, which would likely 
further contribute to observed changes in serotonin concentrations (Takahashiet al., 
2000; Vanderwolf et al., 1997). Finally, many of these results were obtained from 
brain tissue homogenate, rather than in-vivo microdialysis, and dynamic changes 
over time were not observed (Meeusen et al., 2001).  
 
While manipulation of central serotonin in humans has had conflicting results, 
pharmacological manipulation of catecholamines, particularly with reuptake 
inhibitors, has seen more consistent success (Roelands & Meeusen, 2010). 
Chaouloff and co-workers (1987) observed a decrease in serotonin synthesis during 
treadmill exercise after administration of amphetamine in trained rats, which acts via 
primarily catecholaminergic effects. Bailey and co-workers observed that a serotonin 
agonist decreased brain dopamine during prolonged exercise (Bailey et al., 1993) 
and led to the consideration that the ratio of serotonin to dopamine was the 
determining factor (Davis & Bailey, 1997). However, for the reasons stated above 
and the lack of consistent results in studies using nutritional or pharmacological 
manipulation of central serotonin neurotransmission (2010), the role of serotonin in 
fatigue appears to be less important than central catecholamines and will no longer 
be considered in great detail . 
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1.4 - Synthesis and Metabolism of Catecholamines 
Dopamine was originally thought only to be the precursor to noradrenaline until it 
was demonstrated to be a neurotransmitter in its own right by Nobel Prize laureate 
Arvid Carlsson in 1957. This quickly led Carlsson to establish the role of dopamine in 
Parkinson’s disease and subsequently in motor function. This became the focus of 
dopamine related research and the understanding of dopamine’s function in the 
brain became defined by this research (Schallert et al., 2009).Dopamine was 
originally associated with movement and then became associated with reward 
(Tobler, 2011), but it is now recognised that dopamine is also highly involved with 
learning, motivation, emotion, affect (Salamone et al., 2007; Wise, 2004) and the 
attribution of value or salience to sensory stimuli (Tobler, 2011).  The role of 
dopamine in motor function thus became a fundamental theme for research in 
cerebral control of exercise. This, combined with the observations by the exercise 
studies in rats mentioned in the previous section (Gerald, 1978; Chaouloff et al., 
1987; Bailey et al., 1993) are perhaps why noradrenaline has received comparatively 
little attention, despite being closely tied with dopamine function, as described below. 
 
Dopamine is synthesised from the amino acid L-tyrosine, which is converted by the 
enzyme tyrosine hydroxylase (TH) and the necessary cofactor tetrahydrobiopterin, to 
L-3,4-dihydroxyphenylalanine (L-DOPA) by the addition of a hydroxyl group. The 
carboxyl group is removed from L-DOPA by the enzyme aromatic L-amino acid 
decarboxylase (AAAD) to form dopamine (see figure 1.1). L-tyrosine can be acquired 
in the diet or synthesised from the essential amino acid phenylalanine, which cannot 
be synthesised by the body. Under normal physiologic conditions, dopamine 
synthesis is considered to be rate limited by the availability of tyrosine and 
tetrahydrobiopterin for hydroxylation by TH. Recent evidence suggests that the 
activity of AAAD is more important than originally thought (Duchemin et al., 2000; 
Duchemin et al., 2010), specifically during rapid short-term synthesis. 
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After decarboxylation of L-DOPA to dopamine, noradrenaline is formed from 
dopamine by dopamine-β-hydroxylase with the addition of a hydroxyl group at the 
second carbon (beta) from the amino group. Catecholamines are inactivated and 
metabolised by monoamine oxidase (MAO) and catechol-O-metyhltransferase 
(COMT). MAO uses oxygen, while COMT transfers a methyl group from the cofactor 
S-adenosylmethionine (SAM). Through other metabolic pathways SAM is also tied to 
monoamine synthesis, as described in section 1.8. Both enzymes are expressed 
within neurons and astroglia as well. This allows for degradation of catecholamines 
within neurons, in the synapse and extrasynaptic space as well, but occurs primarily 
within the neurons that synthesize them (Eisenhofer et al., 2004). Interestingly, 
human prefrontal cortex (PFC) has a high concentration of COMT mRNA, where 
membrane bound COMT can be expressed on the exterior surface of the cell 
membrane postsynaptically (Matsumoto et al., 2003).  
 
Figure 1.1 Cofactors and by-products (Blue): BH4 = Tetrahydrobiopterin; BH2 = Dihydrobiopterin; 
P5P=Pyridoxal-5-phosphate; DHA = Dehydroascorbate; Enzymes (Yellow) TH = Tyrosine 
hydroxylase; AADC = Aromatic L-amino acid Decarboxylase; DβH = dopamine-β-hydroxylase.  
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1.5 - Dopamine Receptors, Adrenoceptors and Signalling 
Dopamine receptors and adrenoceptors belong to a large family of transmembrane 
intracellular signalling proteins called G protein-coupled receptors. G protein-coupled 
receptors stimulate signal transduction through metabotropic instead of ionotropic 
mechanisms. This means that instead of directly opening an ion-channel, which 
rapidly changes the polarity of the neuron membrane, metabotropic receptors affect 
intracellular signalling via complex cascades (See figure 1.2). This in turn influences 
cell metabolism, but generally has a less immediate effect on extracellular signalling, 
including neurotransmitter release into the synapse. However, D1-like receptors 
have also been found to couple with glutamic NMDA receptors, in which case can 
directly stimulate calcium flux into the cell, resulting in a more rapid signalling 
process (Scott & Aperia, 2009).Dopamine receptors have been categorised into two 
separate classes based on their excitatory or inhibitory effects via alteration adenylyl 
cyclase activity and cyclic adenosine monophosphate (cAMP) production. The D1-
like receptors, which consist of D1 and D5, are stimulating G protein (Gs and Golf) -
coupled receptors and stimulate cAMP production by increasing adenylyl cyclase  
activity (Herv et al., 1993). D2-like receptor family, which include D2, D3 and D4, are 
inhibitory G protein (Gi and Go)-coupled receptors and decrease cAMP production by 
inhibiting adenylyl cyclase. While D1-like receptors are relatively well understood, 
D2-like receptors are not. This is due to the existence of various isoforms that differ 
at one of the intracellular functional groups (Jaber et al., 1997; Missale et al., 1998). 
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1.6 - Receptor Subtype and Distribution 
Table 1.1 below shows the relative distribution of the 5 subtypes of dopamine 
receptors in the cerebral cortex, hippocampus, amygdala, striatum, nucleus 
accumbens (NAc), ventral tegmental area (VTA), substantia nigra and the 
hypothalamus. These are several key areas of the brain for controlling exercise 
related behaviours.  
 
Table 1.1 Dopamine receptor and transporter (DAT) expression in 6 areas of the human brain 
(Ciliax et al., 1999; Rankin et al., 2009). Indicated levels of expression are relative expression within 
receptor and transporter groups. +++ indicates very high, ++ indicates high, + indicates significant and 
– indicates not detected. 
 
D1 D2 D3 D4 D5 DAT 
Cortex ++ + + +++ + + 
Hippocampus + + +++ ++ + + 
Amygdala + + +++ ++ - ++ 
Striatum +++ +++ + + ++ +++ 
Nucleus Accumbens +++ +++ +++ + + ++ 
Ventral Tegmental Area + ++ + + - + 
Substantia Nigra ++ ++ ++ + +++ ++ 
Hypothalamus + + + ++ ++ + 
 
The cerebral cortex is involved in relating to the outside world, via primary sensory 
areas, the primary motor area, association areas and limbic areas. The amygdala 
and hippocampus are part of the limbic system, which is involved in memory, 
emotion and motivation. The striatum and NAc are involved in reward, motor control, 
motivation and initiation of behaviour. These are key brain areas within the 
mesocorticolimbic system which is involved in motivation, reward, and learning, 
dysfunction of which is primarily implicated with impulse control disorders and drug 
addiction (Wise, 2004). The VTA and the substantia nigra are the main sources of 
projecting dopaminergic neurons in the brain. The VTA is the source of dopamine for 
the mesocorticolimbic system. The substantia nigra is the source of dopamine for the 
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dorsal striatum, is primarily involved in controlling motor behaviour, dysfunction of 
which is considered the main cause of Parkinson’s disease. Finally, the 
hypothalamus is primarily associated with homeostatic control and neuroendocrine 
secretory function, however, it is also involved in drives and emotional behaviours 
(Nolte, 2009). The anterior and preoptic area of the hypothalamus in particular 
appear to be important for thermoregulation during exercise (Hasegawa et al., 2005), 
with increases in both dopamine and noradrenaline release in the preoptic area 
positively correlated with core temperature (Hasegawa et al., 2011). The VTA 
innervated areas are in turn modulated by noradrenaline (see figure 1.2), particularly 
in the PFC, regulating effort-related function controlling motivation outcomes and 
possibly linking the intensity of input saliency to effort intensity (Puglisi-Allegra & 
Ventura, 2012). 
 
Figure 1.2 Neuroanatomical map, with axes of orientation. Light grey demarks regions of interest. 
Blue arrows represent dopaminergic projections, yellow arrows represent noradrenergic projections. 
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In total 9 different adrenoceptor subtypes have been identified, though their 
categorisation and distribution has not been as well defined as with dopamine 
receptors. The α2 and β adrenoceptors are Gi and Gs, respectively. The α1 
adrenoceptors are Gq, which increases phospholipase C activity, which increases 
cytosolic calcium release. Table 1.2 shows the relative distribution of the 7 subtypes 
of noradrenaline receptors in the cerebral cortex, hippocampus, striatum, 
hypothalamus, thalamus, locus coeruleus and nucleus tractus solitarius (NTS). The 
thalamus is important for information transfer to and from peripheral afferents to the 
cortex via the spinal cord and is modulated by the basal ganglia and noradrenergic 
nuclei to control motor pattern generation and arousal, respectively. The locus 
coeruleus and NTS are particularly important noradrenergic nuclei located in the 
brain stem and modulate the stress response, arousal and interface with the 
mesocorticolimbic system to modulate behaviour and motor control.  
 
Table 1.2 Noradrenaline receptor and transporter (NAT) distribution in 7 areas of the rat brain 
(Nicholas et al., 1996; Schroeter et al., 2000). Indicated levels of expression are relative within 
receptor and transporter groups. +++ indicates very high, ++ indicates high, + indicates significant and 
– indicates not detected. *Unfortunately, the understanding of human adrenoceptor distribution within 
human brain is not as well categorised as dopamine receptors. While interspecies variation of 
receptor and transporter expression is noteworthy, the afferent targets are very similar and the 
comparison is suitable as a general reference.  
  α1b α1d α2a α2b α2c β1 β2 NAT 
Cortex +++ ++ ++ - ++ ++ ++ + 
Hippocampus - +++ + - +++ + + ++ 
Striatum + - - - +++ - - + 
Hypothalamus + - ++ - + - + ++ 
Thalamus +++ + + + + + + ++ 
Locus Coeruleus - - +++ - - - - +++ 
Nucleus Tractus Solitarius - - ++ - - - - ++ 
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The control of synthesis and release of catecholamines are determined by cell 
signalling mechanisms that can also be triggered by the catecholamines themselves 
as inhibitory feedback. TH and AAAD activity is regulated by the number of units 
expressed in a cell and the activity of each unit. TH activity is increased through the 
transfer of phosphate groups (phosphorylation) by protein kinase A, protein kinase C 
and calmodulin-dependent protein kinase II. Protein kinase A and protein kinase C 
are in turn regulated by cAMP and cytosolic calcium levels (Nestler et al., 2008). 
AAAD is also activated by cAMP (Duchemin et al., 2000). Removal of phosphate 
groups (dephosphorylation) of TH by protein phosphatase 2A decreases activity. 
Neurotransmitter synthesis and release in dopaminergic and noradrenergic neurons 
can thus be regulated via D2-like and α2 receptors, respectively (see figure 1.3).  
 
Figure 1.3 Simplified overview of a few key differences between G-protein receptor signalling. Gq 
receptors represent α adrenergic receptors while Gs/olf receptors represent D1 dopamine receptors 
and β adrenoceptors. Gi/o receptors represent D2 and α2 adrenoceptors. Red pluses and minuses 
indicate activation and deactivation respectively. Pathways shown where substantial literature 
supports; Lack of pathways and “?” indicate lack of uniformity in the research. PLC = Phospholipase 
C; DAG = Diacylglycerol; IP3 = inositol triphosphate; AC = Adenylyl Cyclase; cAMP = Cyclic 
adenosine monophosphate; PKA = Protein kinase A; PKC = Protein Kinase C; CaM-KII = 
Ca2+/calmodulin-dependent protein kinases II. DARPP-32 = dopamine and cAMP-related 
phosphoprotein of 32 kiloDaltons; PP1 = Protein phosphatase 1. 
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D1- and D2-like receptors increase and decrease cytosolic calcium levels, 
respectively, which contributes to the modulation of signalling cascades and cell 
metabolism, but also directly affects membrane excitability. Increased cytosolic 
calcium concentrations increases the rapidity with which the membrane may 
repolarise and decreases the refractory period before another action potential may 
be triggered (see figure 1.4).   
 
Figure 1.4 Schematic of an action potential. 
 
In a given neural circuit, catecholamines may increase or decrease activity. As an 
example, excitatory neurotransmission could be increased via D1-like receptors in a 
glutamatergic neuron or D2-like receptors in a GABAergic neuron to decrease 
inhibitory neurotransmission. Conversely, dopamine can decrease excitatory 
neurotransmission in a given circuit by acting at D2-like receptors in glutamatergic 
neurons, or at D1-like receptors at GABAergic neurons (See figure 1.5). Of course, 
this is a gross simplification, but demonstrates the way in which catecholamines can 
modulate neurotransmission differently, dependent on the target receptors and the 
neurons on which they are expressed. An example of this can be found in the 
striatum, the target of the most dopaminergic afferents in the brain. In the striatum 
D1 receptors increase medium-spiny neuron reactivity to glutamatergic signalling 
while D2 decrease medium-spiny neuron reactivity to glutamate (Surmeier et al., 
2007).  
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Figure 1.5 A simplified circuit to depict different ways dopamine signalling can influence a circuit. 
Red represents inhibitory signalling and green represents excitatory signalling. The circuit on the left 
depicts how inhibition of a GABAergic neuron via stimulation of D2-like receptors leads to the 
disinhibition of the top left dopaminergic neuron and excitation of the glutamatergic neuron. The circuit 
on the right depicts how excitation of a GABAergic neuron via D1-like receptors inhibits the top left 
dopaminergic neuron and leads to disinhibition of the glutamatergic neuron. 
 
Catecholamines can also elicit biphasic responses via concentration-dependent 
activation of a combination of inhibitory and stimulatory receptors, which are 
differentially activated due to their expression and their varying affinities for their 
respective neurotransmitter. For example, Tuberoinfundibular dopaminergic (TIDA) 
neurons in the hypothalamus exert a biphasic control of prolactin secretion from the 
pituitary via changes in tonic vs. phasic firing modes. Prolactin feedback at the TIDA 
neurons shifts firing to phasic to increase dopaminergic inhibition of prolactin 
secretion (Lyons et al., 2012), while thyrotropin-stimulating hormone shifts TIDA 
neurons to tonic firing, and potentiates the prolactin response (Lyons et al., 2010). In 
the PFC both dopamine and noradrenaline exhibit an inverted-U effect on cognitive 
function (Arnsten, 2007). Concentration-dependent effects are sometimes dependent 
on the distance from the site of release at which receptors are expressed, which in 
some cases can be relatively large. In these circumstances monoamines act in a 
paracrine or extrasynaptic manner to enable volume transmission, a process 
regulated by release and controlled by reuptake by their respective transporters 
(Fuxe et al., 2010a).Dopamine receptors and transporters are primarily expressed 
extrasynaptically, (Missale et al., 1998), as are noradrenaline receptors and 
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transporters (Schroeter et al., 2000). Because diffusion occurs much faster than 
reuptake, release largely overwhelms uptake and the combination of tonic and 
phasic release determine baseline extracellular neurotransmitter levels (Rice & 
Cragg, 2008). 
 
1.7 - Tonic and Phasic Signalling 
Tonic and phasic signalling are differentiated by the number of action potentials 
within a given period of time. Tonic signalling is characterised by sustained frequent 
action potentials, which maintain background levels of neurotransmitter, while phasic 
signalling is a transient bursting of action potentials in quick succession (see figure 
1.6), which are usually coupled with salient stimuli such as aversive or rewarding 
cues.  
 
Figure 1.6 Train of action potentials in tonic (A) and phasic (B) firing. 
 
These yield comparatively small and large neurotransmitter quantal release, 
respectively. In the striatum, ventral and dorsal baseline dopamine levels are 
modulated by tonic activity from the VTA and substantia nigra pars compacta, 
respectively, and the ventral striatum is particularly sensitive to changes in tonic 
firing from the VTA due to a greater range in extracellular dopamine concentrations 
(Zhang et al., 2009). Supporting this, recent evidence suggests that in the NAc, 
located in the ventral striatum, dopamine reuptake inhibition increased tonic 
stimulation of low-affinity post-synaptic receptors and results in desensitisation to 
phasic dopamine signals (Dreyer & Hounsgaard, 2013). Low levels of baseline 
dopamine levels in the NAc shell are associated with decreased motivation and 
exertion of effort for food, whilst reward-seeking remains intact in rats (Salamone et 
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al., 2003). Tonic dopamine signals in the NAc modulate baseline extracellular 
dopamine and set an ‘average reward’ of current behaviour, which then determines 
the likelihood to exert effort and vigorous responding to reward cues (Niv et al., 
2007). As a result, this relationship between tonic and phasic dopamine signals in 
the NAc affects behaviour (see figure 1.7). In the cerebral cortex, tonic noradrenaline 
acts to modulate the level of arousal, while phasic noradrenaline acts to entrain 
cortical cross-talk toward a specific stimulus (Aston-Jones & Cohen, 2005). 
DAT/NAT blockade mimics enhanced tonic signalling because the tonic stimulation 
of receptors is determined by baseline concentrations, which become enhanced by 
reuptake inhibition, increasing the accumulation of extrasynaptic catecholamines 
from both phasic and tonic release.  
 
Figure 1.7 An example of the relationship between tonic and phasic firing in the NAc. A represents 
a normal balance between tonic and phasic dopamine, whereas B represents a decreased tonic 
dopamine resulting in exaggerated phasic dopamine signalling, which is characterised by impulsive 
behaviour. C represents excessive tonic dopamine, which masks phasic dopamine spikes and is 
observed in pain and stress syndromes (Leknes & Tracey, 2008). 
 
DAT is most heavily expressed in the midbrain and basal ganglia (Hall et al., 1999). 
Here it acts to modulate dopaminergic volume transmission and extrasynaptic 
signalling, which the results from extracellular concentrations of dopamine spill-over 
to extrasynaptic receptors when concentrations are elevated beyond the capacity for 
DAT during phasic signalling (Fuxe et al., 2010). In the midbrain and basal ganglia, 
tonic signalling delivers smaller, but more constant, dopamine release than phasic 
signalling and preferentially activates D2 receptors, which have a higher affinity for 
dopamine than D1 receptors, which only become activated by large phasic 
dopamine releases. This appears to be particularly important in the ventral striatum, 
where a broad range of firing frequencies is present, unlike the dorsal striatum where 
dopamine release is not linearly dependent on firing activity (Rice & Cragg, 2008). 
The dorsolateral striatum, which receives dopaminergic projections from the 
substantia nigra pars compacta, has a lower phasic-to-tonic ratio than VTA 
22 
 
innervated areas. This includes the ventral striatum, PFC and amygdala where the 
contrast between the tonic and phasic dopamine signals modulates attention and 
behavioural selection (Zhang et al., 2009). Human NAT is most heavily expressed in 
the brainstem, (particularly at the locus coeruleus), the thalamus and cortex (Schou 
et al., 2005; Takano et al., 2008). NAT in the locus coeruleus has been considered a 
key target for the treatment of depression (Klimek et al., 1997), while in the cortex it 
is implicated in attention deficit hyperactivity disorder (ADHD)(Pliszka, 2005). 
Attention and behavioural control are also modulated by tonic and phasic 
noradrenaline signals from the locus coeruleus to the cerebral cortex (Aston-Jones & 
Cohen, 2005). Together, the dopaminergic signals from the VTA and the 
noradrenergic signals from the locus coeruleus coordinate to control all motivated 
behaviour and learning (Puglisi-Allegra & Ventura, 2012). These systems are directly 
modulated by bupropion and methylphenidate, which have had relatively consistent 
results in improving exercise performance in warm conditions as described in section 
1.9. Furthermore, these systems directly control the behavioural response to stress. 
Therefore, the performance enhancing effects of these drugs may be due to 
alterations to the stress response within the CNS. 
 
1.8 - Central Catecholamine Precursors and Prolonged Exercise 
Attempts to manipulate central fatigue using precursors for catecholamine synthesis 
have been conflicting. Several studies during prolonged military operational drills 
found that supplementation with tyrosine reduced fatigue and stress while improving 
cognitive and motor performance in soldiers (Salter, 1989; Owasoyo et al., 1992; 
Smith et al., 2003). However, several laboratory exercise studies in humans have 
found no effect of tyrosine supplementation (Strüder et al., 1998; Chinevere et al., 
2002). The apparent disparity in effectiveness might be explained by the type of 
stress endured by soldiers was more prolonged and is perhaps incomparable to that 
experienced in laboratory studies due to differences in motivation and psychological 
stress. L-DOPA is one metabolic step closer to dopamine than tyrosine (see figure 
1.1). L-DOPA has been used to treat motor control disorders in Parkinson’s disease 
for over 40 years and is considered the “gold standard” treatment today (Nagatsu & 
Sawada, 2009). Clinically, L-DOPA is administered with an amino acid 
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decarboxylase (AADC) inhibitor that cannot readily cross the blood-brain barrier; this 
prevents decarboxylation of L-DOPA in the periphery, thereby reducing associated 
gastrointestinal distress and increasing the available L-DOPA to the brain. Tyrosine 
is not an effective treatment for Parkinson’s disease because a symptom of the 
disease is the significantly decreased expression of tyrosine hydroxylase in 
dopaminergic neurons (Javoy-Agid et al., 1990). Only one study to date has 
investigated the effects of L-DOPA administration in healthy participants on exercise 
performance and found no difference in time to exhaustion compared to placebo 
(Meeusen et al., 1997a). The lack of effect observed in the exercise studies above 
may also have been due to having been conducted in normal ambient temperatures. 
A recent study was conducted to examine whether warm conditions might provide a 
better environment to test this relationship and found that acute tyrosine 
administration before exercise did enhance performance (Tumilty et al., 2011). 
However, a follow-up study using the same conditions found no effect on 
performance (Watson et al., 2012).  
 
Catecholamine metabolism is also dependent on methyl-group donors and the one-
carbon cycle. As the primary methyl donor in human physiology, SAM plays a vast 
number of important roles in the body. SAM is directly involved in homoycsteine 
metabolism, the synthesis of creatine, metabolism of several neurotransmitters and 
the regulation of DNA, RNA. SAM is synthesised by the addition of ATP to 
methionine by SAM synthetase. The transfer of the methyl group yields s-
adenosylhomocysteine. S-adenosylhomocysteine hydrolase then removes 
adenosine from homocysteine (see figure 1.8 below). Chronically elevated 
homocysteine levels are associated with folate and B12 deficiencies as well as a 
number of disorders, including depression (Bottiglieri, 2005). SAM has been used to 
treat depression for over 60 years (Papakostas et al., 2003), osteoarthritis (Soeken 
et al., 2002) and is considered potentially useful for liver disorders (Purohit et al., 
2007). Via the transulfuration pathway SAM is involved in the synthesis of 
glutathione (Lu & Mato, 2008) and may effect on synthesis of glutamate and GABA 
as well. SAM is tightly co-dependent with folate and choline metabolism (Bottiglieri, 
2002; Zeisel & Blusztajn, 1994). These are necessary for synthesis of acetylcholine, 
betaine and cell membranes (Zeisel & Blusztajn, 1994). Folate contributes to methyl-
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group metabolism via methyltetrahydrofolate (MTHF), which can regenerate 
methionine via methylation of homocysteine and can therefore contribute to SAM 
synthesis. MTHF is also necessary for tetrahydrobiopterin synthesis, a cofactor for 
synthesis of nitric oxide, serotonin, dopamine and noradrenaline (Bottiglieri et al., 
1992; Stahl, 2007). It is thought to be through this pathway that SAM has been 
shown to improve mood (Fernstrom, 2000). Supporting this, folate deficiency is 
common in depression and has been associated with decreased cerebrospinal fluid 
SAM concentrations (Bottiglieri, 2002). The relationship of SAM to central 
catecholamine metabolism has also been characterised by the effects of L-DOPA 
treatment on SAM concentrations. In rats, brain SAM concentration decreases in 
response to L-DOPA infusions (Chalmers et al., 1971). In humans, L-DOPA 
treatment decreases cerebrospinal fluid SAM concentrations (Surtees & Hyland, 
1990). Similarly, patients receiving L-DOPA treatment for Parkinson’s disease, 
showed a decrease in plasma methionine and SAM, while homocysteine was 
elevated (Müller et al., 2001).  
 
While the effect of SAM supplementation on exercise has not been investigated, 
there have been a few exercise studies investigating related compounds such as 
homocysteine, choline, choline-containing phospholipids and betaine. In recreational 
athletes prolonged exercise has been found to increase blood homocysteine and 
decrease folate and B12 (Herrmann et al., 2003). In addition to increased plasma 
homocysteine, prolonged exercise decreases plasma choline levels. Following the 
Boston marathon have been found to be significantly lower than before the race in 
two studies by the same group (Conlay et al., 1986, 1992). Buchman, Jenden, & 
Roch (1999) investigated plasma free and phospholipid bound choline before, 
immediately after, and 2 days after a marathon in 23 experienced male and female 
marathon runners and found a significant decrease in both free and phospholipid 
bound choline immediately after the race and persisting decreased plasma 
phospholipid bound choline levels 2 days following the race.  
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Figure 1.8 A simplified metabolic map of various roles of SAM important to CNS function. 
NO=Nitric Oxide; BH4 = tetrahydrobiopterin; BH2 = Dihydrobiopterin; Tryp = Tryptophan; Tyr = 
Tyrosine; Adr= Adrenaline; THF = Tetrahydrofolate; 5-MTHF = 5-methyltetrahydrofolate; GSH = 
Glutathione; αKG = alpha-ketoglutarate; SAH = S-adenosylhomocysteine; Ach = Acetylcholine; 
GABA = gamma-aminobutyric acid; PtdEth = Phosphatidylethanolamine; PtdCh = 
Phosphatidylcholine; FFA = Free fatty acids; LysoPtdCh = Lysophosphatidylcholine; GPCh = 
Glycerophosphocholine; PhCh = Phosphocholine; CDP-Ch = Citydine diphosphate-choline 
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Phosphatidylethanolamine N-methyltransferase accepts the methyl- group from SAM 
and converts phosphatidylethanolamine to phosphatidylcholine. Membrane 
phosphatidylcholine is important for membrane physical properties and provides the 
bulk of cell choline stores (Li & Vance, 2008). Cell membrane phosphatidylcholine 
synthesis appears to also be regulated by mechanical strain in cell membranes. 
Cytidine 5’-triphosphate: phosphocholine cytidylyltransferase (CCT) activity is 
modulated by membrane curvature elastic strain (Attard et al., 2000). This occurs 
because CCT is translocated into the membrane to alleviate the elastic curvature 
strain, and this simultaneously activates CCT and thus increases its activity and 
production of phosphatidylcholine. This suggests that physical membrane strain 
during exercise may result in methylation of phosphatidylethanolamine to form 
phosphatidylcholine. Mechanical changes in cell membranes during exercise due to 
during muscle contraction and changes in osmotic pressure may induce increased 
muscle turnover of phosphatidylcholine. Two studies found that supplementation of 
lecithin, which is a mixture of phospholipids including phosphatidylcholine, was able 
to prevent the decline in plasma choline concentrations during prolonged exercise 
(von Allworden et al., 2000;Buchman et al., 2000). However, Jäger and co-workers 
(Jäger et al., 2007) point out in their review of phospholipid supplementation that 
these results should be regarded with caution as there can be great variability in 
marathon times due to variations in courses and environmental conditions. It should 
also be considered that these studies used acute dosing protocols, and because 
plasma choline is extensively metabolised for a number of different processes in 
almost every type of tissue, it is difficult to say what physiological effects it may 
produce, especially over such a small period of time. 
 
The ratio of membrane phospholipid methylation is also important to structural 
function and other methyl-group dependent reactions. This is demonstrated clearly in 
the liver, where deficiencies of phosphatidylcholine to phosphatidylethanolamine 
negatively affect folate and homocysteine metabolism (Zeisel & Blusztajn, 1994), 
supporting the notion that the increased plasma homocysteine and decreased 
plasma choline after prolonged exercise are correlated. Insufficient membrane 
phospholipid methylation disrupts lipid metabolism and lipoprotein export, as can be 
seen in both alcoholic and non-alcoholic steatohepatitis (Li & Vance, 2008). 
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Membrane integrity and fluidity are especially important for neuronal function and 
determine the function of membrane-bound proteins such as receptors and ion 
channels (Lenaz, 1987). This modulation of neuronal membrane fluidity by SAM has 
been observed in old rats, returning membrane fluidity and β-adrenoceptor 
expression in the striatum to juvenile values (Cimino et al., 1984). In human brains 
afflicted by Alzheimer’s, phosphatidylethanolamine  N-methyltransferase activity is 
depressed as well as total phosphatidylcholine in the frontal cortex (Guan et al., 
1999) and cerebrospinal fluid SAM concentrations are low (Bottiglieri et al., 1990; 
Linnebank et al., 2010). Membrane phosphatidylcholine is an important pool for 
acetylcholine synthesis. This is supported by evidence by Párducz, Kiss, and Joó 
(1976) who found that cholinergic sympathetic ganglion neurons lost significant 
membrane phosphatidylcholine in the presence of the choline uptake inhibitor 
hemicholinium during stimulation. Further supporting the connection between folate, 
choline, lipid metabolism, central acetylcholine, SAM and Alzheimer’s, two studies in 
mice have demonstrated the ability of SAM to restore acetylcholine function in folate 
deficient mice (Serra et al., 2008; Chan et al., 2008b). Due to this multifaceted 
relationship to cellular function and acetylcholine, SAM is being investigated as a 
treatment for Alzheimer’s (Chan et al., 2008a).  
 
In addition to roles of methyl group donors in neurotransmission, cell signalling and 
metabolism during exercise, they also have a volemic role. Betaine is formed by 
dehydrogenation of choline, and acts as a methyl-donor and osmolyte. Craig and co-
workers (2010) found that the betaine content of sweat in adolescent girls was 
almost 7 fold greater than in plasma, while choline was 7 fold greater in plasma than 
in sweat. This may explain the volemic, oxygen consumption and thermal strain 
differences observed in a study testing the effects of betaine supplementation on 
exercise performance during running in warm conditions (Armstrong et al., 2008). 
Even at doses of 100mg/kg body weight used by Schwahn and co-workers (2003), 
betaine was still found to be eliminated by metabolism rather than excretion, again 
indicating the importance of consideration for the metabolic versatility of these 
associated compounds when testing their effects on physiology. Central cholinergic 
function modulates motor learning and motor control, reward and motivation (Woolf 
& Butcher, 2011). Central cholinergic tone also influences proopiomelanocortin 
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derived hormones (Meister et al., 2006), and growth hormone (De Marinis et al., 
1997; de Vries et al., 2002). However, the efficacy of SAM in the treatment of 
depression and schizophrenia are attributed to the role SAM plays in catecholamine 
metabolism, as the connection between catecholamines and these disorders is well 
established. The decrease in plasma choline, loss of betaine through sweat and 
increase in homocysteine observed during prolonged exercise, may reflect a 
decreased pool of methyl-group donors. Depending on the magnitude of the effect, 
nutritional status and genetics of an individual, this detriment to methyl group 
metabolism could have significant ramifications for exercise performance. While 
choline and betaine represent a significant pool of methyl-group donors, only SAM is 
recognised for clinical effects on various central nervous disorders. The most 
significant of these effects appear to be mediated by catecholamine metabolism. 
This provides a possible link between decreases in methyl-group donors during 
prolonged exercise, which may subsequently affect catecholamine metabolism via 
SAM-dependent reactions. SAM supplementation may therefore attenuate these 
changes, or increase catecholamine synthesis and influence prolonged exercise 
performance. 
 
1.9 - Catecholamine Reuptake Inhibitors 
Pharmacological manipulations of central catecholamines with reuptake inhibitors 
have provided the most consistent changes to exercise performance, particularly in 
warm conditions. Piacentini and co-workers (2004) found no effect of bupropion, a 
combined dopamine/noradrenaline reuptake inhibitor on exercise performance in 
temperate conditions. In the studies by Watson or Roeland and co-workers (2005a; 
2008, respectively) neither bupropion nor methylphenidate (also a combined 
dopamine/noradrenaline reuptake inhibitor) enhanced time trial performance in 
temperate conditions, respectively, but did in warm conditions. However, in the study 
by Swart and co-workers (2009), an even smaller dose of methylphenidate (20mg 
vs. 8mg) improved duration and power-output during cycling exercise to exhaustion 
at a fixed RPE. Amphetamine has also been found to increase time to fatigue in 
humans in temperate conditions (Chandler & Blair, 1980). The apparent difference 
between these studies on exercise performance may be due to the influence of 
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pacing strategies in the time trial studies (Baron et al., 2011). A recent study found 
no effect for methylphenidate, but found a detrimental effect of reboxetine, a potent 
and selective noradrenaline reuptake inhibitor, on time trial, motor evoked potential 
and a psychomotor vigilance task (Klass et al., 2012). An earlier study using 
reboxetine in temperate conditions found no difference in time trial performance 
(Piacentini et al., 2002), while a study in both warm and temperate conditions found 
a negative effect in both conditions (Roelands et al., 2008a). The relative potencies 
and effects of these drugs will be described and discussed below. Thus far, three 
selective catecholamine reuptake inhibitors have been used in studies investigating 
prolonged exercise in warm conditions: bupropion, methylphenidate and reboxetine 
(Roelands & Meeusen, 2010). Many CNS stimulants originally thought to impart their 
effects primarily via dopamine have been found to have significant effects on 
noradrenaline. This includes those that have been found to benefit exercise 
performance in humans, including amphetamine (Brauer & De Wit, 1997; Rothman 
et al., 2001; Wachtel et al., 2002), bupropion (Dwoskin et al., 2006) and 
methylphenidate (Challman, T.D., and Lipsky, 2000). A recent PET imaging study in 
humans showed the effective dose to occupy 50% (ED 50) of NAT in the thalamus 
by methylphenidate (0.14mg/kg) is less than the ED 50 of methylphenidate for DAT 
in the striatum (0.25mg/kg)(Hannestad et al., 2010). The ED 50 value for DAT in this 
study was similar to that in previous research (Volkow, Wang, Fowler, & Ding, 2005). 
Unfortunately, there is a disparate lack of in-vivo verification for occupancy of the 
NAT in humans. This has been due to difficulties synthesising appropriately selective 
radioligands, however, recent developments with reboxetine analogues, such as 
(S,S)-[11C]methylreboxetine, promise to further elucidate the role of NAT in 
neuropharmacology (Kiyono et al., 2008). 
 
While the bupropion and methylphenidate have been demonstrated to improve 
exercise performance, reboxetine administration has produced negative effects, 
leading the authors to conclude that noradrenaline negatively influences exercise 
(Roelands et al., 2008a; Klass et al., 2012). While in those studies this effect is 
attributed to central effects of the drug, it deserves some mention that reboxetine has 
significant peripheral activity, which complicates the matter of qualifying the central 
effects. Boschmann and co-workers (2002) conducted a study of the effects of 
30 
 
reboxetine in combination with isoproterenol, a β-adrenergic agonist with negligible 
ability to cross the blood-brain barrier, to investigate the involvement of NAT in 
autonomic control of metabolism. This study found that reboxetine augmented 
responses to isoproterenol for heart rate, systolic blood pressure, serum glucose (in 
male participants), glycerol, and free fatty acids. Reboxetine also increased the 
respiratory quotient in favour of glucose over fat oxidation and interfered with 
adipocyte metabolism clearly demonstrating a peripheral effect of the potent NAT 
blockade by reboxetine. Another study found in healthy normal volunteers an acute 
dose of reboxetine induced a physiological state comparable to orthostatic 
intolerance which is characterised by symptoms of light-headedness, fatigue, 
nausea, orthostatic tachycardia and exercise intolerance (Schroeder et al., 2002). 
While in both papers it is acknowledged that reboxetine’s physiological effects are 
likely to arise from both the peripheral and central nervous systems, it is of 
considerable importance to recognise that effects in either of these systems have 
tremendous potential for impact on exercise performance. Indeed, the resting 
tachycardia observed by Piacentini et al., (2002) (cited as not significant, but ~14% 
higher in reboxetine than placebo), Boschmann et al., (2002), Schroeder et al., 
(2002) and Roelands et al., (2008) may be explained by decreased noradrenaline 
clearance by NAT in the heart, which is more dependent on NAT than any other 
tissue for noradrenaline clearance (Esler et al. 1990; Goldstein, et al. 1988). The 
peripheral effects of reboxetine may also result in sympathetic feedback inhibition. 
Further to this, a recent review and meta-analysis of reboxetine for use in acute 
treatment of major depression found no greater therapeutic effect compared to a 
placebo and higher rates of both adverse events and patient withdrawals due to 
adverse events (Eyding et al., 2010). Therefore, the results of studies using 
reboxetine should be considered carefully before drawing conclusions about the role 
of noradrenaline.  
 
The primary mode of action for bupropion has been considered to be via DAT 
blockade due to findings from in-vitro studies and studies in rats. However, in-vitro 
studies remove the element of bupropion metabolism, which occurs in the liver, and 
rats do not metabolise bupropion the same way that humans (mice, guinea pigs and 
dogs) do. Humans rapidly and extensively metabolise bupropion, predominantly to 
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the metabolites hydroxybuproprion and threohydrobuproprion (Bondarev et al., 
2003). In humans, bupropion metabolites accumulate at levels 10-100 times greater 
in plasma (Damaj et al., 2004) and 6 times greater concentration and cerebrospinal 
fluid respectively than bupropion (Cooper et al., 1994). Furthermore, it has been 
found in guinea pigs, which have the most similar pharmacokinetic profile for 
bupropion to humans in rodent models (Suckow et al., 1986), that bupropion 
metabolites accumulate in brain tissue more than bupropion (DeVane, Laizure, & 
Cameron, 1986) in a linear relationship to the observed plasma ratios. Additionally, a 
study using rats found that bupropion only increased extracellular dopamine 
concentrations in the NAc using doses that were significantly higher than are used in 
clinical doses (25mg/kg)(Nomikos et al., 1992). There is considerable evidence that 
the differential effects of bupropion metabolites contribute significantly to its action.  
 
Several human studies using acute doses of bupropion have found the area under 
the curve (AUC) for hydroxybupropion and threohydrobuproprion in ranges roughly 
4-36 times greater than bupropion, with hydroxy-metabolites obtaining the maximum 
plasma concentration (Cmax) and AUC values, while hydro-metabolites had the 
longest elimination half-life values (Stewart et al., 2001; Turpeinen et al., 2007; 
Kharasch et al., 2008). Similarly, in-vitro binding tests have found that bupropion and 
hydroxybupropion are equally bound by plasma proteins, while threohydrobuproprion 
is bound 5 times less. hydroxybupropion can exist as two pairs of enantiomers (4 
diastereomers) but in human plasma, only the enantiomers (2S,3S)- and (2R,3R)-
hydroxybupropion are found, respectively identified as (+) and (-) by their optical 
rotation (Suckow, Zhang, & Cooper, 1997). The (+)-hydroxybupropion isomer more 
potently inhibits NAT than DAT in vitro (Damaj et al., 2004), while (-)-
hydroxybupropion had no significant effect on either. Kharasch et al., (2008) found 
roughly 95% Cmax of hydroxybupropion in humans as (-)-hydroxybupropion leaving 
the more active (+)-hydroxybupropion in quantities over 10 times less than 
bupropion. In the same study (+)-hydroxybupropion contributed only 2% to the AUC 
for overall hydroxybupropion due to the significantly shorter elimination half-life. 
Because (-)-hydroxybupropion and (+)-threohydrobuproprion are found in the highest 
concentrations in humans, it seems reasonable to conclude that the majority of the 
effects are contributed by these metabolites. This may explain the comparatively 
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weak reuptake inhibition observed in human imaging studies. Recently, Egerton and 
co-workers(2010) found that after a single clinical dose (150mg sustained release 
formula) there was no observable change in striatal extracellular dopamine 
concentrations in normal healthy volunteers as measured by [11C]raclopride positron 
emission tomography. Other studies have similarly found that DAT occupancy by 
bupropion does not correlate with therapeutic efficacy (Argyelán et al., 2005). 
Therefore, the contribution of noradrenaline reuptake inhibition to bupropion’s 
therapeutic effect at clinical doses appears to more significant than originally 
thought. Because amphetamine, bupropion and methylphenidate all inhibit 
noradrenaline and dopamine reuptake, the function and roles of both catecholamines 
should be considered with respect to exercise and stress. 
 
1.10 - Measuring Central Catecholaminergic Activation via Pituitary 
Hormones 
While the application of microdialysis techniques has enabled measurement of 
neurotransmitter release during exercise in rodents, the measurement of changes in 
central neurotransmission is fairly limited in human exercise studies. Modern imaging 
techniques are often not suitable due to expense, access to experienced operators 
and logistical problems with performing exercise in or close to the equipment. 
However, it is possible to measure changes in central catecholaminergic activity 
indirectly via changes in circulating pituitary hormones. Although a large number of 
neurotransmitters and hormones affect pituitary hormone secretion, the effects of 
monoamines on the secretion of adrenocorticotropic hormone (ACTH), growth 
hormone (GH) and prolactin  have been well characterised. Prolactin secretion is 
inhibited by high concentrations of dopamine, which is released by 
tuberoinfundibular neurons at the pituitary as an inhibitory feedback mechanism in 
response to circulating prolactin. Noradrenaline weakly increases prolactin secretion 
by inhibiting tuberoinfundibular dopamine release (Freeman et al., 2000). While It is 
well established that dopamine stimulates GH secretion, noradrenaline has opposing 
actions at α and β adrenoceptors on GH secretion, but it is generally accepted that 
endogenous noradrenaline increases GH secretion (Müller et al., 1999). An 
important mediator of the hypothalamic-pituitary-adrenal (HPA) stress response is 
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corticotropin-releasing factor (CRF). Noradrenaline stimulates CRF release from 
projections of the paraventricular nucleus of the hypothalamus (PVN) to the 
hypothalamo-hypophyseal portal system, which stimulates the secretion of ACTH 
into the blood stream. Circulating ACTH then acts at the adrenal glands to increase 
circulating cortisol (Tsigos & Chrousos, 2002). 
 
Monitoring the hormonal response of individuals to nutritional and pharmacological 
interventions or stressors has become an important tool in both a clinical setting and 
in exercise physiology to provide information regarding alterations in central 
neurotransmission, or the individual variability and sensitivity to such changes. 
Although the regulation of pituitary hormone secretion is complex and modulated by 
a number of other neurotransmitters and hormones, changes in circulating 
concentrations can be a useful guide. Nonetheless, caution must be exercised when 
interpreting the results as complex interactions between factors which increase and 
factors which decrease secretion of these hormones may conflate the significance of 
a given hormonal response. This is particularly true during stress, when peripheral 
and central physiological changes, as well as psychological changes can all 
contribute to the regulation of their secretion (described below).  
 
1.11 - Central Stress Signalling During Prolonged Exercise  
A great deal of emphasis has been given to central dopamine in central fatigue and 
the role of dopaminergic neurons in motor control and motivation, while 
comparatively little attention has been given to the role of noradrenaline. This is in 
spite of being directly involved in many of the same processes as well as being a 
critical component of the stress response. Of the noradrenergic nuclei, the locus 
coeruleus has received the most attention due to its aberrant activity in depression 
(Nestler et al., 1999) and possibly attention deficit hyperactive disorder (Pliszka, 
2005; Del Campo et al., 2011). Many drug treatments for these disorders, such as 
anti-depressants, modulate locus coeruleus activity (West et al., 2009) including 
bupropion (Cooper et al., 1994) and methylphenidate (Devilbiss & Berridge, 2006; 
Ishimatsu et al., 2011). The locus coeruleus is well known for its role in the 
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attention/arousal system, involved in waking from sleep and promoting alertness or 
mediating the fight/flight stress response. Recent evidence has demonstrated a more 
complex role for the locus coeruleus in behavioural flexibility and implicate its 
dysfunction in a broad range of behavioural disorders (Devilbiss & Berridge, 2006). 
The evidence suggests that both insufficient and excessive noradrenaline activity 
may result in psychomotor, cognitive, attention-arousal dysfunction, as well as 
depression, anxiety disorders and ADHD (Aston-Jones et al., 1999; Nieuwenhuis et 
al., 2005; Aston-Jones & Cohen, 2005; Aston-jones et al., 2007). 
 
Whether the predominant stressor during prolonged exercise in a warm environment 
is core temperature, cardiovascular strain or both, the stress systems recruited in the 
CNS which dictate the behavioural response are the same. These systems are 
heavily dependent upon central catecholamine function in both their bottom-up 
signalling of the stress event and the top-down control of the behavioural response. 
The signalling of peripheral stress within the CNS is determined by two key areas of 
the brain: the hypothalamus and the brain stem (Joëls & Baram, 2009). The 
hypothalamus and noradrenergic nuclei of the brainstem are interconnected and 
coordinate the activation of the stress system. Two of these nuclei are especially 
suited to coordinate the stress response. The A2 nucleus of the nucleus tractus 
solitarius receives ascending afferents via the spinal cord, while the locus coeruleus 
does not; however, both are heavily interconnected throughout the brain and spinal 
cord. They are instrumental in providing the sympathetic activation required for 
exercise, both directly via spinal pathways and indirectly via the HPA axis. As 
described in section 1.10, noradrenaline stimulates CRF release from the PVN, 
resulting in activation of the HPA axis and increases in circulating ACTH and cortisol. 
Circulating cortisol acts in a negative feedback loop to decrease CRF and ACTH 
secretion from the PVN and hypothalamo-hypophyseal portal, respectively (Tsigos & 
Chrousos, 2002). However, the HPA feedback loop can be overridden by 
noradrenergic afferents from the locus coeruleus and A2 at the PVN, increasing CRF 
secretion and HPA activity during acute stress (Ziegler et al., 1999).  
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In both the A2 (Glass et al., 2001) and the locus coeruleus (Nestler et al., 1999) α2 
autoreceptors provide negative feedback to noradrenaline release, however, this 
regulatory mechanism may become overridden during acute stress. The afferents 
from the A2 also increase CRF signalling within the CNS via projections from the 
hypothalamus  and amygdala (Johnson et al., 2011). Both the hypothalamus and 
amygdala send CRF afferents to the locus coeruleus, which forms a feedforward 
system for the activation of the stress response (Koob, 1999; Gold & Chrousos, 
2002). Psychological stress has been found to increase CRF mRNA in the central 
nucleus of the amygdala, but not in the PVN (Makino et al., 1999). This suggests that 
psychological stress can act independently or concert with physiological strain to 
activate or enhance the stress response via these amygdalar afferents (see figure 
1.9).  
 
Figure 1.9 CRF projections in the brain displayed as red arrows.  
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During prolonged exercise CRF, ACTH and arginine vasopressin  have been found 
to increase in a linear time-dependent fashion in male athletes (Inder et al., 2012). 
Both ACTH and arginine vasopressin also increases locus coeruleus neuronal 
activity in a dose-dependent manner (Olpe et al., 1987). Thermal strain also 
increases locus coeruleus neuronal activity (Morilak et al., 1987) and activation of 
locus coeruleus by hemodynamic strain appears to be due to local release of CRF 
(Valentino et al., 1991). Arginine vasopressin secretion is also enhanced by 
hyperosmolality, heat/hyperthermia and hypovolemia (Takamata et al., 1995). 
Consequently, there may be an additive stimulatory effect on locus coeruleus activity 
during prolonged exercise in the heat, which increases as core temperature and 
blood osmolality increase while blood pressure decreases. Similarly, circulating 
adrenaline is increased during prolonged exercise in warm environments (Febbraio, 
2001), which can stimulate the A2 via ascending sympathetic afferent feedback 
(Rinaman, 2011). Collectively, this provides a link between the thermoregulatory 
strain, the resulting demands on the cardiovascular system described by Cheuvront 
and co-workers (Cheuvront et al., 2010) and the catecholaminergic neural circuits 
within the CNS, which modulate the behavioural response.  
 
The mesocorticolimbic circuit is where dopamine and noradrenaline interact to 
coordinate the behavioural stress response. The locus coeruleus projects the 
cerebellum, thalamus, hippocampus, and cerebral cortex, while the A2 projects to 
the locus coeruleus, amygdala and NAc and both nuclei project to the hypothalamus 
(Rinaman, 2011). Therefore, the A2 more directly controls emotion and affect during 
stress, while also modulating the locus coeruleus, which has more direct control over 
sensory informational processing and cognitive function. The mesocorticolimbic 
circuit consists of projections arising from the mesencephalon (or midbrain), the 
cortex and the limbic system. The midbrain projections are primarily from the VTA, 
the dopaminergic nucleus of the brain with the most diverse afferent projections. The 
cortical projections come from the frontal cortex and the limbic system projects from 
the anterior cingulate cortex (ACC) and ventral striatum. This circuit therefore 
integrates sensory, memory, emotional, affective, behavioural, motor and executive 
thought centres, encodes the salience of the stimuli and elicits a response in 
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accordance with the learned expectation of the outcome (Schultz, 1997; Wise, 
2004).  
 
Central to the mesocorticolimbic motivation system is the projection of dopaminergic 
VTA neurons to the NAc (Wise, 2004). This system was originally considered the 
pleasure centre of the brain, with dopamine release being responsible for the 
‘hedonic impact’ of drugs and rewarding stimuli. Interestingly, evidence is 
accumulating to support the notion that both aversive unpleasant stimuli activate the 
motivational system the in the same ways that rewards do, as confirmed by 
microdialysis, electrophysiological and voltammetric studies (Salamone et al., 2007). 
Further supporting this evidence, it has been found that amphetamine enhanced 
aversive responses in animals, and NAc lesions interfere with aversive responses 
(Kelley and Berridge 2002). Dysfunction of the mesocorticolimbic circuit is also 
implicated in pathological pain disorders (Borsook et al., 2007). Aversive responses 
can be triggered by noxious stimuli, such as noxious heat, by coupling the 
corticolimbic circuit with the “classic pain circuitry” via nociceptive signals (Becerra et 
al., 2001). The amygdala, which was originally considered the fear centre, is also 
active in these processes. The central nucleus of the amygdala also projects to the 
major brainstem monoamine nuclei, which includes the SN, the VTA, the 
serotonergic Raphé nucleus, and locus coeruleus as well as the hypothalamus 
driving appropriate autonomic and motor responsivity to emotionally salient input 
(Cardinal et al., 2002). The amygdala also has direct interaction with the shell of the 
NAc, PFC and ACC, providing a direct pathway for emotionally salient stimuli to 
influence motivation and behaviour.  
 
Recent discoveries on the significance of locus coeruleus activity have demonstrated 
an important distinction in electrophysiological modes of neuronal firing, which 
modulate behaviour and determine task performance. Increased phasic firing of 
locus coeruleus neurons is associated with improved attention and focus, while 
increased tonic firing of locus coeruleus neurons disengages animals from task 
performance and promotes behavioural adaptation (Aston-Jones & Cohen, 2005). 
This is relevant because CRF has been found to increases tonic but not sensory-
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evoked phasic activity of noradrenergic locus coeruleus neurons in unanesthetized 
rats (Valentinol & Foote, 1987). Similarly, CRF was found to modulate locus 
coeruleus activity in a dose-dependent inverted U-shaped response, initially 
improving task performance, but as the dose increased, promoted behavioural 
flexibility and a shift to searching of alternative activities (Snyder et al., 2012). This 
inverted-U response to locus coeruleus activity is reflected in the control of 
noradrenaline concentrations over PFC function. Because of this concentration-
dependent modulation, this stress/arousal system promotes different behaviours 
depending on the level of activation. Higher levels of noradrenaline activate α1 and 
β1 receptors and take the PFC “off-line” whereas in other regions they provide a 
more optimal neurochemical environment and shifts to more reflexive, instinctive 
behaviour driven more by subcortical structures (Ramos & Arnsten, 2007; Arnsten, 
2009). 
 
The PFC and ACC are interconnected and both send and receive projections to 
catecholaminergic nuclei, collectively contributing to the integration of emotional and 
cognitive processes (Bush et al., 2000) and directing motor behaviour, allowing the 
transformation of intention into action (Paus, 2001). Their activity is also integrated in 
the generation of the error-related negativity (ERN) component of event-related 
potentials measured by electroencephalogram (EEG)(Herrmann et al., 2004). The 
ERN is thought to reflect  internal monitoring errors and has been shown to occur 
even as a result of unperceived, or subconscious errors and are proportionate to the 
degree of mismatch between expectation and outcome (Nieuwenhuis et al., 2001). 
Interoceptive information provided from the insular cortex allows for autonomic 
management of behavioural economics, linking intent, action and consequence 
(Sanfey et al., 2006; Salamone et al., 2009; Medford & Critchley, 2010). Although all 
motivated behaviour is dependent on NAc dopamine (Salamone et al., 2009), the 
appropriate selection and maintenance of behaviour in response to these signals 
appears to be dependent on the ACC, particularly in extended or prolonged 
behaviour (Holroyd & Yeung, 2012). noradrenaline facilitates processing by the ACC, 
while phasic dopamine bursts transmit information based on reinforcement history 
for decision making, particularly in difficult or demanding tasks (Warren & Holroyd, 
2012). 
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The teleoanticipatory centre proposed by St Clair Gibson and co-workers (2006) 
closely mirrors the role of the ACC and ERN. As power output is modulated a 
prediction of performance feedback will be computed. If afferent stress signals do not 
match those predicted by the algorithm, a change in power output may be made to 
compensate and the experience of this change of demand will be reflected in 
perceived exertion. Indeed, the perception of errors acts as aversive, or unpleasant 
stimuli (Hajcak & Foti, 2008). This suggests that when unexpected negative 
teleoanticipatory feedback is received it would have a negative emotional and 
cognitive impact. This may explain the findings by Baden and co-workers (2005) in 
which participants were surprised by a small extension in the amount of exercise 
asked of them, resulting in an increase of negative affect which corresponded with 
an increase in RPE, despite being otherwise well within their means to perform. 
Supporting this notion, negative affect increases the amplitude of ERN in response 
to errors (Wiswede et al., 2009), suggesting a potential feed-forward effect of an 
increasingly negative impact on affect and stress by error detection and awareness. 
There is also evidence supporting the contribution of unconscious stress signals to 
the same teleoanticipatory algorithm for pacing. A study comparing the cycling power 
output at a fixed RPE until power reached below 70% max in different temperatures 
showed that power output is decreased when rate of heat storage is increased 
(Tucker et al., 2006). The relationship between PFC, insular cortex and ACC 
represent a possible neuroanatomical substrate for the subjective experience of 
perceived exertion. This neural construct serves as a bridge between conscious and 
unconscious regulation of effort, in which psychological and physiological strain 
interact and modulate the performance of motivated behaviours. 
 
Because of the difficulty of measuring brain function during exercise, there is little 
direct evidence of the processes underlying central fatigue. However, fatigue during 
exercise in the heat has been associated with decreased EEG cortical β power 
without significant changes to α power, which was positively correlated with ratings 
of perceived exertion (Nybo & Nielsen, 2001b; Rasmussen et al., 2004). β power has 
also been investigated with respect to movement disorders, as relatively high β 
power over the motor cortex is associated with advanced stages of Parkinson’s 
disease and dopamine depletion (Jenkinson & Brown, 2011). Recently, it has been 
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proposed that total cortical β power represents a cross-network communication, 
which maintains the status quo, facilitating and reinforcing the networks promoting 
appropriate behaviour, while decreasing β power is associated with increasing 
bottom-up stimuli, distractibility and promoting a shift in behaviour(Engel & Fries, 
2010). It is worth noting that individuals with ADHD display decreased frontal β 
power compared to controls (Snyder & Hall, 2006) and bupropion, amphetamine and 
methylphenidate, which have been successful in improving performance during 
prolonged exercise in the heat are treatments for ADHD (Wilens, 2006). Similarly, 
clinically relevant doses of psychostimulants preferentially increase extracellular 
catecholamines in the PFC (Berridge & Arnsten, 2012) while also slightly decreasing 
locus coeruleus cell firing by inhibiting reuptake(Stahl et al., 2004; Devilbiss & 
Berridge, 2006). This includes methylphenidate (Berridge et al., 2006) and bupropion 
(Bares et al., 2010) and amphetamine (Berridge & Arnsten, 2012).  
 
1.12 - Summary and Aims 
Studies using central catecholamine reuptake inhibitors have thus far been the most 
successful pharmacological manipulation of central fatigue during prolonged 
exercise, particularly in a warm environment. These drugs share a common 
therapeutic efficacy in treating ADHD and appear to preferentially affect the PFC and 
brain stem nuclei. However, the effects of these drugs during prolonged exercise in 
warm conditions warrants further characterisation. Similarly, few studies have been 
conducted to examine the effects of changes to catecholamine metabolism on 
prolonged exercise performance in warm conditions. Therefore the aim of this series 
of studies is to contribute to both elements of the role of central catecholamines 
during prolonged exercise in a warm environment. The studies described in 
Chapters 3 and 4 are designed to further explore the effects of central catecholamine 
reuptake inhibition with bupropion. Chapter 3 was the first study to examine the 
gender differences in the role of central catecholamines during prolonged exercise. 
The aim of this chapter was to determine whether the same effects observed by 
Watson and co-workers (2005) are the same for women as they were in men. The 
aim of Chapter 4 was to determine the effects of different doses of bupropion on 
exercise performance. Both Chapters 3 and 4 were conducted with funding from the 
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World Anti-Doping Agency, and were designed to help determine the necessary 
guidelines and regulations for bupropion. Chapter 5 was designed as a follow up to 
the study conducted by Meeusen and co-workers (1997). In this study the 
pharmaceutical Sinemet, which is the catecholamine precursor L-DOPA combined 
with an AADC inhibitor (carbidopa), was administered before prolonged exercise and 
had no effect on performance. The study described in Chapter 5 was designed to 
examine the effect of the same pharmaceutical on prolonged exercise in warm 
conditions, with the consideration that warm conditions provide an environment more 
sensitive to central catecholamine function. Furthermore, Chapter 5 included a 
dosing schedule better suited to the pharmacokinetics of this particular drug. The 
study described in Chapter 6 was an experimental probe into alternative nutritional 
manipulation of central catecholamines. SAM is readily available as a nutritional 
supplement in the UK and USA, but is the most heavily researched and supported 
alternative antidepressant treatment (Bottiglieri, 2002). It is hypothesised that these 
manipulations of central catecholamines will improve performance during prolonged 
exercise in warm conditions.  
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Chapter 2 
 
General Methods 
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2.1 - Ethical Approval 
All work described in Chapters 3, 5 and 6 received approval from the Loughborough 
University Ethical Advisory Committee. The study in Chapter 4 was approved by the 
Research Council of the Vrije Universiteit Brussels, Belgium. Prior to the start of 
each investigation all potential participants were first approached either in person, or 
contacted via email or poster. Those expressing an interest in taking part received 
written details approved by the local Ethics Committee outlining the background to 
the study, information regarding the protocol and any possible discomfort or adverse 
effects that could arise during the investigation. Following an opportunity to ask 
questions, those interested in participating completed a health screen questionnaire 
and signed a written statement of consent. In the studies using prescription drugs, 
the health screen questionnaire was viewed by the prescribing doctor to ensure no 
contraindications prior to enrolling in the study. All participants were fully aware from 
the outset that they were free to withdraw from the study at any time without 
providing any reason for doing so.  
 
2.2 - Participants 
Participants were recruited from local university staff and student populations as well 
as local sports clubs. Female participants were recruited in Chapter 3 and male in 
Chapters 4, 5 and 6. Due to the physically demanding nature of the investigations, 
participants were familiar with the sensation of strenuous and prolonged exercise. 
Participants were aged between 18 and 35 for all investigations. Participants 
recruited to take part in the studies investigating responses to exercise in a warm 
environment were unaccustomed to exercise in the heat at the time of the 
investigation. Due to the nature of these series of studies, those with a history of 
psychiatric illness and/or metabolic disease were excluded. For the investigations 
described in Chapters 3, 4, and 5, participants were provided with manufacturer 
information on contraindications and adverse effects, which served as additional 
exclusion criteria. For the investigation described in Chapter 3, only female 
participants who were not using hormonal contraceptives were selected due to a 
potential interaction with bupropion metabolism (described in Chapter 3). Those 
individuals that did not fit the inclusion criteria were thanked for their interest and 
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politely told that their help would not be required. In addition, participants were asked 
to sign an informed consent form after completing a health screen questionnaire 
approved by the prescribing doctor. 
 
2.3 - Experimental Design and Standardisation of Experimental Conditions 
All studies were placebo-controlled trials. All trials were randomised using a Latin-
square design to minimise any order effect and were administered in a double-blind 
manner. All studies employed a cross-over design. The study in Chapter 4 employed 
a randomised 4-block design to control for order effects that may have occurred over 
the 4 experimental trials. Trials were performed at the same time of day to minimise 
the influence of circadian variation. Prior to the start of the experimental trials, a 
familiarisation trial was undertaken to ensure the participants were accustomed to 
the procedures employed during the investigations and to minimise any potential 
learning or anxiety effects. This followed the exact protocol used in the experimental 
trials. In Chapters 3 and 5, an additional single-blind placebo treatment was 
administered to serve as a second familiarisation and provide an extra comparison of 
reliability for any observed effects.  
 
To help ensure metabolic conditions were similar before each experimental trial, 
participants were instructed to record all food and fluid intake (household measures 
technique), as well as any exercise performed, in a diary over the 2 days prior to the 
first trial. Participants were asked to replicate this dietary intake and physical activity 
as closely as possible during the 2 days before subsequent trials. Participants were 
also asked not to perform any strenuous exercise or consume alcoholic beverages in 
the 24 hours prior to all trials. Trials in Chapters 3 and 6 were performed following an 
overnight fast. In Chapter 4, participants consumed a standardised breakfast 90 
minutes before arriving for testing. In Chapter 5, participants were instructed to 
consume a standardised breakfast (provided) 4 hours and 30 minutes before 
entering the lab. These differences in protocol were due to timing of food around 
drug dosing. Participants in all investigations were asked to consume 500mL of plain 
water during the 90 minutes before entering the lab. The environmental conditions 
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for exercise trials were controlled using a climatic chamber with integrated 
thermostat and hygrostat (Weiss Technik UK Ltd, Loughborough, UK). When 
participants were required to remain seated at rest, the ambient temperature was 
maintained within a comfortable range (20-25°C). All trials were separated by at least 
7 days to limit the development of heat acclimation (Barnett and Maughan, 1993).  
 
2.4 - Measurement of Peak Oxygen Uptake 
To determine the workloads required during experimental protocols, participant peak 
oxygen uptake (VO2peak) was determined in advance. This was achieved with a 
discontinuous protocol (Chapters 3, 5, and 6) or continuous (Chapter 4) incremental 
graded exercise test on an electrically braked cycle. The discontinuous protocol 
required participants to complete between 4 and 6 discrete 4 minute increments, 
beginning at an initial workload of 100 watts (W) for male participants (Chapters 5 
and 6) or 50W for female participants (Chapter 3). Depending on the participant’s 
performance in the previous stage (e.g. verbal feedback, ratings of perceived 
exertion, heart rate), the workload was increased by 50 or 25W. Between each bout, 
a supervised rest period of 3 to 5 minutes was observed, during which the participant 
was able to walk around and drink plain water. This was repeated until the 
participant retired through volitional exhaustion. The continuous protocol required 
participants to begin exercise at an initial workload of 80W, with the intensity 
increased by 40W every 3 minutes until volitional exhaustion. Maximum workload 
(Wmax) was determined using the following equation: Wmax = Wout  + (t/180) x 40 
where ‘Wout‘ is the workload of the last completed stage and ‘t’ is the time in seconds 
of the final stage (Jeukendrup et al., 1996). The experimenters provided verbal 
encouragement during both protocols to help ensure a maximal effort. 
 
Expired gas was collected during the last 60 seconds of each stage in the 
discontinuous protocol, using the Douglas bag method. Throughout the continuous 
test, expired gas was analysed using an automated spirometry system (Metamax, 
Cortex, Biophysik GmbH, Germany). At the end of each increment in both protocols, 
heart rate was recorded using telemetry (Polar Favor, Kempele, Finland).The 
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expired gas collected using Douglas bags was analysed for oxygen (O2) and carbon 
dioxide (CO2) composition by drawing gas through a paramagnetic O2 transducer 
and infra-red carbon dioxide analyser (Servomex 1440c, Crowborough, UK). The 
gas analysers were calibrated with gases of known concentration (British Oxygen 
Company, London, UK). The volume of gas expired was measured through a dry 
gas meter (Harvard dry gas meter, Harvard Apparatus Ltd, Kent, UK) and the 
temperature of the expired gas was recorded using an electronic temperature sensor 
at the dry gas meter inlet (Edale Instruments Ltd, Cambridge, UK). All expired gas 
volumes were corrected to standard temperature and pressure for dry gas (STPD). 
Barometric pressure was measured using a standard mercury barometer. O2 
consumption, CO2 production and the respiratory exchange ratio were calculated 
using the equations detailed by Frayn (1983). These data were used to calculate the 
workloads corresponding to the desired percentage of participant’s VO2peak. 
 
2.5 - Exercise Trials 
All the exercise was completed using cycle exercise on a stationary, electrically 
braked cycle ergometer (Lode Corival or Lode Excalibur Sport, Groningen, Holland). 
During the VO2peak test, participants were asked to find a comfortable saddle 
height, which was recorded and used for the remaining trials. In Chapters 3 and 5, 
expired gas was collected every 15 minutes of the steady-state work period to verify 
the workload was correct. In Chapter 6 expired gas was collected every 15 minutes 
for the first hour of exercise to verify the workload and observe any potential 
changes in substrate utilisation. Participants were supervised by the same 
experimenters for all experimental trials to help ensure standardised conditions. To 
assess exercise performance in Chapters 3 and 5, participants completed preloaded 
workload challenge. The preload consisted of cycle exercise at a steady state (60% 
VO2peak), followed by completion of as much work as possible in 30 minutes. During 
this 30 minute workload challenge participants were free to manipulate the workload, 
which was initially set corresponding to 75% VO2peak. No feedback was provided 
regarding power output or heart rate. In Chapter 4 a preloaded time trial (TT) 
protocol was employed. The TT required participants to complete an amount of work 
equal to 30 minutes at 75% Wmax as quickly as possible (Jeukendrup et al., 1996). 
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Participants began the TT at a workload corresponding to 75% Wmax and were free to 
increase or decrease their power output as desired. During the TT a computer 
program displayed a bar indicting the percentage of total work completed to give the 
participant an indication of their progress. No feedback was provided regarding time, 
power output, pedal cadence or heart rate. In Chapter 6, time to exhaustion, defined 
as volitional cessation of exercise or inability to maintain cadence above 50-60 rpm 
after 3 warnings (below which the Lode Corival can no longer apply constant load), 
was used as a performance measure. This method was selected to promote fatigue-
associated physiological and psychological changes that could be affected by SAM 
supplementation.  
 
In all studies, post-void nude body mass was measured before and after exercise to 
quantify sweat loss. This difference was corrected for any urine output and fluid 
ingestion during the trial. These data were not corrected for respiratory water or 
losses due to substrate oxidation. To monitor core body temperature whilst at rest 
and during exercise, participants inserted a flexible rectal thermistor (YSI UK Ltd, 
Hampshire, UK or Gram Corp. LT-8A, Saitama, Japan) 10cm beyond the anal 
sphincter. Surface skin thermistors (Grant Instruments Ltd, Cambridge, UK or Gram 
Corp. LT-8A, Saitama, Japan) were positioned at four sites (chest, upper arm, thigh 
and calf). Thermistors were held securely in contact with the skin using transpire 
medical tape (3M, Loughborough, UK). Weighted mean skin temperature was 
calculated using the methods described by Ramanathan (1964). Ratings of 
perceived exertion (RPE) were assessed at regular intervals during exercise using 
the 15-point Borg scale (Borg, 1982). Ratings of perceived thermal strain were 
assessed at the same intervals using a 21-point thermal sensation scale ranging 
from unbearably cold (-10) to unbearably hot (+10) adapted from Hardy (1970)(see 
appendix). Heart rate was measured at rest and during exercise using short-range 
telemetry (Polar Favor, Kempele, Finland).  
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2.6 - Blood Collection, Handling and Analysis 
In chapters 3, 5 and 6, participants submerged their forearm into warm water (40-
42°C) for approximately 10 minutes to arterialise venous blood and improve visibility 
of superficial veins. In chapter 5 and 6, an indwelling 21 gauge butterfly cannula 
(Surflo winged infusion set, Terumo, Tokyo, Japan) was inserted into a superficial 
forearm vein and a three way tap (Luer-Loc 360, BD Connecta, Heidelberg, 
Germany) was attached to the end to allow repeated blood sampling. The indwelling 
cannula was kept patent by flushing with 2-3mL of heparinized saline after each 
sample. In Chapter 3, blood sampling was done via venepuncture in the antecubeital 
region due to the difficulty of finding superficial forearm veins in female participants. 
In Chapter 4, blood samples were collected from the antecubeital region using the 
vacutainer system. Assays used widely throughout this thesis are described below, 
with assays common to a single study described in the methods section of the 
appropriate chapter. All biochemical analyses performed throughout this thesis were 
performed in duplicate, unless otherwise stated. 
 
In Chapters 3, 5 and 6, collected blood was immediately dispensed into plain tubes 
or tubes containing K2EDTA. Duplicate 100µL aliquots of blood were rapidly 
deproteinised in 1000μL of ice-cold 0.3N perchloric acid. These were centrifuged and 
the resulting supernatant was used for spectrophotometric determination of blood-
glucose using Randox GOD-PAP kit (Randox Laboratories Ltd, Crumlin, UK). EDTA-
treated whole blood was used for the spectrophotometric determination of 
haemoglobin (Hb) by the cyanmethaemoglobin method as well as packed cell 
volume (PCV), which was measured in triplicate using microcentrifugation 
(Hawksley, Sussex, UK). Both Hb and PCV were determined within 2 hours after 
each experimental trial. These data were used to estimate percentage changes in 
blood, plasma and red cell volumes relative to the first sample using the methods 
proposed by Dill and Costill (1974). Untreated and EDTA-treated whole blood was 
centrifuged at 1500g for 15 minutes at 4°C to obtain serum and plasma, respectively. 
The supernatants were transferred into eppendorf tubes and stored at -20°C until 
analysis. In all investigations serum was used to measure cortisol, and in Chapters 
4, 5 and 6, prolactin with enzyme-linked immunosorbent assay (ELISA) kits (DRG, 
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International Inc. New Jersey, USA). For all ELISAs standard curves and a 3 level 
control sera were measured in duplicate, while participant samples were measured 
in singlicate. Additional hormone analysis undertaken in Chapter 3 is described 
therein. 
 
2.7 - Statistical Analysis 
Data are presented as means ± standard deviation (SD). The Shapiro-Wilk test was 
used to examine whether the outcome variables had a normal distribution. 
Homoscedasticity was checked using Levene’s test. Data sphericity was determined 
using the Mauchley’s test, and, where appropriate, further analysis was corrected as 
described by Atkinson and Nevill (2001). Exercise performance data were examined 
using one-way repeated measures of analysis of variance (ANOVA). To identify 
differences in data collected throughout each trial, two-way (time-by-trial) ANOVA 
was employed. Where a significant interaction was apparent pair-wise differences 
were evaluated using the Bonferroni post hoc procedure. Hormone AUC was 
compared using paired-samples t-tests. Statistical significance was accepted at 
P<0.05. Non-parametric data were analysed with Friedman’s test with Wilcoxon-rank 
sum for pairwise comparisons. 
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2.8 – Coefficients of Variation of Methods 
CV averaged from duplicate and triplicate samples 
Measure Method Mean  CV (%) 
Haemoglobin Cyanmethaemoglobin 153.3g/L 0.8 
Packed Cell Volume Microcentrifugation 43.90% 0.7 
Blood Glucose GOD-PAP (Randox) 4.45mmol/L 1.5 
    Serum Prolactin Microplate ELISA 21.29ng/mL 7.4 
Serum Cortisol Microplate ELISA 228.7ng/mL 8.0 
Plasma ACTH Microplate ELISA 108.8pg/mL 10.5 
    Serum FSH Evidence Investigator (Randox) 3.63mlU/mL 4.2 
Serum LH Evidence Investigator (Randox) 4.63mlU/mL 9.0 
Serum Prolactin Evidence Investigator (Randox) 904.7mlU/L 5.0 
Serum Testosterone Evidence Investigator (Randox) 2.63nmol/L 3.8 
Serum Progesterone Evidence Investigator (Randox) 12.74nmol/L 17.4 
Serum Oestrogen Evidence Investigator (Randox) 222.6pmol/L 3.2 
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Chapter 3 
 
The Role of Central Catecholamines in 
the Development of Fatigue in Women 
during Prolonged Exercise in Warm 
Conditions 
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3.1 – Abstract 
Bupropion, a dual noradrenaline/dopamine reuptake inhibitor, improves time trial 
performance in male participants in the heat. Gender differences in 
neuropsychopharmacology have been shown in animal and human studies, but it is 
not known whether these differences may alter the effect of bupropion on exercise 
performance in women. With local ethics committee approval, 9 physically active 
women (Mean ± SD age 21 ± 2 y; height 1.68 ± 0.08 m; body mass 64.1 ± 6.0 kg; 
VO2peak 50.9 ± 7.2 mL/kg/min) were recruited to examine the effect of pre-exercise 
administration of bupropion (4 x 150 mg) on prolonged exercise performance in a 
warm environment (30.2 ± 0.2°C, 50% ± 1% rh). Participants completed a VO2peak 
test, a familiarisation trial, and a single-blinded placebo control trial before a 
randomised, double-blind, placebo-controlled crossover design was employed. 
Experimental trials took place during the first 10 days of the follicular phase of the 
menstrual cycle. Participants cycled for 1 h at 60% VO2peak followed by a 30 min 
workload challenge, during which they were instructed to complete as much work as 
possible. Heart rate, skin and core temperature, and ratings of perceived exertion 
and thermal sensation were recorded throughout exercise. Total work done was 
higher on the buproprion trial (291 ± 48 kJ) than on the single-blind (267 ± 48 kJ, 
P=0.021) and double-blind trials (269 ± 46 kJ, P=0.042). No differences were found 
between all trials for core temperature throughout rest, the first hour or the workload 
challenge. However, at the end of the workload challenge core temperature was 
higher on the bupropion trial (39.5 ± 0.4 °C) than the single-blind (39.2 ± 0.6 °C, 
P=0.028) and double-blind trials (39.2 ± 0.6 °C, P=0.021). Heart rate was also higher 
at the end of the workload challenge on the bupropion trial (185 ± 9 beats/min) than 
the single-blind (180 ± 13 beats/min, P=0.048) and double-blind trials (179 ± 13 
beats/min, P=0.043). The results indicate that during the follicular phase of the 
menstrual cycle an acute dosing protocol of bupropion can improve self-regulated 
work rate in warm conditions.  
 
 
 
53 
 
3.2 – Introduction 
Endurance exercise capacity is reduced in warm conditions. This effect has been 
demonstrated to be ambient temperature-dependent (Galloway & Maughan, 1997) 
and exacerbated by increasing humidity (Maughan et al., 2012).  This is primarily 
due to the significant challenges to thermoregulation and, consequently, fluid 
balance as well (Hargreaves, 2008; Nybo, 2008; Maughan, 2010). This cumulative 
strain results in the eventual onset of fatigue and subsequent impairment in 
performance. This appears to be regulated largely by mechanisms within the CNS 
(as described in section 1.2). Though the cerebral mechanisms for the onset of 
fatigue are currently not understood, there have been many studies attempting to 
manipulate fatigue by altering CNS function. While those attempting to alter fatigue 
via manipulation of serotonin have yielded conflicting results (Meeusen et al., 
2006b), manipulation of central catecholamines has produced more consistent 
changes in the onset of fatigue and exercise performance in warm conditions 
(Roelands & Meeusen, 2010).  
 
The physiological strain during prolonged exercise in the heat is similar for men and 
women, but sex hormone fluctuations throughout the menstrual cycle cause 
important physiological changes, which can affect performance. De Jonge (2003) 
provided a comprehensive review on studies conducted to determine the effects of 
menstrual cycle phases on exercise physiology and performance. The review found 
no differences or conflicting results for haemoglobin, haematocrit, muscle 
contractility and lactate response during the menstrual cycle. However, differences in 
VO2 were observed during higher intensity exercise, which the author attributed to 
cardiovascular strain due to the increased resting body temperature during the luteal 
phase. This effect was exacerbated in warm conditions during light intensity 
intermittent exercise, but not at relatively low intensities (20%, 30% and 60% 
VO2max). A follow up study corroborated this decrease in performance during 
prolonged, high intensity exercise in warm conditions (de Jonge et al., 2012). This 
was characterised by increased resting core temperature, increase rate in core 
temperature rise during exercise as well as increased RPE and perceived thermal 
strain. In summary, it appears that the main performance-affecting factors to 
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consider throughout the menstrual cycle are the fluctuating thermoregulatory 
processes and consequent resting body temperature, which is increased during the 
luteal phase. This negatively affects high intensity prolonged exercise in normal 
temperature and even more so in high ambient temperatures.  
 
Ovarian sex hormones appear to modulate thermoregulation by regulating brown 
adipose tissue thermogenesis by directly acting at the progesterone receptors and 
sympathetic modulation by estrogen in the CNS (Quarta et al., 2012). In addition to 
energy balance and thermoregulation, ovarian sex steroids modulate CNS activity in 
a number of ways, including the stress response (Chrousos et al., 1998) and activity 
in areas of the brain associated with motor function and motivation (McEwen & 
Alves, 1999). Estrogen has been shown to modulate dopaminergic 
neurotransmission (Colzato et al., 2010; Disshon, Boja, & Dluzen, 1998) and 
increases activity of tryptophan hydroxylase, an enzyme involved in serotonin 
synthesis, decreases 5HT1a autoreceptor binding, and modulates the serotonin 
transporter, which leads to increased expression in the hypothalamus (Bethea et al., 
2002).  In addition to the challenges presented by de Jonge (2003), the interaction 
between ovarian sex steroids and monoaminergic neurotransmission suggest 
possible sex-dependent differences in physiological and performance outcomes in 
response to pharmacological manipulation of CNS activity. 
 
Women are more susceptible to depression than men, though this may be due to 
sociological factors, rather than differences in physiology (Piccinelli, 2000; Nolen-
Hoeksema, 2001). Nonetheless, there appear to be gender differences in response 
to antidepressants; women tend to respond better to selective-serotonin reuptake 
inhibitors and worse to tricyclic antidepressants than men (Young et al., 2009). While 
there are gender differences in neuropharmacology due to sex hormone interactions 
(Young & Becker, 2009), there are also differences in attitudes and expectations. 
Women are generally more willing to seek help, whereas this is generally stigmatised 
amongst men (Addis & Mahalik, 2003). Furthermore, gender differences in placebo 
and nocebo responses have been observed, with men more affected by expectancy 
and women to conditioning (Klosterhalfen et al., 2009). Women are more likely to 
55 
 
report adverse side-effects during placebo treatment than men (Mora et al., 2011), 
while men tend to be more susceptible to placebo analgesia (Aslaksen et al., 2011). 
All of the studies conducted to investigate the effects of pharmacological 
manipulation of fatigue during prolonged exercise in warm conditions to date, have 
used male participants. It is therefore not known whether the same increases in 
exercise capacity during prolonged exercise in warm conditions will be seen in 
women. The aim of the present investigation is to determine the effects of bupropion, 
a dual dopamine /noradrenaline reuptake inhibitor on performance during prolonged 
exercise in warm conditions in physically active women. It is therefore hypothesised 
that acute administration of bupropion will improve prolonged exercise performance 
in women during the same menstrual cycle phase. 
 
3.3 – Methods 
Nine habitually active women were recruited (age 21 ± 2 y; height 1.68 ± 0.08 m; 
body mass 64.1 ± 6.0 kg; VO2peak 51 ± 7 mL/kg/min). All participants actively took 
part in regular endurance exercise training, but were not accustomed to exercise in a 
warm environment at the time of the study. Prior to their admission to the study, 
participants were provided with information regarding the purpose and design of the 
study, including manufacturer information for bupropion. Thereafter, if participants 
confirmed their interest and eligibility, a statement of informed consent was signed. 
The Loughborough Ethics Advisory Committee approval number for this study was 
R10-P7. As oral contraceptives have been shown to interfere with bupropion 
metabolism via cytochrome P450 2B (Palovaara et al., 2003), this study investigated 
participants not taking any form of hormonal contraception. To account for the 
hormonal fluctuations in the menstrual cycle, visits were coordinated with 
participants in relation to the self-reported length of cycle and the onset of menses 
as has been done in other studies (e.g: Minson et al., 2000). Accordingly, those 
reporting irregular menstrual cycles and pregnancy were excluded from the study. 
The primary concern was to schedule the max test and experimental trials to fall 
within the follicular phase to avoid the increased cardiovascular strain and 
subsequent VO2 described by de Jonge (2003) during the luteal phase. A recent 
study found the follicular phase to last between a minimum of 10 days after the onset 
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of menses and a maximum of 22 days (Fehring et al., 2006). Therefore, participants 
were asked to visit the laboratory one week after the onset of menses for their max 
test and the following week for a familiarisation trial in order to minimise any learning 
or anxiety effects. Within a week of the onset of their next menses, participants 
completed a single-blinded placebo control trial. This served as both an experimental 
trial to compare against the double-blinded crossover trials and as a second 
familiarisation. Following the single-blinded placebo control trial a randomised, 
double-blind, placebo-controlled crossover design was employed. These trials were 
scheduled as soon as possible after the onset of the following menses and 7 days 
later for the cross-over trial (see figure 3.1 below). While this scheduling was subject 
to the participants’ availability, the timing of the visits was coordinated in the same 
manner with respect to their menstrual cycle. In the 24 hours preceding the 
experimental trials participants took either placebo (~1g starch/capsule) or bupropion 
(4 x 150 mg spread over 24 h).  
 
Figure 3.1 This schematic is an example of lab visit scheduling for the control for the hormonal and 
basal body temperature fluctuations throughout the menstrual cycle. 
 
The experimental trials were designed to be similar to previous studies (Watson et 
al., 2005a; Roelands et al., 2008d, 2008b). To determine the work rates for the 
familiarisation and experimental trials, an incremental discontinuous VO2peak test to 
volitional exhaustion was performed by participants using a Lode Corival cycle 
ergometer (Lode B.V., Groningen, Netherlands) in an environmental chamber 
(Weiss-Gallenkamp, UK) at 20°C and 50% relative humidity as described in Chapter 
2. VO2peak was then used to calculate work rates corresponding to this value using 
linear regression. The standardisation of pre-trial conditions is outlined in Chapter 2. 
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The experimental protocol is illustrated in figure 3.2. Participants were asked to cycle 
at a work rate corresponding to 60% VO2peak for 60 min, followed by a 30 minute 
workload challenge, in which participants were asked to complete as much work as 
possible. Initial work rate during the workload challenge corresponded to 75% 
VO2peak; thereafter participants were free to manipulate the work rate to complete 
as much as they felt possible. 
 
Participants arrived at the laboratory in the morning (before 9 am), overnight fasted 
and having consumed 500mL of plain water. After the collection of baseline 
measurements during the rest period, participants entered the climatic chamber 
maintained at 30.2 ± 0.2°C, 50% ± 1% relative humidity to begin exercise. During 
exercise, participants were permitted to drink water ad libitum. Water consumption 
was recorded by weight and deducted from post-exercise body mass, to enable the 
calculation of sweat loss. Throughout the trial heart rate, core and skin temperatures, 
were measured every 5 minutes. During the 15 minute rest period subjective thermal 
sensation was measured. During the 1 hour fixed work rate period subjective thermal 
sensation and rating of perceived exertion were measured every 15 minutes, when 
expired gas samples were also collected for verification of work rate. During the time 
trial subjective thermal sensation and rate of perceived exertion were measured 
every 10 minutes. Standardised verbal encouragement was provided by the 
experimenter to help ensure a maximal effort. Feedback during the time trial was 
limited to the time lapsed (power output, cadence, heart rate, etc.) were hidden from 
the participant. Following completion of the workload challenge and the collection of 
the final blood sample, participants left the climatic chamber. Skin thermistors were 
removed and participants removed the heart rate telemetry band and rectal 
thermistor in privacy before towelling off and nude body mass was recorded behind a 
screen. 
 
During the experimental trials a maximum of four 5mL blood samples were drawn. 
Samples were collected at rest, after 30 minutes and at the end of the hour steady 
state period as well as upon completion of the time trial. Due to the difficulty of blood 
sampling from some of the female participants, only the resting blood sample 
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became a priority for hormone measurement to confirm the phase of the menstrual 
cycle. The 5mL blood samples were drawn into dry syringes and immediately 
dispensed into 1mL and 2.5mL tubes containing potassium EDTA (1.5mg/mL) and 
the remaining whole blood into 5mL plain tubes. The 2.5mL EDTA tubes were kept 
on ice. The 1mL EDTA blood samples were used to analyse haemoglobin and 
haematocrit, allowing for estimation of percentage changes in blood, plasma and red 
cell volumes relative to the first resting sample (Dill & Costill, 1974). Two aliquots of 
100µL were pipetted from the 1mL EDTA tubes into eppendorfs containing 1mL of 
0.3M perchloric acid kept on ice for measurement of blood glucose. The 2.5mL 
EDTA and 5mL plain tubes were centrifuged to obtain plasma and serum, 
respectively, which was then frozen at -20°C and later -80°C for hormone analysis at 
a later date. Cortisol was measured using ELISA kits (DRG, International Inc. New 
Jersey, USA). Follicle-stimulating hormone, luteinising hormone, prolactin, 
testosterone, progesterone and oestrogen were measured using a Randox Evidence 
Investigator and Fertility Array Biochips (Randox Laboratories Ltd, Crumlin, UK) in 
order to confirm the menstrual cycle phase the participants were in during each 
experimental trial. 
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Figure 3.2 Schematic demonstrating the order and frequency of procedures during experimental 
trials. 
 
3.4 – Results 
Total work done was higher during the buproprion trial (291 ± 48 kJ), than during the 
single-blind (267 ± 48 kJ, P=0.021) and double-blind trials (269 ± 46 kJ, P=0.042) 
(figure 3.3A). The difference between the crossover trials represents an increase in 
performance of 7.5 ± 9.6% in the bupropion trial (figure 3.4). There was no evidence 
of an order effect during the experimental trials (visit 1 267.1 ± 48.2 kJ, visit 2 282.8 
± 36.5 kJ, visit 3 277.1 ± 54.3 kJ; P=0.230). During the bupropion trial, 7 of 9 
participants completed more work than in the double-blind placebo trial; individual 
work completed during each trial is presented in figure 3.3B. 
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A 
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Figure 3.3 Exercise performance by trial (A) and individual performance (B) in each trial. * denotes 
a significant difference for bupropion vs single-blind and double-blind placebo trials (P=0.021 and 
0.042, respectively). 
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Figure 3.4 Individual percentage change in exercise performance between the double-blind 
placebo and bupropion trial. The thick black line represents the average change in performance 
(+7.5%). 
 
Exercise resulted in a significant elevation in core temperature over resting values 
(P<0.05). Despite the apparent trend for greater core temperature during the 
bupropion treatment, no differences were found between trials for core temperature 
at rest or during the first hour or the workload challenge (P>0.05). However, at the 
end of the workload challenge core temperature was higher during the bupropion 
trial (39.5 ± 0.4 °C), than during the single-blind (39.2 ± 0.6 °C, P=0.028) and 
double-blind trials (39.2 ± 0.6 °C, P=0.021) (figure 3.5A). Weighted mean skin 
temperature rose rapidly with the first 15 minutes of exercise in all trials, becoming 
relatively stable thereafter (figure 3.5B). There were no significant differences for 
weighted mean skin temperature between groups (P>0.05).  
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Figure 3.5 Core (A) and weighted mean skin (B) temperature at rest and during exercise. * denotes 
a significant difference for bupropion vs single-blind and double-blind placebo trials (P=0.028 and 
0.021, respectively). 
 
Heart rate increased rapidly with the first 10 minutes of exercise in all trials and 
continued to rise slowly thereafter (figure 3.6). Heart rate was higher at the end of 
the workload challenge during the bupropion trial (185 ± 9 beats/min) than the single-
blind (180 ± 13 beats/min, P=0.048) and double-blind trials (179 ± 13 beats/min, 
P=0.043).  
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Figure 3.6 Heart rate at rest and during exercise. * denotes a significant difference for bupropion vs 
single-blind and double-blind placebo trials (P=0.048 and 0.043, respectively). 
 
Ratings of perceived exertion rose slowly through the first hour of exercise and 
climbed rapidly during the workload challenge in all trials (figure 3.7; P<0.01) No 
significant differences were found between trials (P>0.05). Ratings of thermal 
sensation increased rapidly after the first 15 minutes of exercise and continued to 
steadily increase until the end of the workload challenge for all trials (figure 3.8; P 
<0.05). No significant differences were found between trials (P>0.05).  
 
Figure 3.7 RPE during experimental trials. 
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Figure 3.8 Ratings of thermal sensation during experimental trials. 
 
Resting sex hormone levels were not significantly different between trials, nor were 
there any order effects (P>0.05). There were no differences between trials for 
exercise-dependent hormone changes (table 3.1). Only five complete data sets were 
available for these comparisons due to blood collection difficulties. Serum prolactin 
concentration increased at the end of exercise across all trials, but no significant 
differences between trials were observed. Serum testosterone, progesterone, 
oestrogen concentrations were significantly increased at the end of exercise across 
all trials. Cortisol concentration was increased across all trials, but this was not 
significant. There were no significant differences for follicle stimulating hormone or 
luteinising hormone after exercise.  
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Table 3.1 Serum hormones measured at rest and at the end of the each experimental trial. a and b 
denote significant difference (P<0.05) for between rest and end between all trials and within the 
corresponding trial, respectively. FSH=Follicle Stimulating Hormone; LH=Luteinising Hormone; 
PRL=Prolactin; TEST=Testosterone; PRO=Progesterone; EST=Estrogen; CORT=Cortisol. 
    
Single-Blind 
Placebo 
Double-Blind 
Placebo 
Bupropion 
FSH (mIU/mL) 
Rest 3.73 ± 2.12 4.07 ± 2.23 2.99 ± 1.11 
End 3.59 ± 2.40 4.24 ± 2.29 3.19 ± 1.22 
 
     
LH (mIU/mL) 
Rest 5.64 ± 4.25 4.07 ± 2.78 4.10 ± 2.22 
End 5.07 ± 5.35 4.65 ± 3.38 4.31 ± 2.86 
 
     
PRL (mIU/mL) 
Rest 563.7 ± 46.2 673.2 ± 203.4 668.3 ± 244.0 
End 962.2 ± 386.2a 1377.7 ± 730.7ab 1183.3 ± 302.5a 
 
     
TEST (nmol/L) 
Rest 2.30 ± 1.44 1.73 ± 0.58 2.25 ± 0.89 
End 3.14 ± 1.22a 3.21 ± 2.28ab 3.18 ± 1.01ab 
 
     
PRO (nmol/L) 
Rest 6.52 ± 3.02 12.85 ± 19.69 13.72 ± 20.12 
End 7.53 ± 4.14a 18.53 ± 28.53a 17.33 ± 24.03ab 
 
     
EST (pmol/L) 
Rest 177.9 ± 83.7 201.0 ± 206.3 136.4 ± 51.8 
End 196.0 ± 101.6a 435.7 ± 588.5ab 188.7 ± 99.4ab 
 
     
CORT (ng/mL) 
Rest 172.7 ± 17.2 156.0 ± 66.4 183.6 ± 39.1 
End 187.8 ± 44.7 219.9 ± 86.8 222.4 ± 52.5 
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No significant differences were found between trials for haematocrit, haemoglobin or 
glucose (n=6). Haematocrit and haemoglobin increased across all trials after 
exercise as non-significant trends (P=0.074 and P=0.053, respectively). These 
trends manifested as a significant increase in percentage change in plasma volume 
compared to rest and within the single-blind placebo trial (table 3.3). Blood glucose 
was increased significantly at the end of exercise across and within all trials (table 
3.2).  
 
Table 3.2 Haematocrit (Hct), haemoglobin (Hb), and glucose from rest to end of each trial. a and b 
denote significant difference (P<0.05) for between rest and end across all trials and within the 
corresponding trial, respectively. 
  
Single-Blind 
Placebo 
Double-Blind  
Placebo 
Bupropion 
Hct (%) 
Start 40.7 ± 1.4 41.0 ± 1.3 40.6 ± 1.3 
End 42.4 ± 1.5 42.3 ± 1.5 41.7 ± 1.8 
Hb (g/L) 
Start 139.9 ± 9.0 141.2 ± 6.1 139.6 ± 7.8 
End 145.4 ± 9.3 144.1 ± 7.3 143.6 ± 8.2 
Glucose (mmol/L) 
Start 4.6 ± 0.3 4.4 ± 0.3 4.2 ± 0.4 
End 6.5 ± 1.6ab 6.3 ± 1.4ab    6.3 ± 1.1ab 
 
Table 3.3 Percentage changes in blood volume (BV), cell volume (CV) and plasma volume (PV) at 
the end of each trial. Calculated using the method described by Dill and Costill (1974). 
a
 and 
b
 denote 
significant difference (P<0.05) for between rest and end between all trials and within the 
corresponding trial, respectively. 
 
Single-Blind 
Placebo 
Double-Blind 
Placebo 
Bupropion 
ΔBV% -2.8 ± 3.1 
 
-0.8 ± 4.1 
 
-3.1 ± 2.3 
ΔCV% 1.0 ± 3.5 
 
1.8 ± 2.5 
 
0.1 ± 2.7 
ΔPV% -5.4 ± 3.4ab 
 
 -2.4 ± 6.6a 
 
 -5.1 ± 4.9a 
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No differences between were observed for sweat loss (figure 3.9) or steady state 
expired gas values between trials (P>0.05). Expired gas showed a steady increase 
of %VO2peak throughout steady state exercise, but this was not significant (P>0.05).  
 
Figure 3.9 Sweat losses as calculated by changes in body mass adjusted for water consumption 
during exercise. 
 
3.5 – Discussion 
The onset of fatigue during prolonged exercise in warm conditions is more rapid and 
appears to be more heavily affected by factors residing within the CNS compared to 
exercise of a similar intensity undertaken in thermoneutral environments. Previous 
studies have found that acutely increasing central catecholaminergic activity, via 
administration of a dual dopamine/noradrenaline reuptake inhibitor, can improve 
exercise performance in warm conditions compared to a placebo. Gender 
differences in the regulation of neurotransmission and response to 
neuropharmacological interventions, as well as sex hormone-dependent fluctuations 
in thermoregulation, may alter this performance response to dopamine/noradrenaline 
reuptake inhibitors. The aim of this investigation was to determine whether or not 
performance benefits would manifest with the same pharmacological manipulation in 
women.  
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The results of the present study demonstrate that an acute administration of 
bupropion during the early follicular phase can improve performance in women 
during prolonged exercise in warm conditions. Oestrogen and progesterone levels 
were not significantly different between trials, suggesting that the method of 
controlling for menstrual cycle phase was successful. The lack of difference between 
trials for core temperature, skin temperature, heart rate, RPE, and ratings of thermal 
sensation during rest and steady state exercise support this. The increase in 
performance was comparable to those found by Watson and co-workers (2005) and 
Roelands and co-workers (Roelands et al., 2012) who were also using bupropion 
(7.5% vs. 9% and 5%, respectively). The dose to body mass ratio for this study was 
9.4mg/kg, while it was 7.98mg/kg and 8.15mg/kg, respectively, in the others. As the 
increase in performance falls between the two, there does not appear to be any 
obvious dose-dependent differences in performance. However, the inherent 
variability in response to pharmacological manipulation may obscure this 
relationship. In addition to genetic variation neurological factors, bupropion 
pharmacology would be affected by variation in cytochrome PY450B2. In general, 
there do not appear to be any gender differences for bupropion efficacy for treatment 
of smoking cessation or depression, or in pharmacokinetics for adult men and 
women (Dwoskin et al., 2006). In agreement with this, the results of this study 
appear to demonstrate that bupropion has similar effects for men and women during 
prolonged exercise in a warm environment.  
 
Hyperthermia and the resulting challenges to cardiovascular function and 
thermoregulation are considered to be primary contributors to the development of 
fatigue in warm conditions (Hargreaves, 2008; Nybo, 2008; Maughan, 2010). 
However, it appears that pharmacological manipulation of central catecholamines 
can, in part, override processes that mediate hyperthermic fatigue. This is not only 
evidenced by the increases in performance, but the significantly higher core 
temperatures and heart rates achieved at the end of the workload challenge in the 
present study and the time trials in previous studies using similar pharmacological 
agents (Watson et al., 2005a; Roelands et al., 2008d, 2012). The concept of a critical 
core temperature has been proposed (González-Alonso et al., 1999) and in the 
present study core temperatures approached those described by Nielsen and co-
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workers (Nielsen et al., 1993). However, the validity of a critical core temperature as 
the main determining factor of fatigue during prolonged exercise in the heat has 
recently been considered less important than the impact of increased cardiovascular 
strain (Cheuvront et al., 2010; Sawka et al., 2012). Because the higher core 
temperature and heart rate were only significant at the end of the workload 
challenge, they are likely due to the increased work rate during the bupropion trial, 
rather than pharmacologically induced changes in thermoregulation or sympathetic 
activity. This effect was also observed in the study by Watson and co-workers 
(Watson et al., 2005a). Despite completing more work and achieving higher core 
temperature and heart rates at the end of the workload challenge, perceived exertion 
and ratings of thermal sensation were not significantly different.  
 
It has been proposed that pacing strategy relies upon teleoanticipatory algorithm of 
behavioural economics which utilises peripheral feedback to calibrate power output 
and this process is interrelated to perceived exertion (St Clair Gibson et al., 2006). In 
this model, power output is modulated and subsequent period of uncertainty ensues 
as the new adjustments take time to affect a change detected in the periphery. The 
error detected by the teleoanticipatory algorithm contributes to perceived exertion. 
For example, if afferent stress signals do not match those predicted by the algorithm, 
a change in power output may be made to compensate and the experience of this 
change of demand will be reflected in perceived exertion. However, peripheral stress 
signals alone do not explain perceived exertion. There is a psychological and 
emotional component of stress that is affected by, but not dependent upon, 
peripheral signals or external stimuli. This has been demonstrated in a study where 
participants were deceived into thinking the amount of exercise they had to complete 
was less than was asked during experimental trials (Baden et al., 2005). During the 
minute after the deception, RPE increased, while ratings of affect decreased 
significantly, without changes in physiological indices or power output.  
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There is neurobiological support for the integration of the emotional and cognitive 
aspects of RPE with the teleoanticipatory algorithm, as proposed by St Clair Gibson 
and co-workers (2006). ERN in event-related potentials detected via EEG, which are 
associated with errors during internal-monitoring at the ACC, have been 
demonstrated to be aversive stimuli, increasing stress and promoting negative affect 
(Hajcak & Foti, 2008). ERN at the ACC have been shown to occur even as a result 
of unperceived, or subconscious errors (Nieuwenhuis et al., 2001). This suggests 
that when unexpected negative teleoanticipatory feedback is received it would have 
a negative emotional and cognitive impact, supporting the findings by Baden and co-
workers (2005). Furthermore, negative affect increases the amplitude of ERN in 
response to errors (Wiswede et al., 2009), suggesting a potential feed-forward effect 
of an increasingly negative impact on affect and stress by error detection. The neural 
networks associated with affect, cognition, and the cognitive/emotional experience of 
stress are interconnected and catecholamines are key neurotransmitters in their 
function (Ashby et al., 1999). This will be reviewed in greater detail in the general 
discussion. By altering the perception and/or impact of stress or exertion, bupropion 
may allow for greater power output to be maintained relative to peripheral feedback. 
This is supported by a study in temperate conditions using another 
dopamine/noradrenaline reuptake inhibitor methylphenidate during which 
participants were instructed to maintain work rate at an RPE of 16 until they could no 
longer maintain a work rate of 70% the initial value for two minutes (Swart et al., 
2009). Participants maintained a higher power output for longer at the same RPE 
during the methylphenidate trial, without significant differences in other 
measurements between trials. A study comparing the rates of fatigue at a fixed RPE 
in different temperatures showed that power output is decreased at the same RPE 
with increasing temperature (Tucker et al., 2006). Therefore, heat strain appears to 
contribute to the same teleoanticipatory algorithm for pacing strategy, which appears 
to be modulated by central catecholamines. Acute reuptake inhibition of dopamine 
and noradrenaline may interfere with the negative feedback of stress in the control of 
power output. The results of the present study indicate that this effect is similar for 
women during the follicular phase of the menstrual cycle.  
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There were several limitations with the present study. The lack of blood samples 
precluded a more robust depiction of hormone and blood volume changes 
throughout exercise. In addition to the method for controlling menstrual cycle phase, 
basal body temperature tracking could have been included; however, this is not 
necessarily reliable (Bauman, 1981). Requesting self-testing with ovulation kits to 
identify the end of the follicular phase may have improved the reliability of trial 
coordination. Future studies should investigate whether the effects of bupropion are 
preserved during the luteal phase and check for possible hormone interactions 
(described in section 3.2). In summary, the results of the present study suggest that 
acute administration of bupropion can improve self-regulated work rate for women 
exercising in warm conditions during the follicular phase of the menstrual cycle. 
Despite the apparent trend for greater core temperature during the bupropion 
treatment, this difference was not significant. In conclusion, acute administration of 
bupropion at therapeutic levels appears to have similar performance effects for both 
men and women in warm conditions. This suggests a common mechanism for 
fatigue during prolonged exercise in warm environments that can be manipulated 
with a combined dopamine/reuptake inhibitor.  
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Chapter 4 
 
A Dopamine/Noradrenaline Reuptake 
Inhibitor Improves Performance in the 
Heat, But Only at the Maximum 
Therapeutic Dose 
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4.1 – Abstract 
Bupropion, a dopamine/noradrenaline reuptake inhibitor, has previously enabled 
participants to maintain a higher power output with the same perception of effort and 
thermal sensation reported during the placebo session. However, it is not known if 
lower doses exert the same effects during exercise in high ambient temperature. Ten 
healthy well-trained male cyclists participated in this study. Participants ingested 
either placebo or a dose of bupropion (Bup50:150mg; Bup75:225mg; 
Bup100:300mg) the evening before and on the morning of the experimental trial. All 
trials were conducted in 30°C conditions (humidity 40-60%). Participants cycled for 
60min at 55%Wmax, immediately followed by a time trial to measure exercise 
performance. The maximal dose of bupropion significantly improved performance 
(p=0.035), while the lower doses did not change performance compared to a placebo 
condition (p>0.05).Bupropion significantly increased core temperature at the end of 
exercise and during recovery in all trials compared to placebo (p<0.05). Heart rate 
was significantly higher in the Bup100 trial during the recovery period after exercise 
(p<0.05). No changes in ratings of perceived exertion and thermal sensation were 
found. An ergogenic effect was only present when the highest dose (2 x 300mg) was 
administered to the participants. Despite an increase in core temperature and 
improved performance, there was no change in the perception of effort or thermal 
sensation. 
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4.2 – Introduction 
Exercise capacity during endurance exercise has been demonstrated to be ambient 
temperature-dependent (Galloway & Maughan, 1997) and exacerbated by increasing 
humidity (Maughan et al., 2012). These effects appear to be driven by the 
physiological challenges to thermoregulatory and fluid balance factors (Hargreaves, 
2008; Nybo, 2008; Maughan, 2010). This cumulative strain results in the eventual 
onset of fatigue and subsequent impairment in performance. This appears to be 
regulated largely by mechanisms within the CNS (as described in section 1.2). 
These challenges appear to be temporarily overridden by acute administration of 
drugs that inhibit catecholamine reuptake in the CNS (Roelands & Meeusen, 2010).  
 
Bupropion is a dual dopamine/noradrenaline reuptake inhibitor that was introduced in 
1980s as a new and atypical antidepressant (Stahl et al., 2004). In excess of 40 
million people use bupropion for various clinical purposes (Jefferson et al, 2005). In 
2003 bupropion was removed from the WADA list of prohibited substances, to be 
placed on the WADA monitoring list. Recently it was shown that use of bupropion 
and other anti-depressant medications are becoming increasing prevalent amongst 
elite athletes (Machnik et al., 2009). Watson and co-workers demonstrated that 
bupropion can enhance exercise performance in warm conditions (Watson et al., 
2005a). The maximum recommended daily dosage for bupropion is 300mg, but the 
performance effect was found using 600mg within a 24 hour period. Many in vivo 
animal studies have found bupropion to increase dopamine and noradrenaline 
throughout the brain. However, these studies should be regarded conservatively, as 
doses used are typically far in excess of the maximum dosage used in human 
studies relative to body mass. Bupropion metabolites are relatively weaker dopamine 
reuptake inhibitors and collectively act more potently in inhibiting noradrenaline 
reuptake at the NAT (Damaj et al., 2004). Human metabolism of bupropion renders 
the overall effects less potent in directly inhibiting dopamine reuptake than in rats. 
Dose-dependent pharmacokinetic studies have revealed a relatively linear 
relationship between metabolites (Suckow et al., 1986). This suggests that drug 
effects are determined by total transporter occupancy, rather than a change in its 
direct action, such as is the case with amphetamine. Human positron emission 
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tomography (PET) imaging studies have found sub-chronic dosing of 150mg/day for 
3 days, followed by 300mg/day for 7 days of bupropion produced mean DAT 
occupancy of 26% (Learned-Coughlin, 2003) and a 4-week 300mg/day study found 
20.84% (Argyelán et al., 2005). Recently, a study using the same dosages, 
achieving the same level of DAT occupancy, did not significantly increase 
extracellular dopamine in the striatum (Egerton et al., 2010). No appreciable 
increase in extracellular dopamine in the striatum were found even with 50% DAT 
blockade and only surprisingly small increases in extracellular dopamine with almost 
complete blockade (Volkow et al., 2002a). However, using a similar dose this 
research group showed a small, but significant increase (10%) in extracellular 
dopamine release in response to food stimulation (Volkow et al., 2002b).  
 
It was originally believed that both methylphenidate and bupropion inhibit DAT more 
potently than NAT. This was due to estimation of NAT blockade made using 
radiolabelled Nisoxetine, which has greater affinity for NAT than noradrenaline in the 
conditions used, resulting in underestimation of binding (Reith et al., 2005). Using 
radiolabelled noradrenaline instead, methylphenidate and bupropion are found to 
have 5 and 2 times greater affinity for NAT than DAT, respectively, and 
methylphenidate has 38 and 15 times greater affinity for NAT and DAT, respectively, 
than bupropion (Eshleman et al., 1999). Similarly, bupropion has been found to 
reduce the electrophysiological activity of the locus coeruleus by 50% (IC50) at 
13mg/kg compared to the 42mg/kg needed to reduce activity at dopaminergic 
neurons by the same amount (50%) in rats (Cooper et al., 1994). In the study by 
Watson and co-workers (Watson et al., 2005a) as well as the previous chapter the 
dose averaged at 8mg/kg. Together, the dose-dependent effects observed in human 
imaging, animal and in vitro studies suggest that both bupropion more potently 
occupies NAT than DAT in humans. The efficacy of such a relatively low dose would 
imply that striatal increased sensitivity to striatal phasic dopamine and stimulus 
salience is not necessarily the determining mechanism by which these drugs 
improve exercise performance. In spite of the large amount of research investigating 
the effects of these drugs at the striatum, recent evidence suggests that the 
therapeutic doses used preferentially affect the PFC (Berridge et al., 2006), where 
DAT expression is minimal (Hall et al., 1999) and NAT expression is high (Logan et 
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al., 2007). Here, extracellular dopamine is actively cleared by NAT (Morón et al., 
2002), suggesting that for significant dopaminergic reuptake inhibition to occur in the 
PFC, the NAT must also be blocked.  
 
The dose-dependent effects of these dual reuptake inhibitors are dependent on 
linear increases in blockade of both transporters. The resulting neurophysiological 
effects, however, are dependent on transporter expression at relevant 
neuroanatomical structures. Drug effects will therefore be determined by unique 
concentration thresholds at various structures throughout the brain and their 
interactions. Since often lower doses of bupropion than those used in previous 
studies are prescribed, it is important to investigate whether there is a dose-
response relationship for this pharmacological agent with regard to exercise in high 
ambient temperature. Previous research on the effects of bupropion during 
prolonged exercise performance in a warm environment (Watson et al., 2005 and 
Chapter 3) suggests that the maximal dose will improve exercise performance, so it 
is hypothesised that there will be a linear, dose-dependent improvement in 
performance.  
 
4.3 – Methods 
Ten healthy males (age 25 ± 4 y; height 1.82 ± 0.05 m; body mass 73.6 ± 9.1 kg; 
Wmax 351 ± 28 W; VO2peak 64 ± 6 mL/kg/min) participated in this investigation. All 
participants were well-trained cyclists or triathletes, but were not accustomed to 
exercise in a warm environment at the time of the study. Prior to the start of the 
study all volunteers received written information regarding the nature and purpose of 
the experimental protocol. Following an opportunity to ask any questions, a written 
statement of consent was signed. The protocol employed was approved by the 
Research Council of the Vrije Universiteit Brussels, Belgium. The experimental 
design used in this study is identical to the protocol used by Watson and co-workers 
(2005) and Roelands and co-workers (Roelands et al., 2008d, 2008a). All 
participants completed a preliminary maximal exercise test, a familiarisation trial and 
4 experimental trials. The preliminary trial consisted of continuous incremental cycle 
77 
 
exercise to volitional exhaustion and was used to determine the power output 
required to elicit 55% and 75% of maximal workload (Wmax) and VO2max. A 
familiarisation trial was undertaken to ensure the participants were accustomed to 
the procedures employed during the investigation and to minimize any potential 
learning or anxiety effects. This trial was identical to the experimental trials in all 
respects. Experimental trials were undertaken in warm (30oC) conditions with relative 
humidity maintained between 40 – 60%. Experimental trials were separated by 7 
days to minimise the development of heat acclimation and to ensure drug washout. 
Participants were instructed to record dietary intake and physical activity during the 
two days before the first trial, and to replicate this in the two days prior to the 
subsequent experimental trials. No exercise, alcohol or caffeine consumption was 
permitted in the 24 hours before each trial.  
 
Participants ingested a placebo (200mg lactose) or a dose of bupropion (Bup50: 
150mg; Bup75: 225mg; Bup100: 300mg) the evening before and on the morning of 
the experimental trial. A dose of 150mg is typically administered during the first week 
of the treatment in depression or to assist in the cessation of smoking, while 300mg 
is equivalent to the maximal daily therapeutic dose (Holm & Spencer, 2000). The 
treatment was randomized and administered in double-blind crossover manner. All 
capsules were prepared by an independent pharmacy to appear indistinguishable 
with regard to dimensions, weight and colour. Experimental trials were designed in 
accordance with previous studies in this laboratory (Watson et al., 2005a; Roelands 
et al., 2008d, 2008c). Participants entered the laboratory in the morning 
approximately 90 minutes after consuming a standard breakfast that included 500mL 
of plain water. Nude post-void body mass was measured after which participants 
inserted a rectal thermistor 10cm beyond the anal sphincter for the measurement of 
core temperature. Surface skin temperature probes were attached to four sites 
(chest, upper arm, thigh and calf) to enable the determination of weighted mean skin 
temperature (Ramanathan, 1964) and a heart rate telemetry band was positioned. 
Participants were dressed in only cycling shorts, socks and shoes for all trials. 
Participants then entered a climatic chamber maintained at the appropriate 
environmental condition and rested in a seated position for 15 minutes. During this 
period temperatures and heart rate were recorded at 5 minute intervals and a resting 
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venous blood sample was drawn immediately before the start of exercise. The 
exercise protocol consisted of 60 minutes constant load exercise at a workload 
corresponding to 55 % Wmax, followed by a TT to measure exercise performance. 
There was a 1 to 2 minute delay between the end of the constant load exercise and 
the beginning of the TT, to program the ergometer. The TT required the participants 
to complete a predetermined amount of work equal to 30 minutes at 75 % Wmax as 
quickly as possible (Jeukendrup et al., 1996). Participants began the TT at a 
workload corresponding to 75 % Wmax, but were free to increase or decrease their 
power output as desired from the outset. During the TT a computer program 
displayed a bar indicating the percentage of total work completed to give the subject 
an indication of their progress. Throughout the protocol no feedback was provided 
regarding time lapsed, power output, pedal cadence or heart rate. During exercise 
participants had ad libitum access to plain water. 
 
Core and skin temperatures and heart rate were recorded at 5 minute intervals 
during exercise. Ratings of perceived exertion (RPE; Borg 1982) and thermal 
sensation (assessed using a 21-point scale ranging from unbearable cold to 
unbearable heat; adapted from Hardy 1970) were assessed every 15 minutes during 
the initial 60 minute constant load period and at 10 minute intervals during the TT. 
Venous blood samples were drawn after 60 minutes of constant load exercise and at 
the end of the TT. Following the completion of the TT participants returned to a 
seated position where recovery was monitored for 15 minutes (see figure 4.1). The 
probes and cannula were then removed and nude body mass was re-measured to 
allow the estimation of sweat losses. Venous blood samples were drawn directly into 
pre-cooled vacutainer tubes). 10mL samples were collected into plain tubes and left 
to clot for 1 hour at room temperature before centrifugation. The resulting serum was 
stored at –20oC for the determination of prolactin and cortisol. Samples for plasma 
ACTH were collected into 4.5mL tubes containing K3EDTA. All hormones were 
measured using ELISA kits. A 0.5mL aliquot of whole blood was extracted and used 
for the determination of haemoglobin and haematocrit, with these used to estimate 
percentage changes in plasma volume relative to the pre-exercise sample. 
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Figure 4.1 Schematic of experimental trials. 
 
4.4 – Results 
All participants completed all experimental trials with no reported side effects. 
Participants finished the TT significantly faster in the Bup100 trial compared to the 
placebo trial (p=0.035; placebo: 33’42” ± 2’12”, Bup100: 32’06” ± 1’54”; Fig. 1) 
equivalent to a ~5% reduction in time to completion. TT performance during the 
Bup50 (p=0.411) and the Bup75 (p=0.423) trials were not significantly different to the 
placebo trial (figure 4.2). A linear performance response to increasing dose was not 
apparent for the majority of participants (figure 4.3).  
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Figure 4.2 Group time trial performance * denotes significant difference compared to placebo 
(32’06” ± 1’54 vs. 33’42” ± 2’12”, respectively; p=0.035). 
 
 
Figure 4.3 Individual time trial performance. Thick black line represents the mean. 
 
Exercise caused a gradual increase in core temperature in all trials (p=0.001; figure 
4.4A). In all bupropion trials, there was a tendency for the core temperature to be 
increased during the time trial compared to the placebo trial. Core temperature rose 
significantly higher in Bup100 trial (40.0 ± 0.6°C) than during the placebo trial (39.5 ± 
0.6°C) near the end of the TT and during recovery (p<0.05). During the Bup50 and 
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Bup75 trial significantly higher core temperatures were reached compared to the 
placebo trial during recovery phase (p<0.05). No differences in weighted mean skin 
temperature were apparent between the placebo and bupropion trials (figure 4.4B). 
Skin temperature increased during exercise in all conditions, reaching a plateau after 
10 min of exercise. 
A 
 
B 
 
Figure 4.4 Core (A) and weighted mean skin (B) temperature throughout trials. Significant 
differences (P<0.05) compared to placebo at the corresponding time point are denoted as # for 
Bup50, § for Bup75, and * for Bup100. 
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Heart rate increased significantly in all trials (p<0.001). In the Bup100 trial heart rate 
showed a tendency to be increased near the end of exercise and was significantly 
higher during the recovery phase compared to the placebo (p<0.024; figure 4.5). No 
differences in heart rate were found between the lower doses of bupropion and the 
placebo trial.  
 
Figure 4.5 Heart rate during experimental trials. Significant difference compared to placebo 
(P<0.05) denoted by * for Bup100. 
 
Both RPE and TS scores significantly increased during exercise (p<0.05; figure 4.6). 
Ratings of perceived exertion were similar between the placebo and different 
bupropion treatments. The participants’ ratings of thermal sensation were also not 
influenced by the drug treatment. The loss of body mass after exercise, corrected for 
fluid intake, did not show any change due to the bupropion administration.  
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Figure 4.6 RPE (A) and ratings of thermal sensation (B) during experimental trials. 
 
All measured hormone concentrations rose during exercise in all trials (figure 4.7). 
ACTH similarly increased significantly after constant load exercise (P<0.005) and at 
the end of TT had increased significantly compared to at rest (P<0.001). Rise in 
circulating cortisol concentrations were significant only at the end of TT in all trials 
(P<0.05) compared to at rest and after the constant load exercise. Prolactin 
concentrations were significantly elevated at the end of TT and had increased 
significantly compared to both at rest (P<0.001) and after the initial 60 min (P<0.001) 
for all trials.  
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Figure 4.7 Circulating hormone concentrations throughout and within trials. Significant difference 
(P<0.05) compared to placebo is indicated as * and significant difference compared to both rest and 
60min is denoted as **. Within trial significant difference (P<0.05) compared to baseline and 60min is 
denoted as 
a 
and 
b
, respectively. 
 
There were no differences between trials in haematocrit, haemoglobin or percent 
changes in blood volume, cell volume or plasma volume. Packed cell volume and 
haemoglobin significantly increased compared to baseline overall (P<0.05), but only 
significantly increased between steady state and the end of the time trial in all trials 
except at 75% dose (table 4.1). This trend was preserved through the calculation for 
percentage changes in blood volume and plasma volume, while cell volume did not 
significantly change throughout (table 4.2). There were no differences between trials 
for sweat loss (figure 4.8). 
 
Table 4.1 Haematocrit (Hct) and haemoglobin (Hb) during experimental trials. a and b denote 
significant difference between start and 60min, respectively. 
 
 
Placebo Bup50 Bup75 Bup100 
Hct (%) 
Start 42.3± 2.2 42.3 ± 2.7 42.6± 2.6 42.5± 2.4 
60min 43.9 ± 2.9a 43.7± 3.3a 44.0 ± 3.2a 44.2 ± 3.3a 
End 44.8± 2.9ab 44.6 ± 3.7ab 44.6± 3.8a 45.4± 3.2ab 
Hb (g/L) 
Start 149.9± 9.0 149.5 ± 10.4 150.1 ± 9.9 150.7± 9.1 
60min 157.1 ± 11.2a 156.0± 13.4a 156.8± 12.8a 157.0 ± 12.1a 
End 159.3 ± 11.5ab 158.5± 13.9ab 159.1± 14.5a 160.5± 11.9ab 
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Table 4.2 Percentage changes in blood, cell and plasma volume compared to rest throughout trials 
as calculated by the method put forth by Dill and Costill (1979). 
a
 and 
b
 denote significant difference 
between start and 60min, respectively. 
  
Placebo Bup50 Bup75 Bup100 
ΔBV% 
60min -4.5± 1.5a -4.0± 2.4a -4.1± 2.2a -3.9± 2.3a 
End -5.8 ± 1.9ab -5.5± 2.2ab -5.4 ± 2.7a -6.0 ± 1.7ab 
ΔCV% 
60min -0.9± 1.3 -1.0 ± 1.2 -0.9± 1.2 -0.1± 0.5 
End -0.3 ± 1.4 -0.6± 0.9 -1.1± 1.2 0.3± 1.2 
ΔPV% 
60min -7.2± 3.1a -6.3 ± 3.9a -6.6 ± 3.7a -6.8 ± 4.3a 
End -9.9± 3.8ab -9.3 ± 4.3ab -8.8± 4.8a -10.7± 3.3ab 
 
 
Figure 4.8 Post-exercise corrected body mass losses due to sweat. 
 
4.5 – Discussion 
Previous studies have found that acutely increasing central catecholaminergic 
activity via dual dopamine/noradrenaline reuptake inhibitors can improve exercise 
performance in warm conditions compared to placebo. The present study is the first 
to investigate the effects of a range of lower doses. The results of the present study 
demonstrate that only the maximum acute dose of bupropion improved performance 
in during prolonged exercise in warm conditions. The increase in performance was 
comparable to those found by Watson and co-workers (2005) and in those in 
Chapter 3 (5% vs. 9% and 7.5% respectively). Acute manipulation of central 
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catecholaminergic neurotransmission can enhance performance in the heat, despite 
the attainment of core temperatures in excess of those observed during the placebo 
trial. Bupropion is not currently included in the list of prohibited substances, meaning 
that athletes are currently free to use this agent in training and competition. A 
consequence of this improvement in performance was the maintenance of a greater 
rate of heat production, resulting in the attainment of a higher core temperature 
towards the end of the TT phase of the trial. In a similar manner to previous 
investigations (Watson et al., 2005; Roelands et al., 2008a), this was accompanied 
by a lack of difference in perceived exertion or ratings of thermal sensation, so it 
seems possible that the use of drugs of this nature has the potential to increase the 
likelihood of developing heat illness.  
 
This ability to maintain a higher power output and attain higher core temperatures 
may be due to catecholaminergic modulation of error detection in the 
teleoanticipatory algorithm described by St Clair Gibson and co-workers (2006). Heat 
strain appears to contribute to the same teleoanticipatory algorithm for pacing 
strategy. A study comparing the rates of fatigue at a fixed RPE in different 
temperatures showed that power output is decreased at the same RPE with 
increasing temperature (Tucker et al., 2006). As power output is modulated a 
prediction of performance feedback will be computed. If afferent stress signals do not 
match those predicted by the algorithm, a change in power output may be made to 
compensate and the experience of this change of demand will be reflected in 
perceived exertion. Methylphenidate, another dopamine/noradrenaline reuptake 
inhibitor, has been demonstrated to alter this relationship in RPE and power-output 
in a study controlling for RPE. Participants maintained a higher power output for 
longer at the same RPE during the methylphenidate trial (Swart et al., 2009). The 
perception of exertion has also been demonstrated to be related to affect (Baden et 
al., 2005). This is supported by evidence from research focused on the ACC, which 
has been identified as a key neuroanatomical structure for internal monitoring and 
autonomic management of behavioural economics (Sanfey et al., 2006; Salamone et 
al., 2009). The relationship between affect and RPE may be explained by internal-
monitoring errors acting as aversive stimuli, increasing stress and promoting 
negative affect (Hajcak & Foti, 2008). ERN at the ACC has been shown to occur 
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even as a result of unperceived, or subconscious errors (Nieuwenhuis et al., 2001). 
This suggests that when unexpected negative teleoanticipatory feedback is received 
it would have a negative emotional and cognitive impact, supporting the findings by 
Baden and co-workers (2005). Furthermore, negative affect increases the amplitude 
of ERN in response to errors (Wiswede et al., 2009), suggesting a potential feed-
forward effect of an increasingly negative impact on affect and stress by error 
detection. The neural networks associated with affect, cognition, and the 
cognitive/emotional experience of stress are interconnected and catecholamines are 
key neurotransmitters in their function (Ashby et al., 1999). This includes the PFC, a 
key target of action for therapeutic doses of methylphenidate (Berridge et al., 2006) 
and bupropion (Bares et al., 2010). PFC and ACC are interconnected, collectively 
contributing to the integration of emotional and cognitive processes, and 
catecholamines modulate their activity  (Bush et al., 2000). Their activity is also 
integrated in the generation of the ERN (Herrmann et al., 2004). By altering the 
perception and/or impact of stress or exertion, acute bupropion administration may 
allow for greater power output to be maintained relative to peripheral feedback.  
 
The prevalence of antidepressant and psychostimulant use appears to be increasing 
among elite athletes (Eichner, 2008; Machnik et al., 2009). While many individuals 
may have legitimate reasons for seeking this type of treatment, the inappropriate use 
of these agents by athletes to enhance performance is also a distinct possibility. The 
combination of manipulating catecholaminergic neurotransmission and strenuous 
exercise in the heat has been shown to enable the attainment of higher core 
temperatures, potentially increasing the risk of heat illness (Watson et al., 2005; 
Roelands et al., 2008a). Because lower doses of bupropion (compared with the 
recommended maximal daily dose) are often prescribed (150mg/day), the present 
study investigated the dose–response effects of acute administration of bupropion on 
performance, thermoregulation and hormonal responses to prolonged exercise in 
warm conditions. Given that an ergogenic effect was present only when the highest 
dose (2 x 300mg) of bupropion was administered, this suggests a threshold at which 
the reuptake inhibition of dopamine and noradrenaline begin to affect performance. 
In addition, administration of a more potent catecholaminergic agent (such as 
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methylphenidate) results in greater performance improvements (Roelands et al., 
2008a).  
 
The therapeutic use of these drugs entails chronic administration over a period of 
weeks, months or years. A previous study using a sub-chronic dosing protocol (10-
day) reported no benefit to exercise performance (Roelands et al., 2009). Daily 
administration of bupropion has been found to result in a decrease in the tissue 
levels of dopamine, lower concentrations of its metabolites, and a reduction in 
voluntary motor activity (Santamaría & Arias, 2010). The authors attribute this effect 
of bupropion administration over a period of several days to excessive 
dopamine/noradrenaline release, which eventually depletes the tissue pool of 
dopamine. However, it should be noted that this study used very high concentrations 
of bupropion relative to body mass (~30mg/kg). Furthermore, reuptake inhibitors 
typically reduce synthesis of the respective neurotransmitters they affect due to 
negative feedback, as demonstrated by reduction in the presence of synthetic 
enzyme mRNA, which is also the case for bupropion and tyrosine hydroxylase 
(Nestler et al., 1990). This effect has been observed in tandem with the changes in 
electrophysiological adaptations at the locus coeruleus after treatment with 
antidepressants, including bupropion (Nestler et al., 1999). These findings may be of 
interest to WADA, because bupropion is currently on the monitoring program, 
meaning its use by athletes is not restricted in competition, unlike the use of 
methylphenidate or amphetamine. Unfortunately, determining whether an athlete has 
been using the treatment in the appropriate manner would be difficult to determine.  
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Chapter 5 
 
The Effect of a Catecholamine Precursor 
on the Development of Fatigue during 
Prolonged Exercise in Warm Conditions 
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5.1 – Abstract 
Acute doses of the catecholamine precursor L-DOPA and peripheral amino acid 
decarboxylase inhibitor (Sinemet) on prolonged exercise previously failed to change 
exercise performance in normal ambient temperatures. This may have been due to 
the short half-life of L-DOPA and sensitivity to food consumption. Therefore, it is not 
known whether acute doses of L-DOPA timed to reach Cmax during exercise will 
improve prolonged cycling performance in warm conditions. 10 physically active men 
(age 26 ± 4 y; height 1.76 ± 0.08 m; body mass 76.3 ± 10.6 kg; VO2peak 57.4 ± 8 
mL/kg/min) were recruited for this study. Participants cycled for 1 h at 60% VO2peak 
followed by a 30 min workload challenge, during which they were instructed to 
complete as much work as possible. Heart rate, skin and core temperature, as well 
as ratings of perceived exertion and thermal sensation were recorded throughout 
exercise. A finger tap test at the beginning and end of exercise were employed to 
examine fine motor control. No significant difference in exercise performance was 
observed between trials. Prolactin concentrations were significantly increased at the 
end of exercise in all trials (P<0.001) but this response was attenuated at the end of 
exercise for the L-DOPA trial (11.4 ± 5.5 ng/mL) compared to single-blind (23.6 ± 5.6 
ng/mL) and double-blind placebo trials (20.8 ± 3.3 ng/mL; P=0.024). No differences 
between trials were found for all other measures. The results indicate that 
augmenting central catecholamine pools inhibit the normal prolactin response to 
exercise in the heat, but do not alter performance, thermoregulation or sympathetic 
outflow.  
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5.2 – Introduction 
Endurance exercise capacity is reduced in warm conditions in a temperature- 
(Galloway & Maughan, 1997) and humidity-dependent manner (Maughan et al., 
2012).  The main physiological difference to exercise in normal ambient conditions is 
the challenge to thermoregulation and, consequently, fluid balance as well 
(Hargreaves, 2008; Nybo, 2008; Maughan, 2010). This cumulative strain results in 
the eventual onset of fatigue and subsequent impairment in performance. This 
appears to be regulated largely by mechanisms within the CNS (as described in 
section 1.2). Pharmacological inhibition of catecholamine reuptake consistently 
improves performance during prolonged exercise in warm conditions, whereas 
studies attempting to influence catecholamine metabolism have been conflicting 
(Roelands & Meeusen, 2010). L-DOPA is the precursor molecule for dopamine 
synthesis. L-DOPA has been used to treat motor control disorders in Parkinson’s 
disease for over 40 years and is considered the “gold standard” treatment today 
(Nagatsu & Sawada, 2009). Clinically, L-DOPA is administered with an amino acid 
decarboxylase (AADC) inhibitor that cannot readily cross the blood-brain barrier; this 
prevents decarboxylation of L-DOPA in the periphery, thereby reducing associated 
gastrointestinal distress and increasing the delivery of L-DOPA to the brain. To date, 
only one study has investigated the effects of L-DOPA on prolonged exercise 
performance (Meeusen et al., 1997b). This study was conducted in normal ambient 
temperature and reported no effect on exercise performance. This study used 
Sinemet, a combination drug containing L-DOPA and carbidopa, an AADC inhibitor, 
in a ratio of 4:1. Instant Sinemet is designed begin absorption 30 minutes after 
ingestion. Thereafter Cmax of L-DOPA occurs roughly 1 hour after ingestion and the 
half-life is only approximately 2 hours (Contin & Martinelli, 2010). In the study by 
Meeusen and co-workers (1997), the dosing protocol is described as 4mg/kg 
Sinemet and is taken 24 hours before exercise and the morning of the trial. It is not 
clear whether this meant the dose was 4mg/kg Sinemet (4:1 L-DOPA/carbidopa) or 
4mg/kg L-DOPA. Furthermore, it isn’t clear if the 4mg/kg was divided between the 
two doses or if it is taken twice. The study imposed a standardised breakfast before 
exercise. Whether this was before or after the morning dose is not mentioned, but in 
either case, this would have a drastic impact on L-DOPA pharmacokinetics, severely 
reducing circulating L-DOPA concentrations (Contin & Martinelli, 2010). Therefore, 
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the dosing protocol employed was not ideal with respect to L-DOPA 
pharmacokinetics. Nonetheless, peripheral catecholamines were increased as was 
circulating growth hormone, suggesting a central effect. While this study found no 
effect on exercise performance, the effects of central catecholaminergic manipulation 
appears to be more pronounced during exercise undertaken in warm conditions. 
Therefore, the aim of the present study is to determine the effects of a dosing 
protocol designed to provide peak L-DOPA concentrations during a performance test 
during prolonged exercise in a warm environment. It is hypothesised that an acute 
dose of Sinemet will improve prolonged exercise performance in warm conditions.  
 
5.3–Methods 
10 physically active men (age 26 ± 4 y; height 1.76 ± 0.08 m; body mass 76.3 ± 10.6 
kg; VO2peak 57.4 ± 8 mL/kg/min) were recruited to participate in this study. All 
participants took part in regular endurance exercise, but were not accustomed to 
exercise in a warm environment at the time of the study. Prior to their admission to 
the study, participants were provided information regarding the purpose and design 
of the study, including manufacturer information about Sinemet. Thereafter, if 
participants confirmed their interest and eligibility, a statement of informed consent 
was signed. Participants visited the laboratory 5 times in total. The first visit was a 
VO2peak test to determine work rates for the experimental trials. Subsequently, 
participants returned for a familiarisation trial to minimise any learning or anxiety 
effects and to ensure proper work rate configuration. This was followed by a single-
blinded placebo control trial, which served both as an additional comparison against 
experimental trials and as a second familiarisation. The experimental trials which 
followed were arranged in a randomised double-blind, placebo-controlled crossover 
design.  
 
VO2peak was determined by a discontinuous test to volitional exhaustion was 
performed by participants using a Lode Corival cycle ergometer (Lode B.V., 
Groningen, Netherlands) in an environmental chamber (Weiss-Gallenkamp, UK) at 
20° C and 50% relative humidity as described in Chapter 2. VO2peak was then used 
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to calculate work rates corresponding to this value using linear regression. The 
standardisation of pre-trial conditions is outlined in Chapter 2. On the day of testing, 
participants ingested 100/25mg L-DOPA/carbidopa or placebo (glucose) upon 
waking with water. After 1.5 hr, participants consumed a standardised aproteic 
breakfast consisting of two small cereal bars and 500mL of orange juice. 1.5 hr later 
they consumed their second dose of Sinemet. During the following 2.5 hours, 
participants were asked to steadily consume 500mL of water, after which they 
arrived at the laboratory for testing. This dosing protocol was intended to augment 
central catecholamine stores and coordinate peak blood concentrations to occur 
during exercise, while avoiding nausea which is relatively common with 
administration of L-DOPA. Experimental trials were designed to be similar to 
previous studies (Watson et al., 2005a; Roelands et al., 2008d, 2008b;chapters 1 & 
2). Upon arrival participants were asked to void their bowels and bladder, before 
nude body mass was recorded. Participants then changed into cycling clothing, 
positioned a rectal thermistor 10cm beyond the anal sphincter and a radio telemetric 
heart rate monitor in privacy. Surface skin thermistors were placed at four sites 
(triceps, chest, quadriceps and calf) for the measurement of weighted mean skin 
temperature using the Ramanathan method (1964). Whilst seated for 15 minutes in a 
thermoneutral environment a 2g butterfly cannula was introduced to a superficial 
forearm vein to allow repeated blood sampling throughout the experimental protocol. 
Due to the short Cmax and half-life of L-DOPA, participants were asked to consume a 
final dose of Sinemet or placebo immediately before beginning exercise; totalling 
300mg L-DOPA and 75mg carbidopa, which is the minimum recommended daily 
dose to start with treating of Parkinson’s disease.  
 
The experimental protocol is illustrated in figure 5.1. After the collection of baseline 
measurements during the rest period, participants entered the climatic chamber 
maintained at 30.2 ± 0.2 °C, 50% ± 1% relative humidity. Before and after exercise 
participants performed two finger-tap tests with both hands, to determine any 
changes in fine motor control. During exercise, participants were given 100mL of 
water to drink every 10 minutes, amounting to 900mL in total, which was deducted 
from post-exercise body mass, to calculate sweat loss. Throughout the trial heart 
rate, core temperature and skin temperature, were recorded every 5 minutes. During 
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the 15 minute rest period subjective thermal sensation was measured. During the 1 
hour fixed work rate period subjective thermal sensation and rate of perceived 
exertion were measured every 15 minutes. Expired gas samples were also collected 
for verification of work rate at 30 min and just before steady state exercise was 
complete. During the time trial perceived thermal sensation and exertion were 
measured every 10 minutes. Participants were asked to cycle at a work rate 
corresponding to 60% VO2peak for 60 minutes, followed by a 30 minute workload 
challenge, in which participants were asked to complete as much work as possible. 
Initial work rate during the workload challenge corresponded to 75% VO2peak, 
thereafter participants were free to manipulate the work rate to complete as much as 
they felt possible (see figure 5.1). Standardised verbal encouragement was provided 
by the experimenter to help ensure a maximal effort. Feedback during the time trial 
was limited to the time lapsed (power output, cadence, heart rate, etc. were hidden 
from the participant). Following completion of the workload challenge and the 
collection of the final blood sample, participants completed a second finger tap test 
before leaving the climatic chamber. Skin thermistors, heart rate telemetry band and 
rectal thermistor were removed in privacy before towelling off and nude body mass 
was recorded behind a screen. The second measurement of nude body mass was 
used to calculate sweat loss, correcting for the weight of water consumed during 
exercise. 
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Figure 5.1 Schematic of experimental trials. 
 
5.4 –Results 
Multivariate analysis revealed that there were no significant differences between 
trials for performance (P=0.08) (figure 5.2A). Post-hoc paired-sample t-tests were 
employed to observe between trial differences, which revealed a significant 
difference between the single-blind placebo (316.6 ± 49.4 kJ) and L-DOPA trial 
(326.3 ± 48.1; P=0.023) and no significant difference between single-blind and 
double-blind (314.1 ± 42.7; P=0.797), or double-blind placebo and L-DOPA 
(P=0.276). However, because these trials are not conducted under the same 
conditions, the significance is untenable. No order effect was observed on 
performance (P=0.553). Two participants performed substantially worse on their 
double-blind placebo compared to their single-blind placebo trial (see figure 5.2B). 
This resulted in a larger effect size for the L-DOPA trial and should therefore be 
considered with caution (see figure 5.3).   
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Figure 5.2 Total work done during the time trials expressed by trial (A) and for each individual (B). 
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Figure 5.3 Percentage change in performance from double-blind placebo to L-DOPA trials. 
 
Core temperature rose steadily in all trials during exercise, but there was no 
significant difference between trials (figure 5.4A). Weighted mean skin temperature 
rose rapidly in the first 15 minutes of exercise after which it plateaued until the end of 
exercise (figure 5.4B). No significant differences were observed between trials. 
Similarly, heart rate rose rapidly in the first 15 minutes of exercise, then stabilised 
and increased gradually throughout the steady state period. Heart rate increased 
sharply again after the start of the workload challenge and continued to rise slowly 
until the end (figure 5.5). No significant differences were observed between trials.  
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Figure 5.4 Core temperature (A) and weighted mean skin temperature (B) throughout trials. 
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Figure 5.5 Heart rate throughout trials. 
 
Rating of perceived exertion increased throughout exercise (figure 5.6), but no 
significant differences were observed between trials (P=0.853). Ratings of thermal 
sensation rose rapidly in the first 15 minutes of exercise, but remained stable during 
the prolonged exercise period (figure 5.7). During the workload challenge thermal 
sensation ratings rose more rapidly. No significant differences were observed 
between trials (P=0.682).  
 
Figure 5.6 Ratings of perceived exertion throughout exercise. 
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Figure 5.7 Ratings of thermal sensation throughout trials. 
 
Prolactin concentrations were significantly elevated at the end of exercise in all trials 
(P<0.001), but this response was significantly attenuated during the L-DOPA trial 
(11.4 ± 5.5 mIU/mL) compared to single-blind (23.6 ± 5.6 mIU/mL) and double-blind 
placebo trials (20.8 ± 3.3 mIU/mL; P=0.024). Cortisol concentrations were 
significantly increased at the end of exercise in all trials (P=0.001), but there was no 
significant difference apparent between trials (P=0.448). 
 
Figure 5.8 Serum prolactin at rest and after the workload challenge. * denotes significant difference 
from rest (P<0.001). ** denotes significant difference between trials (P=0.024). 
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Figure 5.9 Serum cortisol throughout trials. * denotes significant difference from rest, 30min and 60 
min (P=0.001) 
 
A significant exercise effect was found for finger-tap performance for the dominant 
hand only (P=0.007). This was reflected in an increased number of taps after 
exercise. No significant difference was observed for finger-tap test between trials.  
 
Table 5.1 Number of taps for dominant and non-dominant hands before and after exercise for each 
trial. 
a 
denotes significant difference after exercise (P<0.05). 
 Single-Blind 
Placebo 
Double-Blind 
Placebo L-DOPA 
 Pre Post Pre Post Pre Post 
Dominant 74.4±9.1 77.5±9.0a 74.7±8.3 76.1±11.1 74.4±9.3 77.2±10.6a 
Non 68.3±9.2 72.8±9.4a 69.8±12.6 72.6±12.8 69.1±11.6 72±8.8 
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Table 5.2 Changes in haematocrit (Hct), haemoglobin (Hb), and glucose from rest to end of each 
trial. All values were significantly increased compared to rest (P<0.05). No significant differences 
between trials were observed. 
  
Single-Blind 
Placebo 
Double-Blind 
Placebo L-DOPA 
 
Rest 43.3 ± 1.9 43.4 ± 1.5 43.4 ± 1.4 
Hct (%) 30min 45.2 ± 1.6 44.1 ± 0.9 45.4 ± 1.6 
 
60min 45.1 ± 1.6 44.6 ± 1.7 45.3 ± 1.3 
 
End 45.8 ± 1.7 45.2 ± 1.1 46.1 ± 1.1 
     
 
Rest 151.8 ± 5.8 151.6 ± 5.5 149.0 ± 7.7 
Hb (g/L) 30min 159.3 ± 9.2 156.9 ± 5.9 159.4 ± 6.8 
 
60min 160.6 ± 7.2   162.0 ± 11.0 159.0 ± 6.6 
 
End 163.1 ± 7.3 160.2 ± 5.6 161.6 ± 6.2 
     
 
Rest 4.5 ± 0.9 4.5± 0.9 3.9 ± 0.4 
Glu(mmol/L) 30min 4.5 ± 0.7 4.1 ± 0.5 4.1 ± 0.8 
 
60min 4.7 ± 0.7 4.3 ± 0.7 4.1 ± 0.8 
 
End 5.0 ± 1.1 4.6 ± 0.8 4.6 ± 0.8 
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Table 5.3 Percentage changes in blood volume (BV), cell volume (CV) and plasma volume (PV) at 
the end of each trial. Calculated using the method described by Dill and Costill(1974). All values were 
significantly increased compared to rest (P<0.05). No significant differences between trials were 
observed. 
 
  
Single-Blind 
Placebo 
Double-Blind 
Placebo L-DOPA 
 
30min -4.6 ± 2.5 -4.2 ± 2.3 -6.3 ± 3.7 
ΔBV% 60min -5.5 ± 1.8 -5.8 ± 4.8 -6.2 ± 3.5 
 
End -6.9 ± 1.7 -5.6 ± 1.9 -8.0 ± 3.8 
 
30min -0.3 ± 3.3 -1.7 ± 2.8 -2.1 ± 5.6 
ΔCV% 60min -1.4 ± 1.9 -3.4 ± 4.7 -2.1 ± 5.3 
 
End -1.3 ± 2.0 -1.5 ± 1.8 -2.2 ± 4.7 
 
30min -7.8 ± 2.8 -6.0 ± 3.0 -9.4 ± 3.2 
ΔPV% 60min -8.5 ± 2.9 -7.6 ± 5.3 -9.3 ± 3.0 
 
End -11.1 ± 3.0 -8.8 ± 2.8 -12.4 ± 3.4 
 
No differences between were observed for sweat loss (figure 5.10) or steady state 
expired gas values between trials (P>0.05). Expired gas showed a steady increase 
in %VO2peak throughout the bout of steady state exercise, but there was no 
significant differences apparent between trials (P>0.05).  
 
Figure 5.10 Mean sweat loss during experimental trials. 
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5.5 – Discussion 
The results of the present study suggest that augmenting availability of a 
catecholamine precursor produces no effect on exercise performance, 
thermoregulation or sympathetic outflow. While an effect on brain catecholamine 
production was confirmed through a change in circulating prolactin concentrations, 
no other clear physiological effects were apparent, supporting the findings by 
Meeusen and co-workers (Meeusen et al., 1997b). Inhibition of the prolactin 
response was evident in the L-DOPA trial, which is a common effect of L-DOPA 
treatment that has been well documented (Ben-Jonathan & Hnasko, 2001). This 
indicates that the dosing protocol produced the desired response: elevating brain 
catecholamine synthesis and release. The lack of performance response observed 
may be due to an insufficient increase in synaptic release elicited by the dose used 
in the present study. However, a study using similar dosages to the present study 
found an inverted-U dose-response to L-DOPA on cognitive function associated with 
the inverted-U dose-response to dopamine on PFC function (Onur et al., 2011). In 
the present study, a finger-tap test was employed to examine possible fine motor 
control effects, which is often used as a diagnostic test in experiments concerning 
Parkinson’s disease. No drug effect was observed, but an increase in finger-tap 
performance was observed after exercise. This may be due to increased relative 
arousal, sympathetic outflow or thermal effects on conductivity following intense 
exercise in the heat. While the pathological loss of dopaminergic function in 
Parkinson’s disease provides a completely different environment in which L-DOPA 
can improve motor control, it is worth noting that L-DOPA has been found to exert an 
inverted-U dose-response on transcranial magnetic stimulation-elicited motor-evoked 
responses in healthy young men, using similar doses to those used in the present 
study (Monte-Silva et al., 2010).  
 
Because L-DOPA can increase central catecholamine stores and release without 
altering performance as reuptake inhibition does, perhaps there are regional cerebral 
changes that are affected differently by distinct mechanisms important in the control 
of central fatigue during prolonged exercise in warm conditions. For example, 
catecholamine reuptake inhibition changes the electrophysiology of the locus 
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coeruleus via autoreceptor mediated feedback inhibition (Nestler et al., 1999). 
Despite L-DOPA actively taken up by locus coeruleus neurons for noradrenaline 
synthesis, it has no effect on locus coeruleus electrophysiology in healthy rats 
(Miguelez et al., 2011). In the striatum, ventral and dorsal baseline dopamine levels 
are modulated by tonic activity from the VTA and substantia nigra pars compacta, 
respectively, and the ventral striatum is particularly sensitive to changes in tonic 
firing from the VTA due to a greater range in extracellular dopamine concentrations 
(Zhang et al., 2009). Supporting this, recent evidence suggests that in the NAc, 
located in the ventral striatum, dopamine reuptake inhibition increased tonic 
stimulation of low-affinity post-synaptic receptors and results in desensitisation to 
phasic dopamine signals (Dreyer & Hounsgaard, 2013). In a study in humans, [11C]-
raclopride, a radioisotopic ligand for the D2 receptor, demonstrated that an acute 
dose of 100/25mg L-DOPA/carbidopa did not increase resting extracellular 
dopamine in young healthy human striatum at rest, but did during mental task 
performance (Floel et al., 2008).  
 
Low levels of baseline dopamine levels in the NAc shell are associated with 
decreased motivation and exertion of effort for food, whilst reward-seeking remains 
intact in rats (Salamone et al., 2003). Tonic dopamine signals in the NAc modulate 
baseline extracellular dopamine and set an ‘average reward’ of current behaviour, 
which then determines the likelihood to exert effort and vigorous responding to 
reward cues (Niv et al., 2007). Phasic dopamine signalling is dependent on synaptic 
vesicle exocytosis, whereas tonic dopamine signalling is dependent on non-vesicular 
efflux (Moquin & Michael, 2011). This is supported by evidence in rats that 
demonstrates L-DOPA-induced increases in dopamine release is primarily due to 
increased phasic dopamine quanta (Rodríguez et al., 2007). This may explain why 
vesicular monoamine transporter inhibition by reserpine attenuates L-DOPA induced 
extracellular dopamine increases (Kannari et al., 2000), but does not affect low does 
amphetamine induced extracellular dopamine increases in vivo (Cadoni et al., 1995). 
Indeed, phasic and tonic dopamine releases appear to be affected by two distinct, 
but related pools of presynaptic dopamine: cytosolic or the AMPT-sensitive 
dopamine pool and the vesicular or reserpine-sensitive dopamine pool. These two 
pools of dopamine appear to play a role in distinguishing drug actions and individual 
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variability in sensitivity and susceptibility to particular drug effects (Verheij & Cools, 
2007). In the study by Rodríguez and co-workers (2007), L-DOPA-induced increase 
in dopamine release was found to be reliant on the reserpine-sensitive pool, via 
synaptic vesicle exocytosis.  
 
In summary, provision of L-DOPA, resulting in increased central catecholamine 
synthesis may not be sufficient to alter prolonged exercise performance in warm 
conditions. Despite effects on cognitive function and motor cortex plasticity seen in 
other studies, neither exercise nor finger-tapping performances were affected by 
acute augmentation of central L-DOPA availability. Furthermore, because L-DOPA 
preferentially increases dopamine quantal release during phasic signalling, but does 
not alter exercise performance, it may be that the alteration in tonic 
neurotransmission by catecholamine reuptake inhibitors is more important to 
exercise performance. The significance of this distinction will be reviewed in greater 
detail in chapter 7.  
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Chapter 6 
 
The Effect of One Week of Oral S-
adenosylmethionine Supplementation on 
Cycling Performance and 
Thermoregulation in Warm Conditions 
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6.1 – Abstract 
The onset of fatigue during endurance exercise in warm conditions appears to be at 
least partly mediated through mechanisms residing within the central nervous 
system. S-adenosylmethionine (SAM) is a primary methyl group donor, involved in 
the metabolism of several neurotransmitters. It has been used to treat depression, 
but it is not yet known what role SAM may have in exercise performance. With local 
ethics committee approval, 8 physically active males (Mean ± SD age 26 ± 4 y; 
height 1.79 ± 0.07 m; body mass 76.3 ± 10.2 kg; VO2max 55.7 ± 4.0 mL/kg/min) 
were recruited to examine the effect of a week-long oral administration of SAM (2 x 
800 mg/day) on time to exhaustion in a warm environment (30.2 ± 0.2°C, 50 ± 1% 
rh). Participants completed a VO2max test and a familiarisation trial before a 
randomised, double-blind, placebo-controlled crossover design was employed. Trials 
consisted of cycle exercise at a power output equivalent to 70% VO2max to volitional 
exhaustion. Heart rate, skin and core temperature, and ratings of perceived exertion 
and thermal sensation were recorded throughout exercise. Blood samples were 
collected at rest, every 15 min of exercise and at exhaustion. No difference in time to 
exhaustion was observed between the placebo (67.5 ± 12.4 min) and SAM (68.5 ± 
12.0 min) trials (P=0.857). Serum prolactin concentration (P=0.009) and weighted 
mean skin temperature (P=0.015) were elevated during exercise in the SAM trial 
compared to placebo. No further differences were found between trials in the other 
measures and no order effects were observed. These results suggest that a week-
long dosing protocol of SAM does not influence time to exhaustion in warm 
conditions, despite evidence supporting an effect on the CNS and thermoregulation.  
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6.2 – Introduction 
Endurance exercise capacity is reduced in warm conditions in a temperature- 
(Galloway & Maughan, 1997) and humidity-dependent manner (Maughan et al., 
2012).  The main physiological difference to exercise in normal ambient conditions is 
the challenge to thermoregulation and, consequently, fluid balance (Hargreaves, 
2008; Nybo, 2008; Maughan, 2010). This cumulative strain results in the eventual 
onset of fatigue and subsequent impairment in performance. This appears to be 
regulated largely by mechanisms within the CNS (as described in section 1.2). 
Manipulation of central catecholamines has produced consistent changes in the 
onset of fatigue and exercise performance in warm conditions (Roelands & 
Meeusen, 2010, Chapters 3+4). Accordingly, research points to an increase in use of 
drugs which act on central catecholamines amongst athletes (Machnik et al., 2009). 
However, there are several over-the-counter alternative treatments for depression 
that may influence central neurotransmission and should be considered as well. 
SAM is a compound which has been researched for over 50 years for its unique 
versatility, efficacy and tolerability (Delle Chiaie, Pancheri, & Scapicchio, 2002). It 
has been used to treat depression (Papakostas et al., 2003), osteoarthritis (Soeken 
et al., 2002) and is considered potentially useful for liver disorders (Purohit et al., 
2007). While it is a prescription drug in Germany, Spain and Italy, it is available over 
the counter and online in the UK and USA. As the primary methyl donor in human 
physiology, SAM plays a vast number of important roles in the body (see figure 1.8). 
These include homoycsteine metabolism, the synthesis of creatine, metabolism of 
several neurotransmitters and the regulation of DNA and RNA. Via the 
transulfuration pathway SAM is involved in the synthesis of glutathione (Lu & Mato, 
2008) and may effect on synthesis of glutamate and GABA as well. SAM also plays 
a role in the one carbon cycle, in which it is tightly co-dependent with folate and 
choline metabolism (Bottiglieri, 2002; Zeisel & Blusztajn, 1994). These are involved 
in acetylcholine and betaine synthesis (Zeisel & Blusztajn, 1994), as well as 
tetrahydrobiopterin  synthesis, which is a cofactor for nitric oxide and monoamine 
synthesis (Bottiglieri et al., 1992; Stahl, 2007).  
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While there have not been any exercise studies with SAM, related compounds such 
as homocysteine, choline, choline-containing phospholipids and betaine have been 
investigated. In recreational athletes prolonged exercise has been found to increase 
blood homocysteine and decreases folate and B12 (Herrmann et al., 2003). 
Synthesis of SAM is directly related to homocysteine metabolism. SAM is 
synthesised by the addition of ATP to methionine by SAM synthetase. The transfer 
of the methyl group yields s-adenosylhomocysteine. S-adenosylhomocysteine 
hydrolase then removes adenosine from homocysteine. Chronically elevated 
homocysteine levels are associated with folate and B12 deficiencies as well as a 
number of disorders, including depression (Bottiglieri, 2005). The efficacy of SAM in 
the treatment of depression and schizophrenia are attributed to the role SAM plays in 
catecholamine metabolism, as the connection between catecholamines and these 
disorders is well established. This is relationship to catecholamine metabolism is 
clearly demonstrated by the effects of L-DOPA treatment on SAM concentrations. In 
rats, SAM brain concentration decreases in response to L-DOPA infusions 
(Chalmers et al., 1971). In humans, L-DOPA treatment decreases cerebrospinal fluid 
SAM concentrations (Surtees & Hyland, 1990). Similarly, patients receiving L-DOPA 
treatment for Parkinson’s disease, showed a decrease in plasma methionine and 
SAM, while homocysteine was elevated (Müller et al., 2001).  
 
The decrease in plasma choline, loss of betaine through sweat and increase in 
homocysteine observe during prolonged exercise may reflect a decrease of on 
methyl group donors. Depending on the magnitude of the effect, nutritional status 
and genetics of an individual, this detriment to methyl group metabolism could have 
significant ramifications for exercise performance. While choline and betaine 
represent a significant pool of methyl-group donors, only SAM is recognised for 
clinical effects on various central nervous disorders. These most significant of these 
effects appear to be mediated by catecholamine metabolism. As central 
catecholamines appear to play a role in the genesis of fatigue during prolonged 
exercise in warm conditions, the aim of the present study was to determine if SAM 
would affect physiological and psychological measures as well as performance 
during prolonged exercise in a warm environment. Because SAM is involved in the 
synthesis of dopamine and noradrenaline, it is hypothesised that by increasing SAM 
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availability, prolonged exercise in warm conditions will be improved by increasing 
central catecholamine concentrations.   
 
6.3 – Methods 
With the approval of the Loughborough Ethics Advisory Committee (reference no. 
R11-P99) eight male volunteers (age 26 ± 4 y; Ht 1.79 ± 0.07 m; mass 75.5 ± 10.9 
kg; VO2peak 57 ± 9 mL/kg/min) were recruited to participate in this randomised 
crossover design study. Volunteers visited the laboratories at Loughborough 
University on 5 separate occasions. The first visit was to complete an incremental 
exercise test to determine VO2peak, which was used to determine the intensity of 
exercise to be undertaken during subsequent tests. A familiarisation trial was 
followed by a double-blind placebo controlled crossover design. Between 
experimental trials participants were asked to visit the labs to collect their supply of 
capsules at the end of the washout period. Experimental trials consisted of two 7 day 
periods, with a 7 day washout period between the first experimental trial and the 
beginning of the following dosing period. The dosing protocol consisted of ingesting 
800mg SAM (Nature Made, USA) or placebo (approximately 1.2g glucose) twice 
daily for 6 days. On day 7, participants took either 800mg of SAM or placebo 
following an overnight fast having consumed 500mL of water and arrived at the 
laboratory for the experimental trial approximately 2 hours thereafter. Since many 
dietary supplements have been reported to contain additional compounds not 
included on the ingredients label (Geyer et al., 2004), samples of the SAM 
supplement were sent to the Centre for Doping Research, German Sport University, 
Cologne for independent testing (analysis report no: S2011005796; see appendix ). 
No additional steroid or stimulant compounds found to be present in the batch. The 
SAM content of the supplement was also confirmed, in house, by fluorimetric post-
column derivitisation on reversed phase HPLC (Birsan et al., 2008). 
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Upon arrival to the laboratory participants were asked to void their bladder and 
bowels, if necessary. Nude body mass was then recorded behind a curtain and 
participants were asked to position a heart rate monitor and rectal thermistor in 
private. Four skin thermistors were positioned and participants were asked to remain 
seated to establish baseline measurements for 15 minutes. At the end of this period, 
a cannula positioned in a superior forearm vein and blood samples were drawn as 
described in Chapter 2 at rest and every 15 minutes throughout the first hour of 
exercise and once upon the cessation of exercise. Participants were then asked to 
enter the environmental chamber, which was maintained at 30°C, 50%rh. Before 
exercise began participants were asked to complete a series of computer-based 
cognitive function tests. These included a visual search test, the Stroop word-colour 
test and a rapid visual information processing (RVIP) test. Upon completion 
participants were asked to cycle to volitional exhaustion at 70% VO2peak, intended 
to last 60-90 minutes. This performance test was selected over a time trial or 
performance challenge as in previous chapters as it was desired to observe the 
effects of SAM on a pronounced state of mental fatigue. During this period skin and 
core temperature were recorded every 5 minutes. Participants were asked to 
consume 100mL of water every 10 minutes during exercise at which point RPE and 
ratings of thermal sensation were recorded. For the first hour of exercise, expired 
gas was collected every 15 minutes to confirm work rate (see figure 6.1). Whole 
blood was used to measure haematocrit, haemoglobin and glucose. Serum was 
used to measure prolactin and cortisol by ELISA. Hormone AUC calculations were 
made using the linear trapezoidal method. 
113 
 
 
Figure 6.1 Schematic of the experimental trials. 
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6.4 – Results 
All participants completed all experimental trials. There was no difference in time to 
exhaustion (figure 6.2) between PLA (67.5 ± 12.4min) and SAM (68.5 ± 12.0min) 
(P>0.05). Two participants appeared to demonstrate a response to SAM 
supplementation, but this was in opposite directions (figure 6.3). 
 
Figure 6.2 Mean times to exhaustion between trials. No significant differences were observed 
between PLA (67.5 ± 12.4min) and SAM (68.5 ± 12.0min) (p>0.05). 
 
 
Figure 6.3 Individual changes in time to exhaustion. 
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Core temperature increased throughout exercise (figure 6.4A) with no differences 
apparent between trials. Weighted mean skin temperature rose rapidly during the 
first 15 minutes of exercise and remained relatively stable until exhaustion (figure 
6.4B). Weighted mean skin temperature remained an average of 0.26°C higher 
throughout exercise in the SAM trial compared to placebo (P=0.015). Heart rate rose 
rapidly during the first 15 minutes of exercise and climbed steadily until exhaustion. 
No differences between trials were observed (P>0.05).  
A 
 
B 
 
Figure 6.4 Core temperature (A) and weighted mean skin temperature (B) during experimental 
trials. * denotes significant difference (P=0.015). 
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Figure 6.5 Heart rate during experimental trials. 
 
Ratings of perceived exertion rose steadily throughout exercise, but there were no 
significant differences apparent between trials (P=0.774; figure 6.6). Ratings of 
thermal sensation increased at the onset of exercise and steadily increased until 
exhaustion. There were no significant differences between trials (P=0.853; figure 
6.7).  
 
Figure 6.6 Ratings of perceived exertion during experimental trials. 
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Figure 6.7 Ratings of thermal sensation during experimental trials. 
 
Serum cortisol concentrations were significantly increased at the end of exercise 
compared to rest (P<0.05), but no significant differences were observed between 
trials (P=0.371; figure 6.8). Prolactin was significantly increased at the end of 
exercise compared to rest (P<0.05) and prolactin AUC was significantly larger in the 
SAM trial (537 ± 152mIU/hr/mL), compared to placebo (453 ± 158mIU/hr/mL) 
(P=0.009; figure 6.9).  
 
Figure 6.8 Serum cortisol area under the curve. 
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Figure 6.9 Serum prolactin area under the curve. * denotes significant difference (P=0.009). 
 
Packed cell volume, haemoglobin were significantly increased compared to baseline 
at 30min and exhaustion (P<0.05) (table 6.1). No differences were observed 
between trials. Glucose was only significantly elevated at the exhaustion compared 
to baseline (P<0.05). No differences were observed between trials. Percentage 
change in blood and plasma volumes all increased compared to baseline at 30min 
and exhaustion (P<0.05) (table 6.2). Cell volume did not change significantly from 
baseline after 30min during the SAM trial (P>0.05), but did during placebo (P<0.05). 
No differences in sweat rate (figure 6.10) or total sweat loss were observed (P>0.05). 
Work rate as determined by percentage of VO2max increased significantly at 
exhaustion compared to the first 15 minutes of exercise (P<0.05), but this response 
was not different between trials (P>0.05).  
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Table 6.1 Haematorcrit (Hct), haemoglobin (Hb) and blood glucose concentrations. a denotes 
significant difference from baseline measure (P<0.05). 
 
 
 
 
 
 
 
 
Table 6.2 Percentage changes in blood volume (BV), cell volume (CV) and plasma volume (PV).a 
denotes significant difference from baseline measure (P<0.05).  
  
Placebo SAM 
ΔBV% 
30min -5.0 ± 2.8a -4.1 ± 2.6a 
End -5.1 ± 2.9a -3.9 ± 2.0a 
ΔCV% 
30min -1.4 ± 0.9a 0.0 ± 1.3 
End -0.9 ± 1.6a -0.4 ± 1.1a 
ΔPV% 
30min -8.0 ± 4.8a -7.6 ± 4.1a 
End -8.6 ± 4.4a -6.7 ± 3.8a 
 
 
 
Placebo SAM 
Hct (%) 
Start 45.1 ± 1.9 45.3 ± 1.6 
30min 46.9 ± 2.5a 47.3 ± 1.7a 
End 47.2 ± 2.5a 46.9 ± 1.8a 
Hb (g/L) 
Start 157.5 ± 9.3 160.4 ± 6.8 
30min 165.6 ± 11.0a 168.1 ± 8.6a 
End 165.8 ± 11.5a 166.9 ± 7.3a 
Glucose 
(mmol/L) 
Start 4.0 ± 0.4 4.0 ± 0.2 
30min 3.9 ± 0.6 4.1 ± 0.5 
End 4.6 ± 0.7a 4.8± 0.6a 
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Figure 6.10 Mean sweat rate between trials.  
 
No exercise effects were observed for visual search and no significant differences 
between trials were observed (P>0.05). Percentage correct scores for RVIP were 
significantly decreased in the SAM trial compared to placebo for both before and 
after exercise (P<0.05; figure 6.11). A non-significant trend (P=0.06) was observed 
for exercise effect on RVIP percentage correct scores. A treatment effect (P<0.01) 
and a treatment x time interaction effect (P=0.01) were observed for reaction times 
during the word-match portion of the Stroop test, but not for the conflicting portion of 
the test (figure 6.12). SAM reaction times were significantly slower (P<0.05) before 
exercise compared to placebo, but was similar to placebo after exercise.  
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Figure 6.11 RVIP proportion correct. Treatment main effect P=0.02, time main effect P=0.06. stime 
1 and 2 represent before and after exercise, respectively. Solid lines represent mean and dotted lines 
represent 95% confidence intervals.  
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Figure 6.12 Stroop reaction times during the word match (left) and conflicted (right). Session time 1 
and 2 represent before and after exercise, respectively. 
 
6.5 – Discussion 
This is the first study to examine the effects of SAM supplementation on exercise. 
The complex and diverse actions of SAM make it difficult to determine the exact 
physiological mechanism, but effects on central monoaminergic effects are likely 
important. This is supported by evidence from human studies whereby SAM exerts 
therapeutic effects via central catecholaminergic metabolism. The present results 
demonstrate a week long dose of SAM does not affect prolonged exercise 
performance in warm conditions, despite increased skin temperature and impaired 
cognitive function. The small increase in skin temperature, increased prolactin and 
impaired cognitive performance, do not appear to have affected exercise 
performance, heart rate, core temperatures, RPE or thermal sensation in this study. 
Core temperature appears to be marginally lower during the SAM trial compared to 
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the placebo condition, possibly due to the increased heat loss at the skin, but this 
response was not statistically significant.  
 
Previous studies have found that acutely increasing central catecholaminergic 
activity via dual dopamine/noradrenaline reuptake inhibitors can improve exercise 
performance in warm conditions compared to placebo. The neural networks 
associated with affect, cognition, and the cognitive/emotional experience of stress 
are interconnected and catecholamines are key neurotransmitters in their function 
(Ashby et al., 1999). This includes the PFC, a key target of action for therapeutic 
doses of methylphenidate (Berridge et al., 2006) and bupropion (Bares et al., 2010). 
The present study, however, may provide evidence suggesting that lower PFC 
dopamine does not necessarily negatively affect prolonged exercise performance in 
warm conditions. Because the difference in Stroop reaction times normalised 
between trials at the end of exercise may indicate that at the point of fatigue during 
placebo PFC dopamine concentration had surpassed the apex of the inverted-U 
response. This stress induced switch to taking the PFC offline may serve to favour 
dorsal- and sub-cortical control over behaviour, effectively reducing executive control 
over behaviour (Arnsten, 2009), but does not appear to be a causative factor in the 
voluntary cessation of exercise per se.  
 
Prolactin secretion appears to be positively correlated to skin temperature 
independently of core-temperature (Low et al., 2005; Mündel et al., 2006). 
Exogenous SAM increases COMT activity and COMT expression is much higher in 
the periphery, where COMT-dependent methylation of catecholamines is much more 
significant than in the CNS (Männistö & Kaakkola, 1999). Peripheral noradrenaline 
acts as a vasoconstrictor (Charkoudian, 2003), and by increasing COMT activity, 
increased SAM may have reduced peripheral noradrenaline, thereby disinhibiting 
cutaneous blood flow and temperature, which may explain the increased circulating 
prolactin during the SAM trial. This effect has been demonstrated in patients with 
COMT polymorphism (Kang et al., 2010). However, monoamines tonically inhibit, 
while acetylcholine increases prolactin secretion (Freeman et al., 2000). Because 
SAM increases monoamine turnover and may enhance cholinergic tone, a less 
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inhibited prolactin response to the increased skin temperature may explain the 
findings of the present study, at least in part. A study using a potent noradrenaline 
reuptake inhibitor found decreased prolactin and higher core temperature after 
exercise than placebo in normal ambient temperature despite a lower rate of exertion 
(Roelands et al., 2008a). This could be due to decreased heat dissipation through 
the skin due to increased cutaneous vasoconstriction. However, no differences in 
skin temperature were detected in that study.  
 
The source of the effects on cognitive function are difficult to pinpoint without more 
direct measurement of brain function and any rationalisation will rely heavily on 
speculation. Nonetheless, there is some evidence from previous studies 
investigating cognitive function to draw upon. Monoaminergic and cholinergic tone in 
the frontal cortex are determining factors for Stroop and RVIP performance. 
Cholinergic tone is positively correlated with cognitive function and cholinergic 
agonists improve performance (Callaway et al., 1992). As SAM favourably affects 
cholinergic tone, changes in cholinergic neurotransmission cannot explain our 
results. Acute-tryptophan depletion and catecholamine depletion by alpha-methyl-
para-tyrosine (AMPT) improve Stroop performance and decrease attention 
performance, respectively (Booij et al., 2003). Therefore, changes in serotonergic 
neurotransmission cannot explain our results either. SAM has been found to improve 
cognitive function in schizophrenics with the low COMT-activity MET/MET genotype, 
whilst reducing peripheral noradrenaline, providing evidence of its capacity to 
increase COMT enzyme activity in humans (Strous et al., 2009). Both noradrenaline 
and dopamine exert a concentration-dependent inverted-U effect on cognitive 
function in the PFC (Arnsten, 2007). COMT inhibition does not appear to affect 
dopamine release or turnover in the striatum, while it potentiates dopamine efflux in 
the PFC in rats (Männistö & Kaakkola, 1999). This does not appear to be 
accompanied by increased noradrenaline efflux however, which may be due to the 
relatively large number of noradrenaline transporters in the PFC (Tunbridge et al., 
2004). This regional selectivity may explain why central COMT inhibition does not 
appear to have reinforcing/addictive effects, but can enhance cognitive function 
(Apud et al., 2007). The inverted-U relationship for prefrontal catecholamines is 
extended to COMT activity. This is demonstrated by studies assessing cognitive 
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function between COMT genotypes in which the less active MET/MET genotype 
exhibits faster reaction times during the Stroop test than the more active VAL/VAL 
genotype under normal conditions (Reuter et al., 2005), but reverses after 
administration of amphetamine (Mattay et al., 2003). Similarly, the opposite relative 
performance after exercise observed in this study may be explained by increased 
COMT activity in the SAM trial. As PFC function is impaired during stress via 
excessive catecholamine efflux (Arnsten, 2009), what was detrimental in the placebo 
condition may have ameliorated the condition of the SAM trial. 
 
In conclusion, the results of the present study suggest that SAM supplementation for 
1 week affects thermoregulation and central neurotransmission without altering 
exercise performance. The results of this study may have implications for athletes for 
whom sustained attention and reaction times are important (i.e.: tennis, team sports, 
etc.). SAM may be of benefit to athletes with the MET/MET polymorphism, to reduce 
elevated dopamine in the PFC, improving cognitive function without directly affecting 
exercise performance. While this study attempted to saturate the various 
physiological pools for the extensive metabolism of SAM by use of a week-long 
dosing protocol, future studies should determine the effects of an acute dose as the 
neurophysiological adaptations to sub-chronic exposure may alter any potential 
impact on exercise performance, as is the case with bupropion (Roelands et al., 
2009).  
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Chapter 7 
 
General Discussion 
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7.1 – Background  
Fatigue during prolonged exercise in warm conditions occurs long before muscle 
glycogen depletion (Parkin et al., 1999; Febbraio, 2000). Prolonged exercise in warm 
environments places considerable strain on the thermoregulatory and cardiovascular 
systems (Hargreaves, 2008; Nybo, 2008; Maughan, 2010; Cheuvront et al., 2010). 
Prolonged heat strain and fluid loss results in further diminished capacity to dissipate 
heat (Crandall & González-Alonso, 2010). This cumulative  physiological strain may 
result in eventual fatigue via mechanisms residing within the CNS (Nybo, 2008). 
Central catecholaminergic signalling coordinates the behavioural response to stress 
(Chrousos & Gold, 1992) and coping (Pascucci et al., 2007; Snyder et al., 2012; 
Cabib & Puglisi-Allegra, 2012). Pharmacological inhibition of 
dopamine/noradrenaline reuptake has consistently improved performance during 
prolonged exercise in warm conditions, whereas studies attempting increase 
catecholamine metabolism have not (Roelands & Meeusen, 2010).The aim of the 
work described in the present thesis was to further characterise the role of central 
catecholamines during prolonged exercise in warm conditions.  
 
7.2 – Effects of Central Dopamine/Noradrenaline Reuptake Inhibitors on 
Prolonged Exercise Performance in Warm Conditions  
The results of Chapters 3 and 4 are in agreement with similar research in which dual 
dopamine/noradrenaline reuptake inhibitors at therapeutic doses improves exercise 
performance during prolonged exercise in warm conditions (Watson et al., 2005a; 
Roelands et al., 2008d). In all of the above studies, exercise performance was 
improved without significant changes to heart rate, core temperature, skin 
temperature, RPE, or thermal sensation, during steady state exercise. Changes in 
core temp and HR during the time trial were a consequence of the maintenance of 
an increased power output. Together these findings support the hypothesis that 
dopamine/noradrenaline reuptake inhibitors improve performance during prolonged 
exercise in warm conditions through central mechanisms rather than affecting 
changes in the periphery. Since the increased power outputs during time 
trial/workload challenge were not accompanied with increased RPE, it appears that 
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dopamine/noradrenaline reuptake inhibitors may alter the function of the 
teleoanticipatory system as proposed by St. Clair Gibson and co-workers (2006).  
 
The results of Chapter 3 suggest that these effects are extended to women in the 
follicular phase of the menstrual cycle; during which circulating sex hormones 
concentrations are at the lowest point. This was the first study to investigate the 
effects of central catecholamine manipulation during prolonged exercise in warm 
conditions in female participants. This strengthens the argument for a common 
underlying central mechanism for the decrease in power output observed during 
prolonged exercise in warm compared to temperate conditions. A similar core 
temperature and heart rate response was observed during the workload challenge 
compared to that observed for male participants during the time trial in previous 
studies (Watson et al., 2005a). Despite a slightly larger dose compared to those in 
the studies using male participants (9.4 vs. 8.0-8.2mg/kg), there was a similar effect 
size for exercise performance. As oestrogen and progesterone alter 
thermoregulation (Janse de Jonge, 2003) and may interact with drug effects (Young 
& Becker, 2009), future studies should determine the effect of bupropion and other 
centrally-acting dopamine/noradrenaline drugs also persist during the luteal phase.  
 
The results of Chapter 4 suggest that there is a threshold point where reuptake 
inhibition facilitates performance during prolonged exercise in warm conditions. This 
study investigated a dose-response relationship for bupropion on exercise 
performance, and was the first exercise study to use less than the maximum 
therapeutic dose. Only the maximum dose appeared to significantly influence 
exercise performance. This may be explained by a level of redundancy in the 
expression of monoamine transporters, such that partial blockade may not 
sufficiently affect reuptake to alter neurotransmission (Blier, 2008). Egerton and co-
workers (2010) found who found that 150mg bupropion, which produces a striatal 
DAT occupancy of about 26% (Learned-Coughlin, 2003), had no effect on 
extracellular dopamine concentrations in humans. Similarly, Volkow and co-workers 
(2002) induced DAT occupancy of 60% with methylphenidate and found insignificant 
increases in extracellular dopamine. However, striatal DAT occupancy levels may 
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not be the best predictor of effects on exercise. For example, Swart and co-workers 
(2009) found that 10mg methylphenidate, which has been found to produce 40% 
occupancy (Volkow et al., 1998), improved exercise performance in temperate 
conditions. In contrast, neither 300mg bupropion (Watson et al., 2005a) or 20mg 
methylphenidate (Roelands et al., 2008d), which has been found to induce 54% DAT 
occupancy (Volkow et al., 1998) found no improvements in performance in 
temperate conditions. Volkow and co-workers (Volkow et al., 2005) later 
demonstrated that striatal dopamine was more dependent on dopaminergic neuron 
activity and dopamine release, during an engaging task, for example.  
 
However, the apparent inconsistency in DAT occupancy as a predictor of exercise 
effects may be due to differences in methodology instead. Swart and co-workers 
(2009) used time to exhaustion, while Watson and co-workers (2005) and Roelands 
and co-workers (2008) used time trials as a measures of performance. As time trial 
performance is more susceptible to individual pacing strategies than time to 
exhaustion (Hinckson & Hopkins, 2005), it may be possible that time trials aren’t 
quite as robust or sensitive in detecting performance changes made by interventions 
(Laursen et al., 2007). However, more studies are required to determine the relative 
sensitivity of time to exhaustion versus time trials to the effects of 
dopamine/noradrenaline reuptake inhibition. Nonetheless, the difference in results 
underscores the contribution of heat strain to the centrally regulated component of 
performance. Another component of dopamine/noradrenaline reuptake inhibitors not 
characterised by striatal DAT imaging studies are the effects on NAT, which is the 
primary transporter for dopamine in the PFC, a key area for their therapeutic effects. 
 
Low, clinically relevant doses of psychostimulants preferentially increase 
extracellular catecholamines in the PFC (Berridge & Arnsten, 2012) while also 
slightly decreasing locus coeruleus cell firing by inhibiting reuptake (Stahl et al., 
2004; Devilbiss & Berridge, 2006)(see figure 7.1). This includes methylphenidate 
(Berridge et al., 2006) and bupropion (Bares et al., 2010) and amphetamine 
(Berridge & Arnsten, 2012). DAT expression appears to be correlated with D2-like 
receptor expression (Hall et al., 1999). The PFC expresses greater concentrations of 
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D1-like receptors than D2-like; accordingly, there is little DAT expression in cerebral 
cortical areas (Hall et al., 1999). Whereas reuptake inhibition normally increases 
stimulation of D2 autoreceptors to control dopamine release via feedback inhibition, 
the mesoprefrontal dopamine neurons do not express D2 autoreceptors (Lammel et 
al., 2008) and  PFC D1 receptors uniquely appear to be targets for tonic dopamine 
(Dreher & Burnod, 2002; Thurley et al., 2008). The increase in PFC dopamine by 
these drugs appears to be mediated by blockade of PFC NAT, which acts as the 
primary transporter for dopamine in the PFC (Morón et al., 2002). Dopamine may 
also be co-released from noradrenergic neurons in the PFC (Devoto & Flore, 2006). 
Low-dose psychostimulants also reduce the metabolic cost required for optimal 
mental performance, improve connectivity within cortical executive areas and reduce 
interference from irrelevant stimuli and interruption of focus (Swanson et al., 2011). 
This may suggest that these drugs improve task performance by increasing 
executive control over attentional and behavioural resources. 
 
Figure 7.1 Key neuroanatomical targets for dopamine/noradrenaline reuptake inhibitors at 
therapeutic doses represented by red targets. Blue and yellow arrows represent dopaminergic and 
noradrenergic projections, respectively.  
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PFC noradrenaline has been shown to be involved in mediating amphetamine 
induced behavioural activation and dopamine efflux in the NAc (Ventura et al., 2003; 
McKittrick & Abercrombie, 2007). Novel stressors increase noradrenaline release 
within the mPFC which parallels the enhancement of mesoaccumbens dopamine 
release (Pascucci et al., 2007). However, dopamine in the mPFC inhibits stress-
induced dopamine release in the NAc (King et al., 1997; Pascucci et al., 2007), while 
noradrenaline is necessary for NAc dopamine release by stress or by amphetamine 
(Darracq et al., 1998; Ventura et al., 2003; Mitrano et al., 2012). Tonic dopamine in 
the NAc appears to mediate stress-induced aversive behaviour, and inhibition of this 
stress-induced increase in tonic dopamine prevents this withdrawal behaviour (Cabib 
& Puglisi-Allegra, 2012). However, diminished tonic dopamine in the NAc shell also 
results in larger phasic signals, which promote behavioural switching and reflect 
increased salience of motivationally relevant stimuli. The ventromedial PFC appears 
to exert control over both phasic and tonic signalling in the NAc shell, by suppressing 
phasic dopamine and increasing tonic dopamine signalling, both acting to prevent 
selection of task-irrelevant behaviour (Ghazizadeh et al., 2012). Insufficient tonic 
dopamine in the NAc shell potentiates the impact of phasic D1 signalling from limbic 
inputs and facilitates behavioural flexibility, while excessive tonic dopamine inhibits 
PFC input to the NAc (Goto et al., 2007). This relative ratio between tonic and phasic 
dopamine depends on the state of the organism, but tonic dopamine levels appear to 
represent the utility of on-going behaviour, with decreases resulting in concomitant 
reduction of vigour of effort (Niv et al., 2007).  
 
A recent study in humans using arterial spin labelling MRI also investigated the 
effects of methylphenidate on the blood oxygen level dependent signal in a large 
number of extrastriatal structures (Marquand et al., 2012). The authors found a 
decreased signal in many of the structures involved in the stress-response including 
the NTS, hypothalamus and amygdala and an increase in activity in 
mesocorticolimbic structures. This supports both top-down and bottom-up alterations 
in activation, which is reflected in behavioural and EEG tests with effective ADHD 
treatments (Kenemans & Kähkönen, 2011). The increased prefrontal catecholamines 
may enable better executive control over sub-cortical structures involved in 
generating stress-mediated behaviours (as described in section 1.11). The 
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noradrenergic brainstem nuclei, the amygdala, and the NAc all receive afferent 
projections from the PFC. In rats, medioventral PFC inactivation (Amat et al., 2005) 
and activation (Amat et al., 2008) has been found to increase and decrease the 
impact of stress, respectively, by afferent control of brainstem and limbic structures 
(Maier & Watkins, 2010). Improved executive control via the PFC may facilitate the 
maintenance of desired behaviour by strengthening the input to the insular cortex or 
ACC, possible candidates for the input and output centres of the teleoanticipatory 
system, respectively. Alternatively, or concomitantly, a decreased reactivity of the 
noradrenergic nuclei may occur due to increased autoreceptor stimulated feedback 
inhibition as a result of reuptake inhibition. This might result in reduced or delayed 
stress-signalling within the CNS and a prevention of the associated behavioural shift. 
Whether by PFC-mediated top-down effects or by inhibition of bottom-up stress 
signalling, these neurobiological mechanisms provide a possible framework within 
the teleoanticipatory model for how power output is increase without changes in 
perceived exertion.  
 
7.3 – Effects of a Catecholamine Precursor on Prolonged Exercise 
Performance in Warm Conditions 
The results of Chapter 5 suggest that despite observing changes in central 
neurotransmission, as measured by the inhibition of the prolactin response, no 
differences were observed to performance, core or skin temperature, heart rate, 
RPE, thermal sensation, blood glucose, haemoglobin or haematocrit. Central 
catecholamines appear to play a greater role in the development of fatigue during 
prolonged exercise in warm conditions than in temperate conditions. Subsequently, 
studies in warm conditions should theoretically be more sensitive to changes 
induced by catecholamine precursors. Only one study has found improved 
performance in warm conditions with a catecholamine precursor (L-tyrosine)(Tumilty 
et al., 2011), while a more recent study using the same exercise conditions, but with 
a more robust increase and maintenance of plasma L-tyrosine concentrations found 
no difference in performance or cognitive function (Watson et al., 2012). The results 
of the latter study and the findings in Chapter 5 support the conclusion that acute 
oral administration of catecholamine precursors does not improve prolonged 
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exercise performance in the heat. This is in agreement with the majority of studies 
using L-tyrosine in temperate conditions, in which no effect on exercise performance 
has been found (Meeusen et al., 2006a). The lack of effect of catecholamine 
precursors on exercise performance may be related to the lack relative clinical 
efficacy in treating either ADHD or depression. Although catecholamine precursors 
appear to produce changes in cognitive function (Owasoyo et al., 1992; Onur et al., 
2011) and can produce changes in striatal dopamine in humans (Floel et al., 2008), 
they do not appear to consistently affect exercise performance. This may suggest 
that in the majority of healthy individuals catecholamine synthesis is not a 
determining factor in exercise performance. While genetic factors may determine the 
effect of precursor availability, they would similarly affect changes to reuptake 
inhibition.  
 
The effects of drugs with therapeutic efficacy for treatment of ADHD, which include 
amphetamine, methylphenidate, and bupropion (Wilens, 2006), do not share the 
same neuropharmacological effects as L-DOPA. Specifically, drugs which are 
effective in treating ADHD affect behavioural and EEG measures of top-down control 
and selective attention, while L-DOPA does not (Kenemans & Kähkönen, 2011). The 
reasons for these differences are not fully understood, but may be due to the relative 
differences in combined changes of dopamine and noradrenaline transmission. For 
example, although L-DOPA is actively taken up by locus coeruleus neurons for 
noradrenaline synthesis, it has no effect on locus coeruleus electrophysiology in 
healthy rats (Miguelez et al., 2011), while both acute bupropion and methylphenidate 
slightly decrease locus coeruleus activity (Cooper et al., 1994; Devilbiss & Berridge, 
2006). Further differences may be due to relative changes between tonic and phasic 
neurotransmission (Sikström & Söderlund, 2007). Evidence in rats suggests that L-
DOPA-induced increases in dopamine release is primarily due to increased phasic 
dopamine quanta (Rodríguez et al., 2007). There is supporting evidence from human 
imaging studies for this; the capacity of dopamine synthesis as measured by striatal 
[18F]fluorometatyrosine uptake observed with PET appears to be predictor of 
outcome-specific reversal-learning performance, which is determined by phasic 
dopamine (Cools et al., 2009). Another PET study found that acute treatment with L-
DOPA did not increase striatal D2 receptor binding as measured by [11C]raclopride at 
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rest, but during motor learning, a small increase associated with phasic spiking was 
observed (Floel et al., 2008). A similar effect has been observed for methylphenidate 
in PET imaging of [11C]raclopride binding (Volkow et al., 2005). Although both appear 
to increase striatal dopamine during engaging tasks, L-DOPA does not appear to 
influence performance, suggesting that striatal dopamine may not be a good 
predictor of the performance enhancing effects of dopamine/noradrenaline reuptake 
inhibition. This supports the notion that extrastriatal catecholamines may be more 
important for the performance enhancing effects of bupropion and methylphenidate. 
Supporting this, it is the effect of these drugs on extrastriatal catecholamines which 
appears to be more important for their efficacy in the treatment of ADHD and 
depression.  
 
7.4 – Effects of S-adenosylmethionine on Prolonged Exercise Performance in 
Warm Conditions  
SAM is a widely available nutritional supplement with clinical antidepressant qualities 
related to monoamine metabolism. The study in Chapter 6 appears to be the first 
exercise study investigating the effects of SAM supplementation on performance. It 
was thought at the onset of the study that a protocol to ensure the saturation of the 
various metabolic pathways related to SAM would be more conducive to providing 
results, but it is possible that this approach may have precluded any definitive effects 
on performance; the week long supplementation period may have resulted in an 
adaptation to the CNS, altering the response to the intervention. This neurobiological 
response is commonly reported when centrally-acting drugs are used in the 
management of many psychiatric disorders (e.g. depression) and a similar effect was 
observed when bupropion was administered chronically by Roelands and co-workers 
(2009). Despite the apparent changes in cognitive performance in tests that are 
influenced by cortical catecholamines, no clear effect on exercise performance was 
observed. The present results does suggest that supplementation of SAM for one 
week influences baseline measures of cognitive function, associated with attention, 
as well as elevating the skin temperature and prolactin concentrations during 
prolonged exercise in warm conditions, without altering performance. However, the 
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diverse metabolic fates of SAM make it difficult to precisely determine the 
physiological cause of these effects.  
 
The antidepressant qualities of SAM are comparable to typical tricyclic 
antidepressants, both in efficacy (Mischoulon & Fava, 2002) and the effects on EEG 
(Saletu-Zyhlarz et al., 2002). These EEG patterns are distinct to methylphenidate 
(Saletu et al., 2006) and appear to be more similar to imipramine (Anderer et al., 
2002; Saletu et al., 2010), a tricyclic antidepressant with primarily serotonergic and 
noradrenergic effects (Lee et al., 1982). The changes in P300 amplitude and latency 
indicate effects on the locus coeruleus and phasic noradrenergic cortical signalling 
(Nieuwenhuis et al., 2005). Supporting this, small decreases in α and β power 
observed by Saletu-Zhylarz and co-workers (2002) suggests a decreased level of 
arousal, which could be due to decreased cortical noradrenaline (Berridge & Morris, 
2000). This is also reflected in the increased reaction times and decreased attention, 
similar to what we observed in our study. After exercise, these effects appeared to 
be normalised, perhaps due to stress-induced arousal and cortical catecholamine 
efflux (Arnsten, 2009). To date there is no evidence of effects for SAM at receptors 
or transporters, meaning any changes in signalling are likely a result of changes in 
metabolism.  
 
SAM has been found to improve cognitive function in participants with schizophrenia 
with the low COMT-activity MET/MET genotype, whilst reducing peripheral 
noradrenaline, providing evidence of its capacity to increase COMT enzyme activity 
in humans (Strous et al., 2009). This may explain the increased skin temperature 
and increased prolactin release observed in this study. Similarly, participants with 
less active MET/MET genotype exhibits faster reaction times during the Stroop test 
than the more active VAL/VAL genotype under normal conditions (Reuter et al., 
2005), but reverses after administration of amphetamine (Mattay et al., 2003). This 
suggests the inverted-U relationship for prefrontal catecholamines described by 
Arnsten (2007) may be regulated, in part, by COMT activity. This is supported by 
evidence suggesting COMT plays a greater role in the degradation of 
catecholamines than MAO in the PFC, than elsewhere in the brain (Matsumoto et al., 
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2003; Tunbridge et al., 2004; Seamans & Yang, 2004). The opposite relative 
performance after exercise observed in this study may be explained by increased 
COMT activity in the SAM trial, although this is merely speculation at this point. As 
PFC function is impaired during stress via excessive catecholamine efflux (Arnsten, 
2009), what was detrimental in the placebo condition may have ameliorated the 
condition of the SAM trial. The results in Chapter 6 indicate that future studies are 
required before a definitive conclusion can be made regarding the effects of SAM on 
exercise performance. Primarily, the same tests should be conducted using an acute 
dose to determine if the central effects of this drug are connected to performance. 
 
7.5 – Conclusion and Future Research 
Pharmacological inhibition of dopamine/noradrenaline reuptake has consistently 
improved performance during prolonged exercise in warm conditions, whereas 
studies attempting increase catecholamine synthesis have not (Roelands & 
Meeusen, 2010). The studies contained within this thesis have attempted to further 
characterise this apparent difference. Central catecholaminergic signalling 
coordinates the behavioural response to stress (Chrousos & Gold, 1992) and coping 
(Pascucci et al., 2007; Snyder et al., 2012; Cabib & Puglisi-Allegra, 2012). 
Therapeutic doses of dopamine/noradrenaline reuptake inhibitors used in human 
exercise studies preferentially effect the PFC and the dopaminergic and 
noradrenergic nuclei which innervate it: the VTA and locus coeruleus, respectively 
(Berridge & Arnsten, 2012). This may result in improved executive control, a reduced 
impact of stress on behavioural switching, or a combination of both. The difference 
between catecholamine precursors and reuptake inhibitors may be due to 
differences in combined changes of dopamine and noradrenaline transmission or 
changes to tonic and phasic release, which would have differing effects on 
autoreceptor mediated feedback inhibition and subsequent signalling dynamics. The 
results of the studies presented in this thesis support the distinction in the effects of 
reuptake inhibition compared to increased synthesis of catecholamines on exercise 
performance. This suggests that future research be conducted with more 
consideration on the roles of catecholamines in particular areas of the brain.   
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Unfortunately, imaging of human brain activity during exercise remains impractical 
due to the numerous constraints of the imaging equipment. Therefore, future 
research could investigate the effects of bupropion, amphetamine or 
methylphenidate on EEG during prolonged exercise in warm conditions, to determine 
whether the changes in cortical activity reflect the performance enhancing effects of 
these drugs. Because all of these drugs are effective treatments for ADHD, the 
connection between ADHD, central catecholamines and prolonged exercise in warm 
conditions should be explored. Further pharmacotherapies for ADHD could be 
investigated, such as Atomoxetine. Studies comparing differences in prolonged 
exercise in adults with ADHD on and off their medication may further develop our 
understanding of the impact of catecholamines on the regulation of prolonged 
exercise. The importance of genetic differences in catecholamine metabolism and 
signalling, such as COMT polymorphism, could be explored. To further categorise 
gender differences, a study to investigate the effects of dopamine/noradrenaline 
reuptake inhibition on prolonged exercise in warm conditions in women during the 
luteal phase would help elucidate the impact of the menstrual cycle on exercise 
performance and the drug effects. Animal models provide the most flexibility and 
power for directly measuring changes within the CNS, but it may be difficult to devise 
an appropriate animal model for examining central fatigue, as motivation and stress 
will be difficult to control for in the context of goal-direction and executive control of 
behaviour. Forced behaviour alters the impact of stress on catecholamine systems 
(Cabib & Puglisi-Allegra, 1994), therefore, it would be necessary to develop a model 
in which animal exercise is self-motivated. This might be achieved by conditioning a 
fixed-ratio schedule or fixed-interval for rewards dependent on exercise performance 
or duration, respectively.  
Key points: 
1) The effects of bupropion on exercise performance in warm conditions appear 
to be similar in both men and women. 
 
2) There is a threshold for dosage at which the effects of bupropion on exercise 
performance manifest. 
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3) Increased availability of central catecholamine precursor does not appear to 
improve performance during prolonged exercise in warm conditions. This 
suggests site-specific changes in signalling within the CNS are responsible for 
the effects of dopamine/noradrenaline reuptake inhibitors, rather than a 
simple increase or decrease of neurotransmitter availability.  
 
4) 7-day SAM supplementation does not influence exercise capacity in the heat. 
To further characterise the role of methyl-group donors in the synthesis of 
catecholamines and how this may affect exercise performance, future SAM 
studies employing acute dosing protocols are required.   
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Appendix 
Thermal Sensation Scale 
 -10  Cold impossible to bear 
-9 
-8  Very cold, shivering hard 
-7 
-6  Cold, light shivering 
-5 
-4  Most areas of the body feel cold 
-3 
-2  Some areas of the body feel cold 
-1 
0   Neutral 
1 
2   Some areas of the body feel warm 
3 
4   Most areas of the body feel hot 
5 
6   Very hot, uncomfortable 
7 
8   Extremely hot, close to limit 
9 
10  Heat impossible to bear 
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